



Urbanisation and neighbourhood deprivation impact chronic pharmacological pain treatment - a large scale longitudinal cohort study in the Netherlands

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000731
Article Type:	Research
Date Submitted by the Author:	13-Dec-2011
Complete List of Authors:	Leue, Carsten; Maastricht University Medical Centre, Department of Psychiatry and Medical Psychology Buijs, Servaas; IMS Helath, Strik, Jacqueline; Maastricht University Medical Centre, Psychiatry and Medical Psychology Lousberg, Richel; Maastricht University Medical Centre, Psychiatry and Medical Psychology Smit, Jasper; IMS Health, van Kleef, Maarten; Maastricht University Medical Centre, Anaesthesiology van Os, Jim; Maastricht University Medical Centre, Psychiatry and Medical Psychology
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Mental health, Health services research, Medical management, Anaesthesia
Keywords:	Pain management < ANAESTHETICS, MENTAL HEALTH, PAIN MANAGEMENT, PRIMARY CARE, Substance misuse < PSYCHIATRY

SCHOLARONE™
Manuscripts

Original article

Pain and the City:

Observational evidence supporting contextual effects on persistent pain

Carsten Leue, consultant^{*1}, Servaas Buijs, statistician², Jacqueline Strik, consultant¹, Richel Lousberg, lecturer¹, Jasper Smit, statistician², Maarten van Kleef, professor³, Jim van Os, professor^{1,4}

¹ Department of Psychiatry and Psychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical Centre, Maastricht, The Netherlands.

² IMS Health BV, Capelle aan den IJssel, The Netherlands.

³ Department of Anaesthesiology, Maastricht University Medical Centre, Maastricht, The Netherlands.

⁴ King's College London, King's Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, United Kingdom.

* Correspondence:

C. Leue, Department of Psychiatry and Medical Psychology, Maastricht University Medical Centre, PO BOX 616 (DRT 10), NL 6200 MD Maastricht, The Netherlands. Tel: ++31-43-3877444. Fax: ++31-43-3875444. E-mail: c.leue@mumc.nl

Abstract:

Objective: To examine whether urbanization and neighbourhood deprivation would impact chronic pharmacological pain treatment in terms of greater probability of analgesic escalation, accompanied by increased prescription of psychotropic medication.

Design: Longitudinal analysis of a population-based routine prescription database in the Netherlands.

Setting: Representative sample of pharmacies and dispensing general practitioners, covering 73% of the Dutch nationwide medication consumption in primary care and outpatients.

Participants: 449,410 patients aged 15-85 years were included, of whom 166,374 were in the *Starter group* and 283,036 in the *Continuation group* of chronic analgesic treatment.

Main outcome measure: Escalation of analgesics (i.e. change to a higher level of analgesic potency, classified in five levels) in association with urbanization and dichotomous neighbourhood deprivation was analysed over a six-month observation period.

Results: In both *Starter* and *Continuation* groups, escalation was positively associated with urbanization in a dose response fashion (*Starter group*: OR (urbanization level 1 compared to level 5): 1.24; 95% CI 1.18 to 1.30; *Continuation group*: OR 1.19; 95% CI 1.14 to 1.23). A weak but independent association was apparent with neighbourhood deprivation (*Starter group*: OR 1.06; 95% CI 1.02 to 1.11; *Continuation group*: OR 1.04; 95% CI 1.01 to 1.08). Use of somatic and particularly psychotropic co-medication was independently associated with escalation in both groups.

Conclusion: Escalation of chronic analgesic treatment is associated with urban and deprived environments, and occurs in a context of an increased rate of psychotropic medication

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

prescriptions, suggesting pain outcomes are influenced by area influences affecting mental health.

For peer review only

Introduction

The validity of the well-known epidemiological association between urban environment and mental health¹⁻³ is supported by work showing that urban living is associated with increased amygdala activity⁴, a key region in the regulation of stress, affective experience and pain^{5,6}. Pain is the natural comorbid mental experience of somatic conditions^{7,8}. In turn, pain is strongly influenced by comorbid mental disorders^{9,10}. Given evidence of urban impact on risk for mental disorders, including psychiatric medication prescriptions¹¹, we hypothesized that pain outcomes, indexed through prescriptions, would be poorer in urban environments and disadvantaged urban neighbourhoods. Pain outcomes were examined at the level of primary care and specialist outpatient care and defined in two ways: (i) escalation of analgesic treatment (i.e. prescription of more potent analgesics) and (ii) co-prescription of psychotropic medication in addition to analgesic treatment.

Objective

We examined the hypothesis that chronic pharmacological pain treatment of outpatients and patients in primary care would show escalation of analgesics in association with the level of urbanization and neighbourhood index of deprivation. It was predicted that the highest levels of urbanization and neighbourhood deprivation would be associated with escalation of analgesic treatment to more potent pain medication (e.g. tramadol, morphine, methadone, etc.), while lower levels of urbanization and neighbourhood deprivation would be associated with less potent analgesics (e.g. paracetamol, aspirin, ibuprofen, etc.). Furthermore, we examined the hypothesis that escalation of analgesics would predict prescriptions of psychotropic medication (e.g. antidepressants, antipsychotics, mood

1
2
3 stabilizers, etc.) in patients prescribed chronic analgesic treatment. Study hypotheses were
4
5 specified before inspection of the data.
6
7
8
9

10 11 **Method**

12 13 *Data collection*

14
15
16
17 The investigation was carried out by analysing records pertaining to Dutch routine general
18
19 practice and hospital outpatient treatment settings. Data were obtained from the IMS
20
21 Health's longitudinal prescription database (Lifelink, affiliate Capelle ad IJssel, The
22
23 Netherlands)¹². This data source consists of anonymous longitudinal prescription records
24
25 from a representative sample of pharmacies and dispensing GPs, covering 73% of the Dutch
26
27 nationwide medication consumption of outpatients and primary care patients. The
28
29 computerized medication-dispensing histories contain data regarding dispensed
30
31 medications, type of prescriber, dispensing date, dispensed amount of medication,
32
33 prescribed dosage, and length of prescription. Data for each patient were anonymously and
34
35 independently sampled without linkage of prescriptions to the same patient across
36
37 pharmacies, because patients in the Netherlands are usually loyal to a single pharmacy¹³.
38
39 Potential bias caused by patients getting hospitalized, moving to another address or dying
40
41 was minimized by studying chronic pharmacological pain treatment.
42
43
44
45
46
47
48
49
50
51

52 53 *Patient groups*

54
55 Patient selection started with the identification of chronic users of analgesic medication
56
57 during a six-month prescription period (hereafter: observation period). Chronic use was
58
59
60

defined as in receipt of analgesic pharmacotherapy during at least two distinct moments covering an interval of at least two months. In order to track medication for other therapeutic indications (i.e. psychotropic medication and pharmaco-treatment for somatic disorders), patients were observed for a period of six months prior to initiation of analgesic treatment. Next, the cohort with chronic use of analgesics was divided into two groups. *Starters* were defined as patients who had not received any analgesics during the six-month period prior to the observation period (hereafter: *Starter group*). Patients who *continued* with pain medication that was already prescribed in the six month before the observation period formed the second group (hereafter: *Continuation group*). The latter group consisted of all patients who had already received analgesics in the first month of the six-month period prior to the observation period, in order to define chronic analgesic treatment before observation (Figure 1).

Figure 1: Starter group and Continuation Group of chronic analgesic treatment

	Time (months)											
	period prior to observation						observation period					
	1	2	3	4	5	6	7	8	9	10	11	12
starting patients	no Rx for analgesics						first Rx	Rx - Rx ...	last Rx			
continuing patients	first Rx						Rx - Rx - Rx ...	last Rx				

Legend: Schedule of prescriptions (Rx) in Starter group (top) and Continuation group (bottom) of chronic analgesic treatment covering a 12 month period. Months 7 to 12 are the observation period, months 1 to 6 and the pre-observation period.

Data were obtained from the LRx database from month one to twelve as depicted in Figure 1. Statistics were executed at sample level and no projection was applied. Use of other medications (e.g. psychotropic medication and medication for a broad spectrum of somatic conditions) was collected for all patients as well, covering the period of twelve

1
2
3 months, consisting of (i) the pre-observation period (month one to six) and (ii) the
4
5 observation period (month seven to twelve)).
6
7

8
9
10
11 *Escalation of pharmacological pain treatment*
12

13
14 All individual prescriptions of analgesics were observed for each patient in both the Starter
15 and Continuation groups during the observation period and during the six months prior to
16 the observation period. At each dispensing date, analgesics were classified *a priori* in five
17 levels, in order of analgesic potency (Figure 2).
18
19
20
21
22
23
24
25
26
27

28 **Figure 2: Level of analgesic potency***
29

Level	Medication
Level 1	Paracetamol
Level 2	Prostaglandine inhibitors
Level 3	Anti-epileptics (a,b)
Level 4	Weak opiates (c)
Level 5	Strong opiates (d)

30
31
32
33
34
35
36
37
38
39
40
41
42
43 Legend:

- 44 * Level 1 (i.e. lowest potency) to level 5 (i.e. highest potency)
45 (a) Gabapentine, pregabalin and no other anti-epileptic drugs
46 (b) Carbamazepine, valproic acid, lamotrigine and medication of level 1 or 2
47 (c) Tramadol, codeine
48 (d) Methadone, oxycodone, hydromorphone, morphine, buprenorphine, fentanyl, sufentanil,
49 pethidine
50
51
52
53
54
55
56
57
58
59
60

Confirmation of escalation during the observation period was based on the
comparison of analgesic potency at the first dispensing day and the last day of prescription.

1
2
3 The comparison of first and last prescription of analgesics resulted in the following
4
5 categories of analgesic escalation: neutral (i.e. no change of analgesic potency), escalation in
6
7 analgesic treatment (i.e. change to a higher level of analgesic potency), or de-escalation in
8
9 pharmacological pain treatment (i.e. change to a lower analgesic potency) (Table 1).
10
11

12
13 If patients received several analgesics on the same day, both the highest and the
14
15 second highest level of analgesic potency were included in the analyses, in order to define
16
17 escalation categories (e.g. a change from level 5 plus level 2 to level 5 plus level 3 indicating
18
19 that escalation had occurred).
20
21

22 23 24 25 26 *Determinants of escalation in analgesic treatment* 27

28
29 Three groups of variables hypothesized to act as mediators or confounders were included in
30
31 the analyses. The first group were patient characteristics such as sex (0=men, 1=women),
32
33 age (in years) and the location of patient's pharmacy (defined by postal code). The latter
34
35 variable defined the level of urbanization following the definition of the Dutch Central
36
37 Bureau of Statistics (level 1 = highest level of urbanisation, to level 5 = rural environment;
38
39 described in more detail elsewhere^{14 15}) and dichotomously defined neighbourhood
40
41 deprivation (0=no, 1=yes). The dichotomous measure of neighbourhood deprivation was
42
43 developed by the Netherlands Institute of Research in Healthcare (NIVEL), using socio-
44
45 economic indicators such as unemployment rate, average income, population density and
46
47 ethnic variation¹⁶. Healthcare professionals receive higher levels of funding for their services
48
49 in these deprived areas¹⁷. Neighbourhood deprivation was associated with level of
50
51 urbanization: 86% of the sample living in deprived neighbourhoods lived in an area with the
52
53
54
55
56
57
58
59
60

1
2
3 highest level of urbanization. Moreover, the other patients (14%) living in deprived
4
5 neighbourhoods lived in an area with the second highest level of urbanization.
6
7

8
9 Furthermore, psychotropic co-medication was classified into its different classes, and
10
11 somatic co-medication was similarly grouped in 10 classes (ACE inhibitors, angiotensine II
12
13 inhibitors; antidiabetics; beta-blockers; calcium antagonists; functional bowel drugs;
14
15 laxatives; migraine medication; respiratory medication; steroid-antiphlogistics; stomach
16
17 protectors) (Table 1 to 3). In the Starting group, occurrence of co-medication was time-
18
19 coded at three levels according to day of first occurrence (i.e. co-medication prescription
20
21 before start with analgesics, at the same day or after start of analgesic treatment) (Table 2).
22
23 In the Continuation group, occurrence of co-medication was recorded dichotomously
24
25 (presence/absence), since it was impossible to distinguish occurrence of co-medication as
26
27 before or at start of analgesic treatment (Table 3).
28
29
30
31
32
33
34
35

36 *Statistical analysis*

37
38
39 First, we analysed the pattern of (de-) escalation in analgesic treatment by means of an
40
41 ordered logistic multivariable regression model with adjusted odds ratios (and 95%
42
43 confidence interval) using SAS version 9.1¹⁸. Statistical significance for the model was
44
45 defined at conventional alpha of 0.05. The dependent variable in this model was the
46
47 development of a patient's analgesic treatment (de-escalation, neutral, escalation).
48
49 Independent variables, entered simultaneously in the model, were demographic
50
51 characteristics, neighbourhood deprivation, and urbanization, use of psychotropic
52
53 medication and use of somatic medication. In the Starting group, we also included first
54
55 occurrence of co-medication. The significance of the model and the adjusted R-square value
56
57
58
59
60

	Starter group	Continuation Group
--	---------------	--------------------

were used to assess model reliability. Models for Starter and Continuation groups were run separately, given different sample selection criteria. Proportional odds were assumed in the models of escalation and de-escalation of analgesic treatment, and analyses inspected for violation of this assumption. If a determinant was positively associated with escalation of analgesics, absence of this variable was associated negatively with escalation or positively with de-escalation in analgesic treatment (and vice versa). This offered advantage compared to separate models for escalation and de-escalation (such as consistency of model estimates) and avoided double use of patients with a neutral development of analgesic treatment.

Results

Overall, 449,410 patients were included, of which 166,374 were in the Starter group and 283,036 in the Continuation group. The baseline characteristics of both groups are shown in table 1.

Table 1: Baseline characteristics of the patient population with chronic analgesic treatment

		Deprived nb.hoods	Urbanicity ¹ 1	Urbanicity 2-5	Deprived nb. hoods	Urbanicity 1	Urbanicity 2-5
Patients	(Absolute)	12,485	45,458	120,916	21,799	78,358	204,678
Change in	Analgesics ²						
	De-escalation	13.3%	12.1%	10.4%	13.2%	12.5%	11.2%
	Neutral	70.1%	71.6%	74.5%	70.0%	71.4%	73.7%
	Escalation	16.5%	16.3%	15.1%	16.8%	16.1%	15.1%
Gender	Male	39.8%	39.3%	40.3%	36.7%	35.2%	34.6%
	Female	60.2%	60.7%	59.7%	63.3%	64.8%	65.4%
Age (years)	15-25	6.3%	6.1%	6.5%	1.8%	1.6%	1.8%
	26-40	23.8%	19.2%	16.3%	14.0%	10.8%	9.7%
	41-65	50.0%	49.6%	50.9%	56.9%	53.4%	51.8%
	65-85	19.8%	25.2%	26.2%	27.3%	34.2%	36.7%
First	Analgesics						
	Level 1	3.2%	3.9%	4.0%	3.0%	3.8%	4.1%
	Level 2	64.8%	66.6%	72.6%	47.8%	47.1%	53.6%
	Level 3	2.2%	2.5%	2.6%	6.4%	8.1%	8.9%
	Level 4	27.4%	24.2%	18.3%	36.1%	33.9%	27.6%
	Level 5	2.4%	2.9%	2.6%	6.8%	7.2%	5.9%
	level 4/5	29.8%	27.0%	20.8%	42.8%	41.1%	33.5%
Last	Analgesics						
	Level 1	3.4%	3.9%	4.0%	3.4%	4.1%	4.3%
	Level 2	61.9%	63.0%	68.4%	44.5%	44.1%	50.1%
	Level 3	3.0%	3.3%	3.4%	7.0%	8.4%	9.2%
	Level 4	27.6%	24.6%	18.9%	36.8%	34.5%	28.4%
	Level 5	4.1%	5.2%	5.3%	8.3%	9.0%	7.9%
	Level 4/5	31.7%	29.8%	24.2%	45.1%	43.4%	36.3%
Concomitant	Medication ³						
	Any concomitant drug	78.8%	79.0%	77.3%	89.3%	89.6%	88.0%
	Migraine medication	3.9%	3.6%	3.8%	5.9%	5.2%	5.1%
	Any psychotropic medication	35.1%	36.6%	34.8%	51.6%	53.2%	50.2%
	TCA	5.2%	5.0%	5.0%	9.5%	9.4%	9.6%
	Other AD	2.4%	2.0%	1.6%	4.0%	3.3%	2.7%
	Antipsychotics total	4.1%	3.9%	3.1%	6.7%	6.1%	4.9%
	Antipsychotics atypical	2.4%	2.2%	1.5%	4.1%	3.5%	2.5%
	Antipsychotics classic	2.0%	2.1%	1.8%	3.2%	3.2%	2.7%
	Burpropion	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%
	MAO inhibitors	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%
	Mood stabilizers	0.2%	0.3%	0.2%	0.3%	0.4%	0.4%
	Sedatives	27.0%	29.0%	27.4%	41.5%	43.4%	40.6%
	SNRI	2.6%	2.4%	2.2%	4.5%	4.0%	3.5%
	SSRI	7.5%	7.0%	6.4%	10.3%	10.0%	9.0%
	Psycho-stimulants	0.4%	0.5%	0.5%	0.3%	0.5%	0.4%
	Any somatic medication	72.3%	72.6%	71.0%	83.0%	82.9%	81.7%
	Cardiovascular medication ⁴	30.9%	31.4%	30.8%	35.2%	34.9%	34.9%
	Other Somatic medication ⁵	65.2%	65.5%	64.0%	76.9%	76.7%	75.4%

Legend: Patient characteristics are presented as percentages (e.g. age, gender, level of analgesic treatment, change in analgesic treatment (e.g. escalation, de-escalation, and neutral development of prescriptions), and concomitant medication). Absolute patient numbers are presented for the Starter and the Continuation group of chronic analgesic treatment concerning level of urbanicity and for neighbourhood deprivation.

(1) Urbanicity = Urbanization (level 1 = highest level of urbanization; level 5 = rural environment)

(2) Change in pain medication from first to last prescription (neutral = no change in level of potency, escalation = change to a higher level of analgesic potency, de-escalation = change to lower analgesic potency)

- 1
- 2
- 3 (3) Concomitant drug use, observed during a period of 12 month
- 4
- 5 (4) Cardiovascular medication: beta-blocker, calcium antagonist, ACE inhibitor, angiotensine II
- 6 inhibitor
- 7
- 8 (5) Gastro-intestinal medication: anti-diabetics, steroid-antiphogistics, respiratory medication
- 9
- 10
- 11
- 12

13 About 7.6% of all escalating patients were residing in a deprived neighbourhood, and
14 approximately 27.6% were living in the most densely populated areas (urbanization level 1)
15 (Table 1). The majority was female, and there were more patients showing escalation
16 (15.4%) than de-escalation (11.3%) of analgesic treatment. The majority of patients
17 continued a neutral analgesic treatment regime (73.3%) (Table 1). Most of the patients were
18 treated at level 2 or level 4 of analgesic potency. Almost all patients were using other
19 medications, regardless of the different categories in table 1 (84.5%). Around half were using
20 psychotropic medication (45.2%), most were using somatic co-medication (78.1%), and more
21 than a third were using both (38.8%) (Table 1).
22
23
24
25
26
27
28
29
30
31
32
33
34

35 The Starter group mainly initiated an analgesic at level 2 (70.9%) and level 4 (19.9),
36 whereas only 2.6% directly initiated at level 5. However, analgesic potency level 4 and 5
37 increased up to 20.5% respectively 5.2% by the time of the last prescription in the Starter
38 group (Table 1).
39
40
41
42
43
44

45 In the Continuation group, patients already received analgesics at a higher level of
46 potency at inclusion compared to the last observed level of medication potency in the
47 Starter group. Level 4 and 5 was observed in 35.6% at the start of the observation period,
48 increasing to 38.3% at the end of observation period (Table 1).
49
50
51
52
53
54

55 Escalation of analgesic treatment was observed more often in deprived
56 neighbourhoods and the most densely populated areas (16.8% and 16.1% in the
57
58
59
60

1
2
3 Continuation group, respectively 16.5% and 16.3% in the Starting group) compared to lower
4
5 densely populated areas (15.1%) and non-deprived neighbourhoods (15.3.%) (Table 1). The
6
7 proportion of patients with neutral development of analgesic treatment was lower in
8
9 deprived neighbourhoods and areas with the highest degree of urbanization compared to
10
11 less densely populated areas (Table 1).
12
13

14
15 In the Starter group, escalation was positively associated with lower level of first
16
17 observed pain medication. Escalation was furthermore associated, in a dose-response
18
19 fashion, with level of urbanization (highest adjusted Odds Ratio (OR) 1.24 at level 1; 95%
20
21 Confidence Interval (CI) 1.18 to 1.30; compared to reference level 5) (Table 2). Furthermore,
22
23 a weak but independent association existed between escalation and neighbourhood
24
25 deprivation (OR 1.06; 95% CI 1.02 to 1.11) (Table 2). Use of tricyclic antidepressants (TCA),
26
27 mood stabilizers (OR 1.36; 95% CI 1.07 to 1.42), sedatives, cardiovascular medication (OR
28
29 1.16; 95% CI 1.13 to 1.19) and medications for other somatic conditions was associated with
30
31 analgesics escalation, when prescribed *before* start of analgesics (Table 2). Similarly, in the
32
33 Starter group, escalation of analgesic treatment was also associated with the use of selective
34
35 noradrenalin serotonin reuptake inhibitors (SNRI), sedatives (OR 1.82; 95% CI 1.74 to 1.89),
36
37 TCA (OR 2.19; 95% CI 2.03 to 2.36), and antipsychotics (OR 2.43; 95% CI 2.19 to 2.68) when
38
39 prescribed *after* start of analgesics (Table 2). Negative associations with escalation (i.e.
40
41 positive association with de-escalation) were apparent for younger age, female sex, and
42
43 pharmacological migraine treatment. Furthermore, use of antipsychotics was negatively
44
45 associated with escalation if started *simultaneously* with analgesic treatment (OR 0.70; 95%
46
47 CI 0.58 to 0.84) (Table 2).
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The use of selective serotonin reuptake inhibitors (SSRI), before, at or after start of
4
5 analgesic treatment was not associated with escalation of analgesics in the Starter group
6
7
8 (Table 2).
9

10
11 **Table 2: Associations with escalation¹ in pharmacological pain treatment for the *Starter Group* of**
12 **chronic analgesic treatment**
13

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Exposure		Adj. Odds Ratio	Significance ²	CI ³	
				Lower	Upper
Analgesics	Level 1	58.23	*	53.60	63.27
	Level 2	17.92	*	16.75	19.16
	Level 3	4.66	*	4.23	5.14
	Level 4	1.36	*	1.27	1.45
	Level 5	Reference		-	-
Gender	Female	0.97	*	0.95	0.99
	Male	Reference		0.00	0.00
Age (years)	15-25	0.73	*	0.69	0.77
	26-40	0.81	*	0.78	0.84
	41-65	0.87	*	0.85	0.90
	66-85	Reference		-	-
Urbanization ⁴	1	1.24	*	1.18	1.30
	2	1.16	*	1.11	1.22
	3	1.11	*	1.06	1.17
	4	1.07	*	1.02	1.13
	5	Reference		-	-
Deprived Neighbourhood	Yes	1.07	*	1.02	1.11
	No	Reference		-	-
SNRI	⁵ Before start of analgesics	1.05	-	0.96	1.14
	Same start date	1.28	-	0.97	1.69
	After analgesics started	1.26	*	1.09	1.45
	None	Reference		-	-
SSRI	Before start of analgesics	0.97	-	0.92	1.02
	Same start date	0.97	-	0.83	1.15
	After analgesics started	1.07	-	0.97	1.18
	None	Reference		-	-
TCA	Before start of analgesics	1.23	*	1.15	1.32
	Same start date	1.32	*	1.12	1.54
	After analgesics started	2.19	*	2.03	2.36
	None	Reference		-	-
Other AD	Before start of analgesics	1.03	-	0.93	1.15
	Same start date	0.93	-	0.71	1.21
	After analgesics started	1.22	*	1.06	1.42
	None	Reference		-	-
Antipsychotics	Before start of analgesics	0.92	-	0.85	1.01
	Same start date	0.69	*	0.58	0.83
	After analgesics started	2.42	*	2.18	2.67
	None	Reference		-	-
Mood stabilizers	Before start of analgesics	1.40	*	1.10	1.79
	Same start date	0.91	-	0.43	1.89
	After analgesics started	0.71	-	0.39	1.31
	None	Reference		-	-
Sedatives	Before start of analgesics	1.24	*	1.20	1.28
	Same start date	1.25	*	1.18	1.33
	After analgesics started	1.82	*	1.74	1.89
	None	Reference		-	-
Cardio-Vascular drugs	Before start of analgesics	1.16	*	1.13	1.19
	Same start date	0.86	*	0.79	0.95
	After analgesics started	1.35	*	1.26	1.45
	None	Reference		-	-
Other Somatic drugs	Before start of analgesics	1.25	*	1.22	1.29
	Same start date	1.11	*	1.07	1.15
	After analgesics started	1.19	*	1.15	1.23
	None	Reference		-	-
Migraine medication	Before start of analgesics	0.83	*	0.77	0.89
	Same start date	0.95	-	0.78	1.17
	After analgesics started	0.91	-	0.81	1.02
	None	Reference		-	-

- (1) Escalation = change to a higher level of analgesic potency
- (2) Significant variable, p-value<0.05
- (3) 95% CI: confidence interval
- (4) 1 = highest level of urbanization, 5 = rural environment
- (5) Starting date of medication (before, at the same day or after start of analgesics)

In the Continuation group, escalation of analgesics was positively associated with lowest levels of first observed analgesics. Furthermore, escalation was associated with level of urbanization in a dose response fashion (highest adjusted OR 1.19 at level 1; 95% CI 1.14 to 1.23; compared to reference level 5) (Table 3). There was also an association between escalation and deprived neighbourhoods, use of SSRI, SNRI, TCA, all antipsychotics, and sedatives (OR 1.31; 95% CI 1.29 to 1.33) as well as use of somatic co-medication (OR 1.12; 95% CI 1.10 to 1.14) (Table 3). De-escalation was associated with female sex, younger age, treatment of migraine, and use of second-generation antipsychotics (OR 0.80; 95% CI 0.70 to 0.91) (Table 3).

Table 3: Associations with escalation¹ in pharmacological pain treatment for the *Continuation Group* of chronic analgesic treatment

Exposure		Adjusted Odds	Significance ²	95%	CI ³
		Ratio		Lower	Upper
Analgesics	Level 1	16.00	*	15.20	16.85
	Level 2	7.87	*	7.59	8.16
	Level 3	3.14	*	3.00	3.28
	Level 4	1.55	*	1.50	1.61
	Level 5	Reference		-	-
Gender	Female	0.96	*	0.94	0.98
	Male	Reference		-	-
Age (years)	15-25	0.91	*	0.85	0.97
	26-40	0.98		0.95	1.01
	41-65	0.99		0.97	1.01
	66-85	Reference		-	-
Urbanization ⁴	1	1.18	*	1.14	1.23
	2	1.14	*	1.10	1.17
	3	1.08	*	1.04	1.12
	4	1.05	*	1.01	1.09
	5	Reference		-	-
Deprived Neighbourhood	Yes	1.04	*	1.01	1.08
	No	Reference		-	-
SNRI	Total	1.19	*	1.02	1.40
	High dosage	0.95		0.82	1.10
	Low dosage	0.99		0.89	1.11
SSRI	Total	1.03	*	1.004	1.07
TCA	Total	1.19	*	1.06	1.32
	High dosage	1.07		0.97	1.17
	Low dosage	1.12	*	1.01	1.25
Other AD		1.08	*	1.03	1.14
Antipsychotics	Total	1.24	*	1.08	1.43
	Classic	1.01		0.88	1.15
	Atypical	0.80	*	0.70	0.91
Mood stabilizers		0.97		0.85	1.10
Sedatives		1.31	*	1.29	1.34
Migraine		0.95	*	0.91	0.99
Cardio Vascular Drugs		1.12	*	1.10	1.14
Other Somatic Drug classes		1.12	*	1.10	1.14

(1) Escalation = change to a higher level of analgesic potency

(2) Significant variable, p-value<0.05

(3) 95% CI: confidence interval

(4) 1 = highest level of urbanization

Discussion

Escalation of chronic analgesic treatment was observed more often in urban areas and, independently, deprived neighbourhoods within urban areas, suggesting pain outcomes either are associated with individual characteristics that are more prevalent in urban and deprived areas, or subject to contextual influences, like area-level stress or social fragmentation, regardless of individual level characteristics. One individual level variable that may explain part of the association with urbanicity and deprivation is socio-economic status^{19 20}, which was not available for inclusion in the model. Nevertheless, the fact that the association with urbanicity remained with deprivation adjusted for in the same model, suggests that urban effects may not be reducible entirely to individual-level socio-economic status.

Regardless of the underlying mechanism, results clearly echo findings of unconfounded higher rates of poor mental health in urban and deprived neighbourhood environments^{3 4 21}, and suggest that the outcome of mental suffering associated with somatic disorders shows similar predictable variation. Functional pain syndromes and psychiatric disorders show high levels of interdependency²²⁻²⁷, and psychiatric conditions enhance severity of somatic symptoms²⁸. Thus, part of the mechanism underlying the association between pharmacological pain escalation and urban environment may be explained by urbanization increasing the risk for mental ill health. This hypothesis is supported by the findings, as in both the Starter and the Continuation groups, escalation of chronic analgesic treatment was associated not only with urban environment and neighbourhood deprivation, but also with prescription of various psychotropic medications prescribed in association. In general, the positive association of escalating analgesic treatment with psychotropic medication was as strong or even stronger than the association

1
2
3 with prescribed somatic co-medication, with the exception of the observed de-escalating
4
5 effect, in the Continuation group, of second-generation antipsychotics, which possess
6
7 powerful analgesic properties^{29 30}. This is accordance with the literature, given the fact that
8
9 psychiatric conditions can enhance symptom severity in somatic patients²⁸, which
10
11 sometimes may impact even more that the somatic condition itself³¹.
12
13

14
15 However, the question remains to what degree escalation of analgesic treatment and
16
17 its association with psychotropic medication reflects therapeutic efforts to remedy pain,
18
19 treatment of psychiatric comorbidity, or a cause of psychopathology. In the Starter and the
20
21 Continuation group of chronic analgesic treatment, escalation of analgesics was consistently
22
23 and positively associated with the use of TCA. This prescription habit may reflect routine
24
25 paradigms in the pharmacological treatment of pain syndromes^{10 23 32-34}. However, given the
26
27 evidence regarding TCA's efficacy in pain conditions, negative rather than positive
28
29 associations with escalation of analgesics should have been expected. More likely, since the
30
31 association with TCAs was as strong as the association of sedatives with analgesic escalation,
32
33 it may be a reflection of affective or addictive comorbidity in persistent pain, for instance in
34
35 vulnerable cases of opiate-induced sensitization, tolerance and hyperalgesia³⁵⁻⁴¹. Moreover,
36
37 escalation of analgesic treatment in starters of chronic analgesic treatment was even more
38
39 strongly associated with the use of TCA, sedatives, SNRI and antipsychotics, if prescribed
40
41 *after* the start of analgesics. One explanation for stronger associations of escalation in
42
43 analgesics with the use of psychotropic medication if started *after* initiation of analgesic
44
45 treatment may be that psychotropic medication was prescribed in the event of psychiatric
46
47 comorbidity occurring later in course of the syndrome occasioning the pain. This may be
48
49 considered likely, since many patients diagnosed with pain syndromes are suffering from
50
51 mood or anxiety disorders and functional somatic complaints^{37 42}. Furthermore, under-
52
53
54
55
56
57
58
59
60

1
2
3 detection of psychiatric comorbidity may occur early in the course of comorbid psychiatric
4
5 conditions^{25 27 28}.

6
7
8 On the other hand, the strong association of psychotropic medication with escalation
9
10 of analgesics *after* start of analgesic treatment may reflect a direct effect of the
11
12 psychopharmacological intervention itself. Recent findings suggest that not opiates but
13
14 serotonin may be involved in the development of persisting pain^{43 44}. This may also explain
15
16 why antidepressants show stronger positive associations with escalation of analgesic
17
18 treatment if started later, after the initial prescription of analgesics.
19
20

21
22
23 According to the literature^{23 32-35 45}, negative associations of particularly
24
25 antidepressants with escalation of chronic analgesic treatment might have been expected.
26
27 As mentioned earlier, under-detection of psychiatric conditions early in the course of
28
29 analgesic treatment or effects of the pharmacological intervention itself may explain that
30
31 this is not the case^{24 27 37 46}. Nevertheless, there are negative associations with escalation of
32
33 chronic analgesic treatment in, for example, pharmacological migraine treatment. Moreover,
34
35 the use of antipsychotics was negatively associated with analgesic escalation for the Starter
36
37 group if prescribed after start of analgesic treatment. In the Continuation group, de-
38
39 escalation was specifically associated with the use of atypical antipsychotics. This outcome is
40
41 interesting and deserves further investigation, given that limited evidence for the efficacy of
42
43 antipsychotics in pain conditions already exists^{29 30}.

44
45
46
47
48
49 The results of the current study should be seen in the light of several limitations. The
50
51 use of routine data rather than a targeted data collection could have caused more random
52
53 error resulting in type II error. Unidentified confounding may have played a role, as
54
55 randomization was not possible and pre-post designs are sensitive to effects of unmeasured
56
57
58
59
60

1
2
3 changes affecting outcome measures over time. Another limitation is the lack of outcomes
4
5 other than urbanization, psychotropic medication or somatic co-medication. For instance,
6
7 there were no estimates regarding care consumption or illness-related sick leave. Changes in
8
9 patient-related outcomes like illness severity, global functioning, quality of life and
10
11 treatment satisfaction should also form part of prospective evaluations. Furthermore, this
12
13 study only collected data over a twelve-month period. Affect and pain monitoring deserves
14
15 longer evaluation. Finally, due to the study design, associations do not allow for causal
16
17 inference. Finally, due to the study design, associations do not allow for causal
18
19
20
21
22

23 WHAT IS ALREADY KNOWN ON THIS TOPIC

24
25
26
27 Numerous observational studies have observed higher rates of poor mental health in
28
29 urban and deprived neighbourhood environments.
30
31
32

33
34 Pain syndromes and psychiatric disorders show high levels of interdependency, and
35
36 psychiatric conditions enhance severity of somatic symptoms.
37
38
39

40 WHAT THIS STUDY ADDS

41
42
43
44 Escalation of chronic analgesic treatment in persistent pain is associated with urban
45
46 environments and deprived neighbourhoods, and occurs in a context of increased
47
48 levels of psychotropic medications, suggesting persistent pain outcomes are
49
50 associated with area influences affecting mental health.
51
52
53
54

55
56 *Contributors:* CL, SB and JvO were principal investigators of the study. SB analysed the data
57
58 in collaboration with CL, JvO, and JS. CL and JvO drafted the paper. All authors contributed to
59
60

1
2
3 subsequent drafts of the paper, including the final version. JvO is guarantor.
4
5

6
7 *External funding:* Eli Lilly provided funding to IMS Health for data analysis. External funding
8
9 did not support any other aspect of the study. All authors contributed independently from
10
11 funders to this study; and all authors had full access to and can take responsibility for the
12
13 data and analyses.
14

15
16
17 *Competing interests:* All authors have completed the Unified Competing Interest form at
18
19 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
20
21 declare: no support from any organisation for the submitted work, with the exception of
22
23 above-mentioned funding to IMS Health for data analysis; no financial relationships with any
24
25 organisation that might have an interest in the submitted work; and no other relationships
26
27 or activities that could appear to have influenced the submitted work.
28
29

30
31
32 *License for publication:* All authors grant an exclusive license (or non exclusive for
33
34 government employees) on a worldwide basis to the BMJ Publishing Group LTD and its
35
36 licensees, to permit this article (if accepted) to be published in BMJ editions and any other
37
38 BMJPG products and to exploit all subsidiary rights, as set out on:
39
40 <http://resources.bmj.com/bmj/authors/checklists-forms/license-for-publication>.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Lofors J, Sundquist K. Low-linking social capital as a predictor of mental disorders: a cohort study of 4.5 million Swedes. *Social science & medicine (1982)* 2007;64(1):21-34.
2. Thomas H, Weaver N, Patterson J, Jones P, Bell T, Playle R, et al. Mental health and quality of residential environment. *Br J Psychiatry* 2007;191:500-5.
3. Ivory VC CS, Blakely T, Dew K. When does neighbourhood matter? Multilevel relationships between neighbourhood social fragmentation and mental health. *Social science & medicine (1982)* 2011;72:1993-2002.
4. Lederbogen F KP, Haddad L, Streit F, Tost H, Schuch P et al. City living and urban upbringing affect neural stress processing in humans. *Nature* 2011;474(7352):498-501.
5. Hubbard Cs LJ, Bueller J, Stains J, Suyenobu B, Dukes GE, et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. *J Neurosci* 2011;31(35):12491-500.
6. Murrough JW HY, Hu J, Henry S, Williams W, Gallezot JD, et al. Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. *Biol Psychiatry* 2011(Aug 17):[Epub ahead of print].
7. Smith HS HR, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. *Pain Physician* 2011;14(2):E217-45.
8. Price DD CJ, Zhou Q, Verne GN, Perlstein WM, Robinson ME. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models and neuroimaging. *Neuroimage* 2009;47(3):995-1001.
9. Wise TN, Fishbain DA, Holder-Perkins V. Painful physical symptoms in depression: a clinical challenge. *Pain medicine (Malden, Mass 2007)*;8 Suppl 2:S75-82.
10. Goldenberg DL. Pain/Depression dyad: a key to a better understanding and treatment of functional somatic syndromes. *The American journal of medicine*;123(8):675-82.
11. Crump C, Sundquist K, Sundquist J, Winkleby MA. Neighborhood deprivation and psychiatric medication prescription: a Swedish national multilevel study. *Ann Epidemiol*;21(4):231-7.
12. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands. *Osteoporos Int*;22(5):1537-46.
13. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG, Egberts AC. Prevalence and determinants of pharmacy shopping behaviour. *Journal of clinical pharmacy and therapeutics* 2008;33(1):17-23.
14. McKenzie K, Samele C, Van Horn E, Tattan T, Van Os J, Murray R. Comparison of the outcome and treatment of psychosis in people of Caribbean origin living in the UK and British Whites. Report from the UK700 trial. *Br J Psychiatry* 2001;178:160-5.
15. Central Bureau of Statistics. Bevolking der gemeenten van Nederland. *The Hague, The Netherlands: CBS Publications* 1993.
16. Wiegers TA DW. Herijking stedelijke achterstandsgebieden. *Utrecht, The Netherlands: NIVEL publications* 2008.
17. Nza, tariefbeschikking 5000-1900-09-3, 30 juni 2009. <http://www.naz.nl/>.
18. <http://www.sas.com/>.

19. Drukker M, van Os J. Mediators of neighbourhood socioeconomic deprivation and quality of life. *Social psychiatry and psychiatric epidemiology* 2003;38(12):698-706.
20. Skapinakis P, Weich S, Lewis G, Singleton N, Araya R. Socio-economic position and common mental disorders. Longitudinal study in the general population in the UK. *Br J Psychiatry* 2006;189:109-17.
21. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. *Nature*;468(7321):203-12.
22. Hotopf M, Mayou R, Wadsworth M, Wessely S. Temporal relationships between physical symptoms and psychiatric disorder. Results from a national birth cohort. *Br J Psychiatry* 1998;173:255-61.
23. Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. *The American journal of medicine* 1997;103(5):339-47.
24. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. *Archives of general psychiatry* 2005;62(8):903-10.
25. Fink P, Hansen MS, Oxhøj ML. The prevalence of somatoform disorders among internal medical inpatients. *Journal of psychosomatic research* 2004;56(4):413-8.
26. Levy RL, Olden KW, Naliboff BD, Bradley LA, Francisconi C, Drossman DA, et al. Psychosocial aspects of the functional gastrointestinal disorders. *Gastroenterology* 2006;130(5):1447-58.
27. Leue C, Driessen G, Strik JJ, Drukker M, Stockbrugger RW, Kuijpers PM, et al. Managing complex patients on a medical psychiatric unit: an observational study of university hospital costs associated with medical service use, length of stay, and psychiatric intervention. *Journal of psychosomatic research*;68(3):295-302.
28. Meyer T, Klemme H, Herrmann C. Depression but not anxiety is a significant predictor of physicians' assessments of medical status in physically ill patients. *Psychotherapy and psychosomatics* 2000;69(3):147-54.
29. Freudenfeld RN, Murray M, Fuchs PN, Kiser RS. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. *Pain Pract* 2006;6(2):112-8.
30. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. *Cochrane database of systematic reviews (Online)* 2008(4):CD004844.
31. Kim KW, Han JW, Cho HJ, Chang CB, Park JH, Lee JJ, et al. Association between comorbid depression and osteoarthritis symptom severity in patients with knee osteoarthritis. *J Bone Joint Surg Am* 2011;93(6):556-63.
32. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. *JAMA* 2009;301(2):198-209.
33. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. *Gut* 2009;58(3):367-78.
34. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane database of systematic reviews (Online)* 2007(4):CD005454.
35. Krebs EE, Gaynes BN, Gartlehner G, Hansen RA, Thieda P, Morgan LC, et al. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. *Psychosomatics* 2008;49(3):191-8.

- 1
2
3 36. Arnold LM, Hudson JI, Wang F, Wohlreich MM, Prakash A, Kajdasz DK, et al. Comparisons
4 of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients
5 with versus without major depressive disorder. *Clin J Pain* 2009;25(6):461-8.
6
7 37. Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of
8 fibromyalgia and psychiatric disorders. *J Clin Psychiatry* 2006;67(8):1219-25.
9
10 38. Bekhit MH. Opioid-induced hyperalgesia and tolerance. *Am J Ther* 2010;17(5):498-510.
11
12 39. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential role of
13 BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science*
14 2006;311(5762):864-8.
15
16 40. Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D, Knudsen J, et al. Alterations in brain
17 structure and functional connectivity in prescription opioid-dependent patients.
18 *Brain* 2010;133(Pt 7):2098-114.
19
20 41. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review.
21 *Anesthesiology* 2006;104(3):570-87.
22
23 42. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid
24 unexplained clinical conditions. *Best Pract Res Clin Rheumatol* 2003;17(4):563-74.
25
26 43. Chu LF, Dairmont J, Zamora AK, Young CA, Angst MS. The endogenous opioid system is
27 not involved in modulation of opioid-induced hyperalgesia. *J Pain* 2011;12(1):108-15.
28
29 44. Wei F, Dubner R, Zou S, Ren K, Bai G, Wei D, et al. Molecular depletion of descending
30 serotonin unmasks its novel facilitatory role in the development of persistent pain. *J*
31 *Neurosci* 2010;30(25):8624-36.
32
33 45. Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M. Antidepressants for
34 depression in physically ill people. *Cochrane database of systematic reviews (Online)*
35 2010(3):CD007503.
36
37 46. Artigas F, Bel N, Casanovas JM, Romero L. Adaptive changes of the serotonergic system
38 after antidepressant treatments. *Adv Exp Med Biol* 1996;398:51-9.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Level	Medication
Level 1	Paracetamol
Level 2	Prostaglandine inhibitors
Level 3	Anti-epileptics (a,b)
Level 4	Weak opiates (c)
Level 5	Strong opiates (d)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		Time (months)												
		period prior to observation						observation period						
		1	2	3	4	5	6	7	8	9	10	11	12	
starting patients		no Rx for analgesics						first Rx	Rx - Rx ...					last Rx
continuing patients		first Rx						Rx - Rx - Rx ...					last Rx	

For peer review only

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract DONE
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found DONE
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported DONE
Objectives	3	State specific objectives, including any prespecified hypotheses DONE
Methods		
Study design	4	Present key elements of study design early in the paper DONE
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection DONE
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up DONE <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable DONE
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group DONE
Bias	9	Describe any efforts to address potential sources of bias DONE
Study size	10	Explain how the study size was arrived at DONE
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why DONE
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding DONE (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
		(e) Describe any sensitivity analyses

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed DONE (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram DONE
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders DONE (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) DONE
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time DONE <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included DONE (b) Report category boundaries when continuous variables were categorized DONE (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives DONE
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias DONE
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence DONE
Generalisability	21	Discuss the generalisability (external validity) of the study results DONE

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based DONE
---------	----	---

1
2
3 **Original article**
4
5

6 Urbanisation and neighbourhood
7 deprivation impact chronic pharmacological pain treatment - a large
8 scale longitudinal cohort study in the Netherlands
9

10
11 Carsten Leue, consultant ^{*1}, Servaas Buijs, statistician², Jacqueline Strik, consultant¹, Richel
12 Lousberg, lecturer¹, Jasper Smit, statistician², Maarten van Kleef, professor³, Jim van Os,
13 professor^{1,4}
14
15
16
17
18
19
20
21

22 ¹ Department of Psychiatry and Psychology, South Limburg Mental Health Research and
23 Teaching Network, EURON, Maastricht University Medical Centre, Maastricht, The
24 Netherlands.
25
26
27
28

29
30 ² IMS Health BV, Capelle aan den IJssel, The Netherlands.
31
32

33 ³ Department of Anaesthesiology, Maastricht University Medical Centre, Maastricht, The
34 Netherlands.
35
36
37

38 ⁴ King's College London, King's Health Partners, Department of Psychosis Studies, Institute of
39 Psychiatry, London, United Kingdom.
40
41
42
43
44
45
46

47 *Correspondence:
48

49
50 C. Leue, Department of Psychiatry and Medical Psychology, Maastricht University Medical
51 Centre, PO BOX 616 (DRT 10), NL 6200 MD Maastricht, The Netherlands. Tel: ++31-43-
52 3877444. Fax: ++31-43-3875444. E-mail: c.leue@mumc.nl
53
54
55
56
57
58
59
60

Abstract:

Objective: To examine whether urbanization and neighbourhood deprivation would impact chronic pharmacological pain treatment in terms of greater probability of analgesic escalation, predicted by prescriptions of psychotropic medication.

Design: Longitudinal analysis of a population-based routine prescription database in the Netherlands.

Setting: Representative sample of pharmacies and dispensing general practitioners, covering 73% of the Dutch nationwide medication consumption in primary care and outpatients.

Participants: 449,410 patients aged 15-85 years were included, of whom 166,374 were in the *Starter group* and 283,036 in the *Continuation group* of chronic analgesic treatment.

Main outcome measure: Escalation of analgesics (i.e. change to a higher level of analgesic potency, classified in five levels) in association with urbanization and dichotomous neighbourhood deprivation was analysed over a six-month observation period.

Results: In both *Starter* and *Continuation* groups, escalation was positively associated with urbanization in a dose response fashion (*Starter group*: OR (urbanization level 1 compared to level 5): 1.24; 95% CI 1.18 to 1.30; *Continuation group*: OR 1.19; 95% CI 1.14 to 1.23). A weak but independent association was apparent with neighbourhood deprivation (*Starter group*: OR 1.06; 95% CI 1.02 to 1.11; *Continuation group*: OR 1.04; 95% CI 1.01 to 1.08). Use of somatic and particularly psychotropic co-medication was independently associated with escalation in both groups.

1
2
3 *Conclusion:* Escalation of chronic analgesic treatment is associated with urban and deprived
4 environments, and occurs in a context of psychotropic medication prescriptions, suggesting
5 pain outcomes are influenced by area influences affecting mental health.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Introduction

The validity of the well-known epidemiological association between urban environment and mental health¹⁻³ is supported by work showing that urban living is associated with increased amygdala activity⁴, a key region in the regulation of stress, affective experience and pain^{5,6}. Pain is the natural comorbid mental experience of somatic conditions^{7,8}. In turn, pain is strongly influenced by comorbid mental disorders^{9,10}. Given evidence of urban impact on risk for mental disorders, including psychiatric medication prescriptions¹¹, we hypothesized that pain outcomes, indexed through prescriptions, would be poorer in urban environments and disadvantaged urban neighbourhoods. Pain outcomes were examined at the level of primary care and specialist outpatient care and defined in two ways: (i) escalation of analgesic treatment (i.e. prescription of more potent analgesics) and (ii) co-prescription of psychotropic medication in addition to analgesic treatment.

Objective

We examined the hypothesis that chronic pharmacological pain treatment of outpatients and patients in primary care would show escalation of analgesics in association with the level of urbanization and neighbourhood index of deprivation. It was predicted that the highest levels of urbanization and neighbourhood deprivation would be associated with escalation of analgesic treatment to more potent pain medication (e.g. tramadol, morphine, methadone, etc.), while lower levels of urbanization and neighbourhood deprivation would be associated with less potent analgesics (e.g. paracetamol, aspirin, ibuprofen, etc.). Furthermore, we examined the hypothesis that escalation of analgesics would predict prescriptions of psychotropic medication (e.g. antidepressants, antipsychotics, mood

1
2
3 stabilizers, etc.) in patients prescribed chronic analgesic treatment. Study hypotheses were
4
5 specified before inspection of the data.
6
7
8
9

10 11 **Method**

12 13 *Data collection*

14
15
16
17 The investigation was carried out by analysing records pertaining to Dutch routine general
18
19 practice and hospital outpatient treatment settings. Data were obtained from the IMS
20
21 Health's longitudinal prescription database (Lifelink, affiliate Capelle ad IJssel, The
22
23 Netherlands)¹². This data source consists of anonymous longitudinal prescription records
24
25 from a representative sample of pharmacies and dispensing GPs, covering 73% of the Dutch
26
27 nationwide medication consumption of outpatients and primary care patients. The
28
29 computerized medication-dispensing histories contain data regarding dispensed
30
31 medications, type of prescriber, dispensing date, dispensed amount of medication,
32
33 prescribed dosage, and length of prescription. Data for each patient were anonymously and
34
35 independently sampled without linkage of prescriptions to the same patient across
36
37 pharmacies, because patients in the Netherlands are usually loyal to a single pharmacy¹³.
38
39 Potential bias caused by patients getting hospitalized, moving to another address or dying
40
41 was minimized by studying chronic pharmacological pain treatment.
42
43
44
45
46
47
48
49
50
51

52 53 *Patient groups*

54
55 Patient selection started with the identification of chronic users of analgesic medication
56
57 during a six-month prescription period (hereafter: observation period). Chronic use was
58
59
60

1
2
3 defined as in receipt of analgesic pharmacotherapy during at least two distinct moments
4
5 covering an interval of at least two months. In order to track medication for other
6
7 therapeutic indications (i.e. psychotropic medication and pharmaco-treatment for somatic
8
9 disorders), patients were observed for a period of six months prior to initiation of analgesic
10
11 treatment. Next, the cohort with chronic use of analgesics was divided into two groups.
12
13
14 *Starters* were defined as patients who had not received any analgesics during the six-month
15
16 period prior to the observation period (hereafter: *Starter group*). Patients who *continued*
17
18 with pain medication that was already prescribed in the six month before the observation
19
20 period formed the second group (hereafter: *Continuation group*). The latter group consisted
21
22 of all patients who had already received analgesics in the first month of the six-month period
23
24 prior to the observation period, in order to define chronic analgesic treatment before
25
26 observation (Figure 1).
27
28
29
30
31
32

33 **Figure 1: Starter group and Continuation Group of chronic analgesic treatment**
34
35
36

37 Insert Figure 1
38
39
40

41 Legend: Schedule of prescriptions (Rx) in Starter group (top) and Continuation group (bottom) of
42 chronic analgesic treatment covering a 12 month period. Months 7 to 12 are the observation period,
43 months 1 to 6 and the pre-observation period.
44
45
46
47
48

49 Data were obtained from the LRx database from month one to twelve as depicted in
50
51 Figure 1. Statistics were executed at sample level and no projection was applied. Use of
52
53 other medications (e.g. psychotropic medication and medication for a broad spectrum of
54
55 somatic conditions) was collected for all patients as well, covering the period of twelve
56
57
58
59
60

1
2
3 months, consisting of (i) the pre-observation period (month one to six) and (ii) the
4
5 observation period (month seven to twelve)).
6
7
8
9

10 11 *Escalation of pharmacological pain treatment*

12
13
14 All individual prescriptions of analgesics were observed for each patient in both the Starter
15
16 and Continuation groups during the observation period and during the six months prior to
17
18 the observation period. At each dispensing date, analgesics were classified *a priori* in five
19
20 levels, in order of analgesic potency (Figure 2).
21
22
23
24
25
26
27

28 **Figure 2: Level of analgesic potency***

29
30
31 Insert Figure 2
32
33
34

35 Legend:

- 36 * Level 1 (i.e. lowest potency) to level 5 (i.e. highest potency)
37 (a) Gabapentine, pregabalin and no other anti-epileptic drugs
38 (b) Carbamazepine, valproic acid, lamotrigine and medication of level 1 or 2
39 (c) Tramadol, codeine
40 (d) Methadone, oxycodone, hydromorphone, morphine, buprenorphine, fentanyl, sufentanil,
41 pethidine
42
43
44

45 Confirmation of escalation during the observation period was based on the
46
47 comparison of analgesic potency at the first dispensing day and the last day of prescription.
48
49 The comparison of first and last prescription of analgesics resulted in the following
50
51 categories of analgesic escalation: neutral (i.e. no change of analgesic potency), escalation in
52
53 analgesic treatment (i.e. change to a higher level of analgesic potency), or de-escalation in
54
55 pharmacological pain treatment (i.e. change to a lower analgesic potency) (Table 1).
56
57
58
59
60

1
2
3 If patients received several analgesics on the same day, both the highest and the
4
5 second highest level of analgesic potency were included in the analyses, in order to define
6
7 escalation categories (e.g. a change from level 5 plus level 2 to level 5 plus level 3 indicating
8
9 that escalation had occurred).
10
11

12 13 14 15 16 *Determinants of escalation in analgesic treatment* 17

18
19 Three groups of variables hypothesized to act as mediators or confounders were included in
20
21 the analyses. The first group were patient characteristics such as sex (0=men, 1=women),
22
23 age (in years) and the location of patient's pharmacy (defined by postal code). The latter
24
25 variable defined the level of urbanization following the definition of the Dutch Central
26
27 Bureau of Statistics (level 1 = highest level of urbanisation, to level 5 = rural environment;
28
29 described in more detail elsewhere^{14 15}) and dichotomously defined neighbourhood
30
31 deprivation (0=no, 1=yes). The dichotomous measure of neighbourhood deprivation was
32
33 developed by the Netherlands Institute of Research in Healthcare (NIVEL), using socio-
34
35 economic indicators such as unemployment rate, average income, population density and
36
37 ethnic variation¹⁶. Healthcare professionals receive higher levels of funding for their services
38
39 in these deprived areas¹⁷. Neighbourhood deprivation was associated with level of
40
41 urbanization: 86% of the sample living in deprived neighbourhoods lived in an area with the
42
43 highest level of urbanization. Moreover, the other patients (14%) living in deprived
44
45 neighbourhoods lived in an area with the second highest level of urbanization.
46
47
48
49
50
51

52
53 Furthermore, psychotropic co-medication was classified into its different classes, and
54
55 somatic co-medication was similarly grouped in 10 classes (ACE inhibitors, angiotensine II
56
57 inhibitors; antidiabetics; beta-blockers; calcium antagonists; functional bowel drugs;
58
59
60

1
2
3 laxatives; migraine medication; respiratory medication; steroid-antiphlogistics; stomach
4 protectors) (Table 1 to 3). In the Starting group, occurrence of co-medication was time-
5 coded at three levels according to day of first occurrence (i.e. co-medication prescription
6 before start with analgesics, at the same day or after start of analgesic treatment) (Table 2).
7
8 In the Continuation group, occurrence of co-medication was recorded dichotomously
9 (presence/absence), since it was impossible to distinguish occurrence of co-medication as
10 before or at start of analgesic treatment (Table 3).
11
12
13
14
15
16
17
18
19
20
21
22

23 *Statistical analysis*

24
25
26 First, we analysed the pattern of (de-) escalation in analgesic treatment by means of an
27 ordered logistic multivariable regression model with adjusted odds ratios (and 95%
28 confidence interval) using SAS version 9.1¹⁸. Statistical significance for the model was
29 defined at conventional alpha of 0.05. The dependent variable in this model was the
30 development of a patient's analgesic treatment (de-escalation, neutral, escalation).
31
32 Independent variables, entered simultaneously in the model, were demographic
33 characteristics, neighbourhood deprivation, and urbanization, use of psychotropic
34 medication and use of somatic medication. In the Starting group, we also included first
35 occurrence of co-medication. The significance of the model and the adjusted R-square value
36 were used to assess model reliability. Models for Starter and Continuation groups were run
37 separately, given different sample selection criteria. Proportional odds were assumed in the
38 models of escalation and de-escalation of analgesic treatment, and analyses inspected for
39 violation of this assumption. If a determinant was positively associated with escalation of
40 analgesics, absence of this variable was associated negatively with escalation or positively
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Starter group	Continuation Group
--	---------------	--------------------

with de-escalation in analgesic treatment (and vice versa). This offered advantage compared to separate models for escalation and de-escalation (such as consistency of model estimates) and avoided double use of patients with a neutral development of analgesic treatment.

Results

Overall, 449,410 patients were included, of which 166,374 were in the Starter group and 283,036 in the Continuation group. The baseline characteristics of both groups are shown in table 1.

Table 1: Baseline characteristics of the patient population with chronic analgesic treatment

		Deprived nb.hoods	Urbanicity ¹ 1	Urbanicity 2-5	Deprived nb. hoods	Urbanicity 1	Urbanicity 2-5
Patients	(Absolute)	12,485	45,458	120,916	21,799	78,358	204,678
Change in	Analgesics ²						
	De-escalation	13.3%	12.1%	10.4%	13.2%	12.5%	11.2%
	Neutral	70.1%	71.6%	74.5%	70.0%	71.4%	73.7%
	Escalation	16.5%	16.3%	15.1%	16.8%	16.1%	15.1%
Gender	Male	39.8%	39.3%	40.3%	36.7%	35.2%	34.6%
	Female	60.2%	60.7%	59.7%	63.3%	64.8%	65.4%
Age (years)	15-25	6.3%	6.1%	6.5%	1.8%	1.6%	1.8%
	26-40	23.8%	19.2%	16.3%	14.0%	10.8%	9.7%
	41-65	50.0%	49.6%	50.9%	56.9%	53.4%	51.8%
	65-85	19.8%	25.2%	26.2%	27.3%	34.2%	36.7%
First	Analgesics						
	Level 1	3.2%	3.9%	4.0%	3.0%	3.8%	4.1%
	Level 2	64.8%	66.6%	72.6%	47.8%	47.1%	53.6%
	Level 3	2.2%	2.5%	2.6%	6.4%	8.1%	8.9%
	Level 4	27.4%	24.2%	18.3%	36.1%	33.9%	27.6%
	Level 5	2.4%	2.9%	2.6%	6.8%	7.2%	5.9%
	level 4/5	29.8%	27.0%	20.8%	42.8%	41.1%	33.5%
Last	Analgesics						
	Level 1	3.4%	3.9%	4.0%	3.4%	4.1%	4.3%
	Level 2	61.9%	63.0%	68.4%	44.5%	44.1%	50.1%
	Level 3	3.0%	3.3%	3.4%	7.0%	8.4%	9.2%
	Level 4	27.6%	24.6%	18.9%	36.8%	34.5%	28.4%
	Level 5	4.1%	5.2%	5.3%	8.3%	9.0%	7.9%
	Level 4/5	31.7%	29.8%	24.2%	45.1%	43.4%	36.3%
Concomitant	Medication ³						
	Any concomitant drug	78.8%	79.0%	77.3%	89.3%	89.6%	88.0%
	Migraine medication	3.9%	3.6%	3.8%	5.9%	5.2%	5.1%
	Any psychotropic medication	35.1%	36.6%	34.8%	51.6%	53.2%	50.2%
	TCA	5.2%	5.0%	5.0%	9.5%	9.4%	9.6%
	Other AD	2.4%	2.0%	1.6%	4.0%	3.3%	2.7%
	Antipsychotics total	4.1%	3.9%	3.1%	6.7%	6.1%	4.9%
	Antipsychotics atypical	2.4%	2.2%	1.5%	4.1%	3.5%	2.5%
	Antipsychotics classic	2.0%	2.1%	1.8%	3.2%	3.2%	2.7%
	Burpropion	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%
	MAO inhibitors	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%
	Mood stabilizers	0.2%	0.3%	0.2%	0.3%	0.4%	0.4%
	Sedatives	27.0%	29.0%	27.4%	41.5%	43.4%	40.6%
	SNRI	2.6%	2.4%	2.2%	4.5%	4.0%	3.5%
	SSRI	7.5%	7.0%	6.4%	10.3%	10.0%	9.0%
	Psycho-stimulants	0.4%	0.5%	0.5%	0.3%	0.5%	0.4%
	Any somatic medication	72.3%	72.6%	71.0%	83.0%	82.9%	81.7%
	Cardiovascular medication ⁴	30.9%	31.4%	30.8%	35.2%	34.9%	34.9%
	Other Somatic medication ⁵	65.2%	65.5%	64.0%	76.9%	76.7%	75.4%

Legend: Patient characteristics are presented as percentages (e.g. age, gender, level of analgesic treatment, change in analgesic treatment (e.g. escalation, de-escalation, and neutral development of prescriptions), and concomitant medication). Absolute patient numbers are presented for the Starter and the Continuation group of chronic analgesic treatment concerning level of urbanicity and for neighbourhood deprivation.

- (1) Urbanicity = Urbanization (level 1 = highest level of urbanization; level 5 = rural environment)
- (2) Change in pain medication from first to last prescription (neutral = no change in level of potency, escalation = change to a higher level of analgesic potency, de-escalation = change to lower analgesic potency)

- 1
- 2
- 3 (3) Concomitant drug use, observed during a period of 12 month
- 4
- 5 (4) Cardiovascular medication: beta-blocker, calcium antagonist, ACE inhibitor, angiotensine II
- 6 inhibitor
- 7
- 8 (5) Gastro-intestinal medication: anti-diabetics, steroid-antiphogistics, respiratory medication
- 9
- 10
- 11
- 12

13 About 7.6% of all escalating patients were residing in a deprived neighbourhood, and
14 approximately 27.6% were living in the most densely populated areas (urbanization level 1)
15 (Table 1). The majority was female, and there were more patients showing escalation
16 (15.4%) than de-escalation (11.3%) of analgesic treatment. The majority of patients
17 continued a neutral analgesic treatment regime (73.3%) (Table 1). Most of the patients were
18 treated at level 2 or level 4 of analgesic potency. Almost all patients were using other
19 medications, regardless of the different categories in table 1 (84.5%). Around half were using
20 psychotropic medication (45.2%), most were using somatic co-medication (78.1%), and more
21 than a third were using both (38.8%) (Table 1).
22
23
24
25
26
27
28
29
30
31
32
33
34

35 The Starter group mainly initiated an analgesic at level 2 (70.9%) and level 4 (19.9),
36 whereas only 2.6% directly initiated at level 5. However, analgesic potency level 4 and 5
37 increased up to 20.5% respectively 5.2% by the time of the last prescription in the Starter
38 group (Table 1).
39
40
41
42
43
44

45 In the Continuation group, patients already received analgesics at a higher level of
46 potency at inclusion compared to the last observed level of medication potency in the
47 Starter group. Level 4 and 5 was observed in 35.6% at the start of the observation period,
48 increasing to 38.3% at the end of observation period (Table 1).
49
50
51
52
53
54

55 Escalation of analgesic treatment was observed more often in deprived
56 neighbourhoods and the most densely populated areas (16.8% and 16.1% in the
57
58
59
60

1
2
3 Continuation group, respectively 16.5% and 16.3% in the Starting group) compared to lower
4
5 densely populated areas (15.1%) and non-deprived neighbourhoods (15.3.%) (Table 1). The
6
7 proportion of patients with neutral development of analgesic treatment was lower in
8
9 deprived neighbourhoods and areas with the highest degree of urbanization compared to
10
11 less densely populated areas (Table 1).
12
13

14
15 In the Starter group, escalation was positively associated with lower level of first
16
17 observed pain medication. Escalation was furthermore associated, in a dose-response
18
19 fashion, with level of urbanization (highest adjusted Odds Ratio (OR) 1.24 at level 1; 95%
20
21 Confidence Interval (CI) 1.18 to 1.30; compared to reference level 5) (Table 2). Furthermore,
22
23 a weak but independent association existed between escalation and neighbourhood
24
25 deprivation (OR 1.06; 95% CI 1.02 to 1.11) (Table 2). Use of tricyclic antidepressants (TCA),
26
27 mood stabilizers (OR 1.36; 95% CI 1.07 to 1.42), sedatives, cardiovascular medication (OR
28
29 1.16; 95% CI 1.13 to 1.19) and medications for other somatic conditions was associated with
30
31 analgesics escalation, when prescribed *before* start of analgesics (Table 2). Similarly, in the
32
33 Starter group, escalation of analgesic treatment was also associated with the use of selective
34
35 noradrenalin serotonin reuptake inhibitors (SNRI), sedatives (OR 1.82; 95% CI 1.74 to 1.89),
36
37 TCA (OR 2.19; 95% CI 2.03 to 2.36), and antipsychotics (OR 2.43; 95% CI 2.19 to 2.68) when
38
39 prescribed *after* start of analgesics (Table 2). Negative associations with escalation (i.e.
40
41 positive association with de-escalation) were apparent for younger age, female sex, and
42
43 pharmacological migraine treatment. Furthermore, use of antipsychotics was negatively
44
45 associated with escalation if started *simultaneously* with analgesic treatment (OR 0.70; 95%
46
47 CI 0.58 to 0.84) (Table 2).
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The use of selective serotonin reuptake inhibitors (SSRI), before, at or after start of analgesic treatment was not associated with escalation of analgesics in the Starter group (Table 2).

Table 2: Associations with escalation¹ in pharmacological pain treatment for the *Starter Group* of chronic analgesic treatment

For peer review only

Exposure		Adj. Odds Ratio	Significance ²	95% Lower	CI ³ Upper
Analgesics	Level 1	58.23	*	53.60	63.27
	Level 2	17.92	*	16.75	19.16
	Level 3	4.66	*	4.23	5.14
	Level 4	1.36	*	1.27	1.45
	Level 5	Reference		-	-
Gender	Female	0.97	*	0.95	0.99
	Male	Reference		0.00	0.00
Age (years)	15-25	0.73	*	0.69	0.77
	26-40	0.81	*	0.78	0.84
	41-65	0.87	*	0.85	0.90
	66-85	Reference		-	-
Urbanization ⁴	1	1.24	*	1.18	1.30
	2	1.16	*	1.11	1.22
	3	1.11	*	1.06	1.17
	4	1.07	*	1.02	1.13
	5	Reference		-	-
Deprived Neighbourhood	Yes	1.07	*	1.02	1.11
	No	Reference		-	-
SNRI	⁵ Before start of analgesics	1.05	-	0.96	1.14
	Same start date	1.28	-	0.97	1.69
	After analgesics started	1.26	*	1.09	1.45
	None	Reference		-	-
SSRI	Before start of analgesics	0.97	-	0.92	1.02
	Same start date	0.97	-	0.83	1.15
	After analgesics started	1.07	-	0.97	1.18
	None	Reference		-	-
TCA	Before start of analgesics	1.23	*	1.15	1.32
	Same start date	1.32	*	1.12	1.54
	After analgesics started	2.19	*	2.03	2.36
	None	Reference		-	-
Other AD	Before start of analgesics	1.03	-	0.93	1.15
	Same start date	0.93	-	0.71	1.21
	After analgesics started	1.22	*	1.06	1.42
	None	Reference		-	-
Antipsychotics	Before start of analgesics	0.92	-	0.85	1.01
	Same start date	0.69	*	0.58	0.83
	After analgesics started	2.42	*	2.18	2.67
	None	Reference		-	-
Mood stabilizers	Before start of analgesics	1.40	*	1.10	1.79
	Same start date	0.91	-	0.43	1.89
	After analgesics started	0.71	-	0.39	1.31
	None	Reference		-	-
Sedatives	Before start of analgesics	1.24	*	1.20	1.28
	Same start date	1.25	*	1.18	1.33
	After analgesics started	1.82	*	1.74	1.89
	None	Reference		-	-
Cardio-Vascular drugs	Before start of analgesics	1.16	*	1.13	1.19
	Same start date	0.86	*	0.79	0.95
	After analgesics started	1.35	*	1.26	1.45
	None	Reference		-	-
Other Somatic drugs	Before start of analgesics	1.25	*	1.22	1.29
	Same start date	1.11	*	1.07	1.15
	After analgesics started	1.19	*	1.15	1.23
	None	Reference		-	-
Migraine medication	Before start of analgesics	0.83	*	0.77	0.89
	Same start date	0.95	-	0.78	1.17
	After analgesics started	0.91	-	0.81	1.02
	None	Reference		-	-

- (1) Escalation = change to a higher level of analgesic potency
- (2) Significant variable, p-value<0.05
- (3) 95% CI: confidence interval
- (4) 1 = highest level of urbanization, 5 = rural environment
- (5) Starting date of medication (before, at the same day or after start of analgesics)

In the Continuation group, escalation of analgesics was positively associated with lowest levels of first observed analgesics. Furthermore, escalation was associated with level of urbanization in a dose response fashion (highest adjusted OR 1.19 at level 1; 95% CI 1.14 to 1.23; compared to reference level 5) (Table 3). There was also an association between escalation and deprived neighbourhoods, use of SSRI, SNRI, TCA, all antipsychotics, and sedatives (OR 1.31; 95% CI 1.29 to 1.33) as well as use of somatic co-medication (OR 1.12; 95% CI 1.10 to 1.14) (Table 3). De-escalation was associated with female sex, younger age, treatment of migraine, and use of second-generation antipsychotics (OR 0.80; 95% CI 0.70 to 0.91) (Table 3).

Table 3: Associations with escalation¹ in pharmacological pain treatment for the *Continuation Group* of chronic analgesic treatment

Exposure		Adjusted Odds	Significance ²	95%	CI ³
		Ratio		Lower	Upper
Analgesics	Level 1	16.00	*	15.20	16.85
	Level 2	7.87	*	7.59	8.16
	Level 3	3.14	*	3.00	3.28
	Level 4	1.55	*	1.50	1.61
	Level 5	Reference		-	-
Gender	Female	0.96	*	0.94	0.98
	Male	Reference		-	-
Age (years)	15-25	0.91	*	0.85	0.97
	26-40	0.98		0.95	1.01
	41-65	0.99		0.97	1.01
	66-85	Reference		-	-
Urbanization ⁴	1	1.18	*	1.14	1.23
	2	1.14	*	1.10	1.17
	3	1.08	*	1.04	1.12
	4	1.05	*	1.01	1.09
	5	Reference		-	-
Deprived Neighbourhood	Yes	1.04	*	1.01	1.08
	No	Reference		-	-
SNRI	Total	1.19	*	1.02	1.40
	High dosage	0.95		0.82	1.10
	Low dosage	0.99		0.89	1.11
SSRI	Total	1.03	*	1.004	1.07
TCA	Total	1.19	*	1.06	1.32
	High dosage	1.07		0.97	1.17
	Low dosage	1.12	*	1.01	1.25
Other AD		1.08	*	1.03	1.14
Antipsychotics	Total	1.24	*	1.08	1.43
	Classic	1.01		0.88	1.15
	Atypical	0.80	*	0.70	0.91
Mood stabilizers		0.97		0.85	1.10
Sedatives		1.31	*	1.29	1.34
Migraine		0.95	*	0.91	0.99
Cardio Vascular Drugs		1.12	*	1.10	1.14
Other Somatic Drug classes		1.12	*	1.10	1.14

(1) Escalation = change to a higher level of analgesic potency

(2) Significant variable, p-value<0.05

(3) 95% CI: confidence interval

(4) 1 = highest level of urbanization

Discussion

Escalation of chronic analgesic treatment was observed more often in urban areas and, independently, deprived neighbourhoods within urban areas, suggesting pain outcomes either are associated with individual characteristics that are more prevalent in urban and deprived areas, or subject to contextual influences, like area-level stress or social fragmentation, regardless of individual level characteristics. One individual level variable that may explain part of the association with urbanicity and deprivation is socio-economic status^{19 20}, which was not available for inclusion in the model. Nevertheless, the fact that the association with urbanicity remained with deprivation adjusted for in the same model, suggests that urban effects may not be reducible entirely to individual-level socio-economic status.

Regardless of the underlying mechanism, results clearly echo findings of unconfounded higher rates of poor mental health in urban and deprived neighbourhood environments^{3 4 21}, and suggest that the outcome of mental suffering associated with somatic disorders shows similar predictable variation. Functional pain syndromes and psychiatric disorders show high levels of interdependency²²⁻²⁷, and psychiatric conditions enhance severity of somatic symptoms²⁸. Thus, part of the mechanism underlying the association between pharmacological pain escalation and urban environment may be explained by urbanization increasing the risk for mental ill health. This hypothesis is supported by the findings, as in both the Starter and the Continuation groups, escalation of chronic analgesic treatment was associated not only with urban environment and neighbourhood deprivation, but also with prescription of various psychotropic medications prescribed in association. In general, the positive association of escalating analgesic treatment with psychotropic medication was as strong or even stronger than the association

1
2
3 with prescribed somatic co-medication, with the exception of the observed de-escalating
4
5 effect, in the Continuation group, of second-generation antipsychotics, which possess
6
7 powerful analgesic properties^{29 30}. This is accordance with the literature, given the fact that
8
9 psychiatric conditions can enhance symptom severity in somatic patients²⁸, which
10
11 sometimes may impact even more that the somatic condition itself³¹.
12
13

14
15
16 However, the question remains to what degree escalation of analgesic treatment and
17
18 its association with psychotropic medication reflects therapeutic efforts to remedy pain,
19
20 treatment of psychiatric comorbidity, or a cause of psychopathology. In the Starter and the
21
22 Continuation group of chronic analgesic treatment, escalation of analgesics was consistently
23
24 and positively associated with the use of TCA. This prescription habit may reflect routine
25
26 paradigms in the pharmacological treatment of pain syndromes^{10 23 32-34}. However, given the
27
28 evidence regarding TCA's efficacy in pain conditions, negative rather than positive
29
30 associations with escalation of analgesics should have been expected. More likely, since the
31
32 association with TCAs was as strong as the association of sedatives with analgesic escalation,
33
34 it may be a reflection of affective or addictive comorbidity in persistent pain, for instance in
35
36 vulnerable cases of opiate-induced sensitization, tolerance and hyperalgesia³⁵⁻⁴¹. Moreover,
37
38 escalation of analgesic treatment in starters of chronic analgesic treatment was even more
39
40 strongly associated with the use of TCA, sedatives, SNRI and antipsychotics, if prescribed
41
42 *after* the start of analgesics. One explanation for stronger associations of escalation in
43
44 analgesics with the use of psychotropic medication if started *after* initiation of analgesic
45
46 treatment may be that psychotropic medication was prescribed in the event of psychiatric
47
48 comorbidity occurring later in course of the syndrome occasioning the pain. This may be
49
50 considered likely, since many patients diagnosed with pain syndromes are suffering from
51
52 mood or anxiety disorders and functional somatic complaints^{37 42}. Furthermore, under-
53
54
55
56
57
58
59
60

1
2
3 detection of psychiatric comorbidity may occur early in the course of comorbid psychiatric
4
5 conditions^{25 27 28}.

6
7
8 On the other hand, the strong association of psychotropic medication with escalation
9
10 of analgesics *after* start of analgesic treatment may reflect a direct effect of the
11
12 psychopharmacological intervention itself. Recent findings suggest that not opiates but
13
14 serotonin may be involved in the development of persisting pain^{43 44}. This may also explain
15
16 why antidepressants show stronger positive associations with escalation of analgesic
17
18 treatment if started later, after the initial prescription of analgesics.
19
20
21

22
23 According to the literature^{23 32-35 45}, negative associations of particularly
24
25 antidepressants with escalation of chronic analgesic treatment might have been expected.
26
27 As mentioned earlier, under-detection of psychiatric conditions early in the course of
28
29 analgesic treatment or effects of the pharmacological intervention itself may explain that
30
31 this is not the case^{24 27 37 46}. Nevertheless, there are negative associations with escalation of
32
33 chronic analgesic treatment in, for example, pharmacological migraine treatment. Moreover,
34
35 the use of antipsychotics was negatively associated with analgesic escalation for the Starter
36
37 group if prescribed after start of analgesic treatment. In the Continuation group, de-
38
39 escalation was specifically associated with the use of atypical antipsychotics. This outcome is
40
41 interesting and deserves further investigation, given that limited evidence for the efficacy of
42
43 antipsychotics in pain conditions already exists^{29 30}.
44
45
46
47
48
49

50 The results of the current study should be seen in the light of several limitations. The
51
52 use of routine data rather than a targeted data collection could have caused more random
53
54 error resulting in type II error. Unidentified confounding may have played a role, as
55
56 randomization was not possible and pre-post designs are sensitive to effects of unmeasured
57
58
59
60

1
2
3 changes affecting outcome measures over time. Another limitation is the lack of outcomes
4
5 other than urbanization, psychotropic medication or somatic co-medication. For instance,
6
7 there were no estimates regarding care consumption or illness-related sick leave. Changes in
8
9 patient-related outcomes like illness severity, global functioning, quality of life and
10
11 treatment satisfaction should also form part of prospective evaluations. Furthermore, this
12
13 study only collected data over a twelve-month period. Affect and pain monitoring deserves
14
15 longer evaluation. Finally, due to the study design, associations do not allow for causal
16
17 inference. Finally, due to the study design, associations do not allow for causal
18
19
20
21
22

23 WHAT IS ALREADY KNOWN ON THIS TOPIC

24
25
26
27 Numerous observational studies have observed higher rates of poor mental health in
28
29 urban and deprived neighbourhood environments.
30
31

32
33
34 Pain syndromes and psychiatric disorders show high levels of interdependency, and
35
36 psychiatric conditions enhance severity of somatic symptoms.
37
38

39 WHAT THIS STUDY ADDS

40
41
42
43 Escalation of chronic analgesic treatment in persistent pain is associated with urban
44
45 environments and deprived neighbourhoods, and occurs in a context of increased
46
47 levels of psychotropic medications, suggesting persistent pain outcomes are
48
49 associated with area influences affecting mental health.
50
51
52
53

54
55
56 *Contributors:* CL, SB and JvO were principal investigators of the study. SB analysed the data
57
58 in collaboration with CL, JvO, and JS. CL and JvO drafted the paper. All authors contributed to
59
60

1
2
3 subsequent drafts of the paper, including the final version. JvO is guarantor.
4
5

6
7 *External funding:* Eli Lilly provided funding to IMS Health for data analysis. External funding
8
9 did not support any other aspect of the study. All authors contributed independently from
10
11 funders to this study; and all authors had full access to and can take responsibility for the
12
13 data and analyses.
14

15
16
17 *Competing interests:* All authors have completed the Unified Competing Interest form at
18
19 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
20
21 declare: no support from any organisation for the submitted work, with the exception of
22
23 above-mentioned funding to IMS Health for data analysis; no financial relationships with any
24
25 organisation that might have an interest in the submitted work; and no other relationships
26
27 or activities that could appear to have influenced the submitted work.
28
29

30
31
32 *License for publication:* All authors grant an exclusive license (or non exclusive for
33
34 government employees) on a worldwide basis to the BMJ Publishing Group LTD and its
35
36 licensees, to permit this article (if accepted) to be published in BMJ editions and any other
37
38 BMJPG products and to exploit all subsidiary rights, as set out on:
39
40 <http://resources.bmj.com/bmj/authors/checklists-forms/license-for-publication>.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Lofors J, Sundquist K. Low-linking social capital as a predictor of mental disorders: a cohort study of 4.5 million Swedes. *Social science & medicine (1982)* 2007;64(1):21-34.
2. Thomas H, Weaver N, Patterson J, et al. Mental health and quality of residential environment. *Br J Psychiatry* 2007;191:500-5.
3. Ivory VC CS, Blakely T, Dew K. When does neighbourhood matter? Multilevel relationships between neighbourhood social fragmentation and mental health. *Social science & medicine (1982)* 2011;72:1993-2002.
4. Lederbogen F KP, Haddad L, Streit F, et al. City living and urban upbringing affect neural stress processing in humans. *Nature* 2011;474(7352):498-501.
5. Hubbard Cs LJ, Bueller J, Stains J, et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. *J Neurosci* 2011;31(35):12491-500.
6. Murrough JW Huang Y, Hu J, et al. Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. *Biol Psychiatry* 2011(Aug 17):[Epub ahead of print].
7. Smith HS HR, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. *Pain Physician* 2011;14(2):E217-45.
8. Price DD CJ, Zhou Q, Verne GN, et al. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models and neuroimaging. *Neuroimage* 2009;47(3):995-1001.
9. Wise TN, Fishbain DA, Holder-Perkins V. Painful physical symptoms in depression: a clinical challenge. *Pain medicine (Malden, Mass 2007)*;8 Suppl 2:S75-82.
10. Goldenberg DL. Pain/Depression dyad: a key to a better understanding and treatment of functional somatic syndromes. *The American journal of medicine*;123(8):675-82.
11. Crump C, Sundquist K, Sundquist J, et al. Neighborhood deprivation and psychiatric medication prescription: a Swedish national multilevel study. *Ann Epidemiol*;21(4):231-7.
12. Netelenbos JC, Geusens PP, Ypma G, et al. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands. *Osteoporos Int*;22(5):1537-46.
13. Buurma H, Bouvy ML, De Smet PA, et al. Prevalence and determinants of pharmacy shopping behaviour. *Journal of clinical pharmacy and therapeutics* 2008;33(1):17-23.
14. McKenzie K, Samele C, Van Horn E, et al. Comparison of the outcome and treatment of psychosis in people of Caribbean origin living in the UK and British Whites. Report from the UK700 trial. *Br J Psychiatry* 2001;178:160-5.
15. Central Bureau of Statistics. Bevolking der gemeenten van Nederland. *The Hague, The Netherlands: CBS Publications* 1993.
16. Wiegers TA DW. Herijking stedelijke achterstandsgebieden. *Utrecht, The Netherlands: NIVEL publications* 2008.
17. Nza, tariefbeschikking 5000-1900-09-3, 30 juni 2009. <http://www.naz.nl/>.
18. <http://www.sas.com/>.
19. Drukker M, van Os J. Mediators of neighbourhood socioeconomic deprivation and quality of life. *Social psychiatry and psychiatric epidemiology* 2003;38(12):698-706.

- 1
- 2
- 3 20. Skapinakis P, Weich S, Lewis G, et al. Socio-economic position and common mental
- 4 disorders. Longitudinal study in the general population in the UK. *Br J Psychiatry*
- 5 2006;189:109-17.
- 6
- 7 21. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. *Nature*;468(7321):203-
- 8 12.
- 9
- 10 22. Hotopf M, Mayou R, Wadsworth M, et al. Temporal relationships between physical
- 11 symptoms and psychiatric disorder. Results from a national birth cohort. *Br J*
- 12 *Psychiatry* 1998;173:255-61.
- 13
- 14 23. Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients
- 15 presenting with physical complaints: clinical predictors and outcome. *The American*
- 16 *journal of medicine* 1997;103(5):339-47.
- 17
- 18 24. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs
- 19 independent of psychiatric and medical comorbidity. *Archives of general psychiatry*
- 20 2005;62(8):903-10.
- 21
- 22 25. Fink P, Hansen MS, Oxhøj ML. The prevalence of somatoform disorders among internal
- 23 medical inpatients. *Journal of psychosomatic research* 2004;56(4):413-8.
- 24
- 25 26. Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional
- 26 gastrointestinal disorders. *Gastroenterology* 2006;130(5):1447-58.
- 27
- 28 27. Leue C, Driessen G, Strik JJ, et al. Managing complex patients on a medical psychiatric
- 29 unit: an observational study of university hospital costs associated with medical
- 30 service use, length of stay, and psychiatric intervention. *Journal of psychosomatic*
- 31 *research*;68(3):295-302.
- 32
- 33 28. Meyer T, Klemme H, Herrmann C. Depression but not anxiety is a significant predictor of
- 34 physicians' assessments of medical status in physically ill patients. *Psychotherapy and*
- 35 *psychosomatics* 2000;69(3):147-54.
- 36
- 37 29. Freudenfeld RN, Murray M, Fuchs PN, et al. Decreased pain and improved quality of life
- 38 in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. *Pain Pract*
- 39 2006;6(2):112-8.
- 40
- 41 30. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults.
- 42 *Cochrane database of systematic reviews (Online)* 2008(4):CD004844.
- 43
- 44 31. Kim KW, Han JW, Cho HJ, et al. Association between comorbid depression and
- 45 osteoarthritis symptom severity in patients with knee osteoarthritis. *J Bone Joint Surg*
- 46 *Am* 2011;93(6):556-63.
- 47
- 48 32. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with
- 49 antidepressants: a meta-analysis. *JAMA* 2009;301(2):198-209.
- 50
- 51 33. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological
- 52 therapies in irritable bowel syndrome: systematic review and meta-analysis. *Gut*
- 53 2009;58(3):367-78.
- 54
- 55 34. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane database of*
- 56 *systematic reviews (Online)* 2007(4):CD005454.
- 57
- 58 35. Krebs EE, Gaynes BN, Gartlehner G, et al. Treating the physical symptoms of depression
- 59 with second-generation antidepressants: a systematic review and metaanalysis.
- 60 *Psychosomatics* 2008;49(3):191-8.
36. Arnold LM, Hudson JI, Wang F, et al. Comparisons of the efficacy and safety of duloxetine
- for the treatment of fibromyalgia in patients with versus without major depressive
- disorder. *Clin J Pain* 2009;25(6):461-8.

- 1
2
3 37. Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric
4 disorders. *J Clin Psychiatry* 2006;67(8):1219-25.
5 38. Bekhit MH. Opioid-induced hyperalgesia and tolerance. *Am J Ther* 2010;17(5):498-510.
6 39. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential role of
7 BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science*
8 2006;311(5762):864-8.
9 40. Upadhyay J, Maleki N, Potter J, et al. Alterations in brain structure and functional
10 connectivity in prescription opioid-dependent patients. *Brain* 2010;133(Pt 7):2098-
11 114.
12 41. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review.
13 *Anesthesiology* 2006;104(3):570-87.
14 42. Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid
15 unexplained clinical conditions. *Best Pract Res Clin Rheumatol* 2003;17(4):563-74.
16 43. Chu LF, Dairmont J, Zamora AK, et al. The endogenous opioid system is not involved in
17 modulation of opioid-induced hyperalgesia. *J Pain* 2011;12(1):108-15.
18 44. Wei F, Dubner R, Zou S, et al. Molecular depletion of descending serotonin unmasks its
19 novel facilitatory role in the development of persistent pain. *J Neurosci*
20 2010;30(25):8624-36.
21 45. Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people.
22 *Cochrane database of systematic reviews (Online)* 2010(3):CD007503.
23 46. Artigas F, Bel N, Casanovas JM, Romero L. Adaptive changes of the serotonergic system
24 after antidepressant treatments. *Adv Exp Med Biol* 1996;398:51-9.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Starter	Continu-
--	---------	----------

For peer review only

Table 1: Baseline characteristics of the patient population with chronic analgesic treatment

		group			ation group		
		Deprived	Urbanicity ¹	Urbanicity	Deprived	Urbanicity	Urbanicity
		nb.hoods	1	2-5	nb. hoods	1	2-5
Patients	(Absolute)	12,485	45,458	120,916	21,799	78,358	204,672
Change in	Analgesics ²						
	De-escalation	13.3%	12.1%	10.4%	13.2%	12.5%	11.2%
	Neutral	70.1%	71.6%	74.5%	70.0%	71.4%	73.7%
	Escalation	16.5%	16.3%	15.1%	16.8%	16.1%	15.1%
Gender	Male	39.8%	39.3%	40.3%	36.7%	35.2%	34.6%
	Female	60.2%	60.7%	59.7%	63.3%	64.8%	65.4%
Age (years)	15-25	6.3%	6.1%	6.5%	1.8%	1.6%	1.8%
	26-40	23.8%	19.2%	16.3%	14.0%	10.8%	9.7%
	41-65	50.0%	49.6%	50.9%	56.9%	53.4%	51.8%
	65-85	19.8%	25.2%	26.2%	27.3%	34.2%	36.7%
First	Analgesics						
	Level 1	3.2%	3.9%	4.0%	3.0%	3.8%	4.1%
	Level 2	64.8%	66.6%	72.6%	47.8%	47.1%	53.6%
	Level 3	2.2%	2.5%	2.6%	6.4%	8.1%	8.9%
	Level 4	27.4%	24.2%	18.3%	36.1%	33.9%	27.6%
	Level 5	2.4%	2.9%	2.6%	6.8%	7.2%	5.9%
	level 4/5	29.8%	27.0%	20.8%	42.8%	41.1%	33.5%
Last	Analgesics						
	Level 1	3.4%	3.9%	4.0%	3.4%	4.1%	4.3%
	Level 2	61.9%	63.0%	68.4%	44.5%	44.1%	50.1%
	Level 3	3.0%	3.3%	3.4%	7.0%	8.4%	9.2%
	Level 4	27.6%	24.6%	18.9%	36.8%	34.5%	28.4%
	Level 5	4.1%	5.2%	5.3%	8.3%	9.0%	7.9%
	Level 4/5	31.7%	29.8%	24.2%	45.1%	43.4%	36.3%
Concomitant	Medication ³						
	Any concomitant drug	78.8%	79.0%	77.3%	89.3%	89.6%	88.0%
	Migraine medication	3.9%	3.6%	3.8%	5.9%	5.2%	5.1%
	Any psychotropic medication	35.1%	36.6%	34.8%	51.6%	53.2%	50.2%
	TCA	5.2%	5.0%	5.0%	9.5%	9.4%	9.6%
	Other AD	2.4%	2.0%	1.6%	4.0%	3.3%	2.7%
	Antipsychotics total	4.1%	3.9%	3.1%	6.7%	6.1%	4.9%
	Antipsychotics atypical	2.4%	2.2%	1.5%	4.1%	3.5%	2.5%
	Antipsychotics classic	2.0%	2.1%	1.8%	3.2%	3.2%	2.7%
	Burpropion	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%
	MAO inhibitors	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%
	Mood stabilizers	0.2%	0.3%	0.2%	0.3%	0.4%	0.4%
	Sedatives	27.0%	29.0%	27.4%	41.5%	43.4%	40.6%
	SNRI	2.6%	2.4%	2.2%	4.5%	4.0%	3.5%
	SSRI	7.5%	7.0%	6.4%	10.3%	10.0%	9.0%
	Psycho-stimulants	0.4%	0.5%	0.5%	0.3%	0.5%	0.4%
	Any somatic medication	72.3%	72.6%	71.0%	83.0%	82.9%	81.7%
	Cardiovascular medication ⁴	30.9%	31.4%	30.8%	35.2%	34.9%	34.9%
	Other Somatic medication ⁵	65.2%	65.5%	64.0%	76.9%	76.7%	75.4%

Legend: Patient characteristics are presented as percentages (e.g. age, gender, level of analgesic treatment, change in analgesic treatment (e.g. escalation, de-escalation, and neutral development of prescriptions), and concomitant medication). Absolute patient numbers are presented for the Starter and the Continuation group of chronic analgesic treatment concerning level of urbanicity and for neighbourhood deprivation.

(1) Urbanicity = Urbanization (level 1 = highest level of urbanization; level 5 = rural environment)

- (2) Change in pain medication from first to last prescription (neutral = no change in level of potency, escalation = change to a higher level of analgesic potency, de-escalation = change to lower analgesic potency)
- (3) Concomitant drug use, observed during a period of 12 month
- (4) Cardiovascular medication: beta-blocker, calcium antagonist, ACE inhibitor, angiotensine II inhibitor
- (5) Gastro-intestinal medication: anti-diabetics, steroid-antiphogistics, respiratory medication

For peer review only



Observational evidence that urbanisation and neighbourhood deprivation are associated with escalation in pharmacological pain treatment - a longitudinal population-based study in the Netherlands

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000731.R1
Article Type:	Research
Date Submitted by the Author:	03-May-2012
Complete List of Authors:	Leue, Carsten; Maastricht University Medical Centre, Department of Psychiatry and Medical Psychology Buijs, Servaas; IMS Helath, Strik, Jacqueline; Maastricht University Medical Centre, Psychiatry and Medical Psychology Lousberg, Richel; Maastricht University Medical Centre, Psychiatry and Medical Psychology Smit, Jasper; IMS Health, van Kleef, Maarten; Maastricht University Medical Centre, Anaesthesiology van Os, Jim; Maastricht University Medical Centre, Psychiatry and Medical Psychology
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Mental health, Health services research, Medical management, Anaesthesia
Keywords:	Pain management < ANAESTHETICS, MENTAL HEALTH, PAIN MANAGEMENT, PRIMARY CARE, Substance misuse < PSYCHIATRY

SCHOLARONE™
Manuscripts

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract DONE
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found DONE
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported DONE
Objectives	3	State specific objectives, including any prespecified hypotheses DONE
Methods		
Study design	4	Present key elements of study design early in the paper DONE
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection DONE
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up DONE <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable DONE
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group DONE
Bias	9	Describe any efforts to address potential sources of bias DONE
Study size	10	Explain how the study size was arrived at DONE
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why DONE
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding DONE (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
		(e) Describe any sensitivity analyses

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed DONE (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram DONE
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders DONE (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) DONE
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time DONE <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included DONE (b) Report category boundaries when continuous variables were categorized DONE (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives DONE
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias DONE
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence DONE
Generalisability	21	Discuss the generalisability (external validity) of the study results DONE

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based DONE
---------	----	--


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		Time (months)												
		period prior to observation						observation period						
		1	2	3	4	5	6	7	8	9	10	11	12	
starting patients		no Rx for analgesics						first Rx	Rx - Rx ...					last Rx
continuing patients		first Rx						Rx - Rx - Rx ...					last Rx	

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



Original article

Observational evidence that urbanisation and neighbourhood deprivation are associated with escalation in pharmacological pain treatment - a longitudinal population-based study in the Netherlands

Carsten Leue, consultant^{*1}, Servaas Buijs, statistician², Jacqueline Strik, consultant¹, Richel Lousberg, lecturer¹, Jasper Smit, statistician², Maarten van Kleef, professor³, Jim van Os, professor^{1,4}

¹Department of Psychiatry and Psychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical Centre, Maastricht, The Netherlands.

²IMS Health BV, Capelle aan den IJssel, The Netherlands.

³Department of Anaesthesiology, Maastricht University Medical Centre, Maastricht, The Netherlands.

⁴King's College London, King's Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, United Kingdom.

*Correspondence:

C. Leue, Department of Psychiatry and Medical Psychology, Maastricht University Medical Centre, PO BOX 616 (DRT 10), NL 6200 MD Maastricht, The Netherlands. Tel: ++31-43-3877444. Fax: ++31-43-3875444. E-mail: c.leue@mumc.nl

Abstract:

Objective: To examine whether urbanisation and neighbourhood deprivation [are associated with analgesic escalation in](#) chronic pharmacological pain treatment, [and whether escalation is associated with](#) prescription of psychotropic medications.

Design: Longitudinal analysis of a population-based routine [dispensing](#) database in the Netherlands.

Setting: Representative sample of pharmacies, covering 73% of the Dutch nationwide medication consumption in [the](#) primary care and [hospital](#) outpatient [settings](#).

Participants: 449,410 patients aged 15-85 years were included, of whom 166,374 were in the *Starter group* and 283,036 in the *Continuation group* of chronic analgesic treatment.

Main outcome measure: Escalation of analgesics (i.e. change to a higher level of analgesic potency, classified in five levels) in association with urbanisation ([five levels](#)) and dichotomous neighbourhood deprivation, [analysed](#) over a six-month observation period.

Methods: [Ordered logistic multivariate model evaluating analgesic treatment.](#)

Results: In both *Starter* and *Continuation* groups, escalation was positively associated with urbanisation in a [dose](#)-response fashion (Starter group: OR (urbanisation level 1 compared to level 5): 1.24; 95% CI 1.18 to 1.30; Continuation group: OR 1.19; 95% CI 1.14 to 1.23). A weak association was apparent with neighbourhood deprivation (Starter group: OR 1.06; 95% CI 1.02 to 1.11; Continuation group: OR 1.04; 95% CI 1.01 to 1.08). Use of somatic and particularly psychotropic co-medication was associated with escalation in both groups.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion: Escalation of chronic analgesic treatment is associated with urban and deprived environments, and occurs in a context of [adding psychotropic medications](#), suggesting pain outcomes [in part reflect](#) area influences affecting mental health.

For peer review only

Introduction

The validity of the well-known epidemiological association between urban environment and mental health¹⁻³ is supported by work showing that urban living is associated with increased amygdala activity⁴, a key region in the regulation of stress, affective experience and pain^{5,6}.

Pain is the natural comorbid mental experience of somatic conditions^{7,8}. In turn, pain is strongly influenced by comorbid common mental disorders particularly affective disorders⁹¹⁰. Given evidence of urban impact on risk for common mental disorders¹¹, including psychiatric medication prescriptions¹², we hypothesized that pain outcomes, indexed through prescriptions, would be poorer in urban environments and disadvantaged urban neighbourhoods. Pain outcomes were examined at the level of primary care and specialist outpatient care and defined in two ways: (i) escalation of analgesic treatment (i.e. prescription of more potent analgesics) and (ii) co-prescription of psychotropic medication in addition to analgesic treatment.

Objective

We examined the hypothesis that chronic pharmacological pain treatment of hospital outpatients and patients in primary care would show escalation of analgesics in association with the level of urbanisation and neighbourhood index of deprivation. It was predicted that the highest levels of urbanisation and neighbourhood deprivation would be associated with escalation of analgesic treatment to more potent pain medication (e.g. tramadol, morphine, methadone, etc.). Furthermore, we examined the hypothesis that prescriptions of psychotropic medication (e.g. antidepressants, antipsychotics, mood stabilizers, etc.) would

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

be associated with escalation or de-escalation of analgesics in patients prescribed chronic analgesic treatment. Study hypotheses were specified before inspection of the data.

Method

Data collection

The investigation was carried out by analysing records pertaining to Dutch routine general practice and hospital outpatient treatment settings. Data were obtained from the IMS Health's longitudinal prescription database (Lifelink, affiliate Capelle ad IJssel, The Netherlands)¹³. This data source consists of anonymous longitudinal prescription records from a representative sample of pharmacies and dispensing GPs, covering 73% of the Dutch nationwide medication consumption of outpatients and primary care patients. The computerized *medication-dispensing histories* contain data regarding dispensed medications, type of prescriber, dispensing date, dispensed amount of medication, prescribed dosage, and length of prescription. Data for each patient were anonymously and independently sampled without linkage of prescriptions to the same patient across pharmacies, because patients in the Netherlands are usually loyal to a single pharmacy¹⁴.

Furthermore, research from the Dutch Foundation for Pharmaceutical Statistics (SFK) revealed that in the Netherlands, almost all patients make use of a pharmacy located in their area of living. Eighty-two percent of patients are living in a radius of 3 kilometres from their pharmacy¹⁵. Potential bias caused by patients getting hospitalized, moving to another address or dying was minimized by studying chronic pharmacological pain treatment, because there were dispensing records for these patients during the whole study period.

1
2
3
4
5
6
7 *Patient groups*

8
9 Patient selection started with the identification of chronic users of analgesic medication
10 during a six-month prescription period (hereafter: observation period). Chronic use was
11 defined as in receipt of analgesic pharmacotherapy during at least two distinct moments
12 covering an interval of at least two months. In order to track medication for other
13 therapeutic indications (i.e. psychotropic medication and pharmaco-treatment for somatic
14 disorders), patients were observed for a period of six months prior to initiation of analgesic
15 treatment. Next, the cohort with chronic use of analgesics was divided into two groups.
16
17

18
19 *Starters* were defined as patients who had not received any analgesics during the six-month
20 period prior to the observation period (hereafter: *Starter group*). Patients who *continued*
21 with pain medication that was already prescribed in the six month before the observation
22 period formed the second group (hereafter: *Continuation group*). The latter group consisted
23 of all patients who had already received analgesics in the first month of the six-month period
24 prior to the observation period, in order to define chronic analgesic treatment before
25 observation. All data captured a calendar period from May 2008 to September 2009 (Figure
26 1).
27
28
29
30
31
32
33
34
35
36
37
38
39

40
41 **Figure 1: Starter group and Continuation Group of chronic analgesic treatment**

42
43
44
45 Insert Figure 1
46
47
48
49

50 Legend: Schedule of prescriptions (Rx) in Starter group (top) and Continuation group (bottom) of
51 chronic analgesic treatment covering a 12 month period. Months 7 to 12 are the observation period;
52 months 1 to 6 are the pre-observation period.
53
54
55

1
2
3
4
5
6
7 Data were obtained from the LRx database from month one to twelve as depicted in
8
9 Figure 1.. Use of other medications (e.g. psychotropic medication and medication for a broad
10
11 spectrum of somatic conditions) was collected for all patients as well, covering the period of
12
13 twelve months, consisting of (i) the pre-observation period (month one to six) and (ii) the
14
15 observation period (month seven to twelve)).
16
17
18
19

20 *Escalation of pharmacological pain treatment*

21
22
23 All individual prescriptions of analgesics were observed for each patient in both the Starter
24
25 and Continuation groups during the observation period and during the six months prior to
26
27 the observation period. At each dispensing date, analgesics were classified *a priori* in five
28
29 levels, in order of analgesic potency (Figure 2). Five escalation levels were provided, based
30
31 on a minor adaptation of the 3-step WHO-analgesic ladder¹⁶. Levels 5 and 4 are identical to
32
33 WHO steps 3 (strong opioids) and 2 (weak opioids), respectively. WHO step 1 (non-opioid
34
35 analgesics) was refined, in order to enable further and clinically relevant differentiation
36
37 between non-opioid analgesics (level 1: paracetamol, level 2: prostaglandin inhibitors, level
38
39 3: anticonvulsants)¹⁶⁻²⁰. Furthermore, anti-epileptics were divided in anticonvulsants
40
41 predominantly prescribed in pain conditions (level 3a: gabapentin and pregabalin) and
42
43 anticonvulsants with best evidence for epilepsy treatment (level 3b: carbamazepine, valproic
44
45 acid, lamotrigine)¹⁹⁻²¹. In order to avoid prescription for indications of mood stabilisation or
46
47 epilepsy, the latter group was classified at level 3b only if prescribed in combination with
48
49 analgesic medication at level 1 or 2 (i.e. pain indication) (Figure 2).
50
51

52
53 **Figure 2: 5 levels of analgesic potency, modified from the WHO-analgesic ladder¹⁶**
54

1
2
3
4
5
6
7 Insert Figure 2
8
9

10 Legend:

11 Level 1 (i.e. lowest potency) to level 5 (i.e. highest potency)

- 12 (a) Gabapentine, pregabalin **in the absence of** other anti-epileptic drugs
13 (b) Carbamazepine, valproic acid, lamotrigine **in combination with** medication **at** level 1 or 2
14 (c) Tramadol, codeine
15 (d) Methadone, oxycodone, hydromorphone, morphine, buprenorphine, fentanyl, sufentanil,
16 pethidine
17

18
19
20 Confirmation of escalation was based on the comparison of analgesic potency at the first
21 dispensing day and **the last dispensing day within the observation period.**
22
23

24
25 The comparison of first and last prescription of analgesics resulted in the following
26 categories of analgesic escalation: neutral (i.e. no change of analgesic potency), escalation in
27 analgesic treatment (i.e. change to a higher level of analgesic potency), or de-escalation in
28 pharmacological pain treatment (i.e. change to a lower analgesic potency) (Table 1).
29
30
31

32
33 If patients received several analgesics on the same day, both the highest and the
34 second highest level of analgesic potency were included in the analyses, in order to define
35 escalation categories (e.g. a change from level 5 plus level 2 to level 5 plus level 3 indicating
36 that escalation had occurred).
37
38
39
40
41
42
43
44

45 *Determinants of escalation in analgesic treatment*

46

47
48 Three groups of variables hypothesized to act as mediators or confounders were included in
49 the analyses. The first group were patient characteristics such as sex (0=men, 1=women),
50 age (in years) and the location of patient's pharmacy (defined by postal code). The latter
51 variable defined the level of urbanisation following the definition of the Dutch Central
52
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Bureau of Statistics (CBS). Urbanisation is defined by CBS as the number of addresses relative to area surface, conform previous work with this variable in epidemiological studies²². Level 1 (i.e. highest level of urbanisation) consists of more than 2500 addresses per square-kilometre (km²); [level 2 = 1500 to 2500 addresses/km², level 3 = 1000 to 1500 addresses/km², level 4 = 500 to 1000 addresses/km²]. Level 5 (i.e. rural environment) consists of less than 500 addresses/km²; described in more detail elsewhere²³.

Neighbourhood deprivation was defined dichotomously (0=no, 1=yes). The dichotomous measure of neighbourhood deprivation was developed by the Netherlands Institute of Research in Healthcare (NIVEL), using socio-economic indicators such as unemployment rate, average income, population density and ethnic variation. On the basis of empirical research in the Netherlands, NIVEL 's neighbourhood deprivation index (NDI) is calculated as follows:

$$\text{NDI} = ((\ln \text{percentage unemployed people} - 3.0236)/0.37706) - ((\ln \text{average income} - 2.8641)/0.14441) + ((\ln \text{population density} - 7.0132)/1.06699) + ((\ln \text{percentage people of "non-western" ethnicity})/1.11147).$$

NDIs were expressed continuously by NIVEL from low to high. Furthermore, NIVEL defined a dichotomous measure of deprivation at a cut-off of 5.5% (i.e. 885.000 people), in order to assess trends in the proportion of the Dutch population inhabiting an area with the highest NDI and for use in epidemiological research²⁴.

Healthcare professionals receive higher levels of funding for their services in these deprived areas²⁵. Neighbourhood deprivation was associated with level of urbanization: 86% of the sample living in deprived neighbourhoods lived in an area with the highest level of urbanisation. Moreover, the other patients (14%) living in deprived neighbourhoods lived in an area with the second highest level of urbanisation. The majority (76%) of those living in an area of the highest level of urbanisation did not live in a deprived neighbourhood (Table 1).

Table 1: Sample, stratified by Urbanisation and Neighbourhood Deprivation

type of patient	Urbanisation	Deprived Neighbourhood		% within Deprived Nbh	% within Urbanisation
		No	Yes		
Starter group	1	34662	10796	86,5%	23,7%
	2	48673	1689	13,5%	3,4%
	3	31107		-	-
	4	28283		-	-
	5	11164		-	-
	total	153889	12485	100,0%	7,5%
Continuation group	1	59714	18644	85,5%	23,8%
	2	81406	3155	14,5%	3,7%
	3	50852		-	-
	4	48511		-	-
	5	20754		-	-
	total	261237	21799	100,0%	7,7%

Legend: The sample is described in absolute numbers for the Starter and the Continuation group, stratified by living in an urbanised area (level 1 to 5), and a dichotomous measure of neighbourhood deprivation. Furthermore, in the last two columns, tabulations are presented for living in a deprived neighbourhood as a function of level of urbanization (e.g. 86.5% of the sample living in deprived neighbourhoods lived in an area with urbanisation level 1/Starter group) and for level of urbanisation as a function of living in a deprived neighbourhood (e.g. a minority (23.8%) of those living in an area pertaining to urbanisation level 1 lived in a deprived neighbourhood/Continuation group).

Furthermore, psychotropic co-medication was classified into its different classes, and somatic co-medication was similarly grouped in 10 classes (ACE inhibitors, angiotensine II inhibitors; antidiabetics; beta-blockers; calcium antagonists; functional bowel drugs; laxatives; migraine medication; respiratory medication; steroid-antiphlogistics; stomach protectors) (Table 1 to 3). In the Starting group, occurrence of co-medication was time-coded at three levels according to the day of first occurrence (i.e. co-medication prescription before start with analgesics, at the same day or after start of analgesic treatment) (Table 2). In the Continuation group, occurrence of co-medication was recorded dichotomously (presence/absence), since it was impossible to distinguish occurrence of co-medication as before or at start of analgesic treatment (Table 3).

Statistical analysis

First, we analysed the pattern of (de-) escalation in analgesic treatment by means of an

1
2
3
4
5
6
7 ordered logistic multivariable regression model with adjusted odds ratios (and 95%
8 confidence interval) using SAS version 9²⁶. Statistical significance for the model was defined
9 at conventional alpha of 0.05. The dependent variable in this model was the development of
10 a patient's analgesic treatment (de-escalation, neutral, escalation). Independent variables,
11 entered simultaneously in the model, were demographic characteristics, neighbourhood
12 deprivation, and urbanisation, use of psychotropic medication and use of somatic
13 medication. In the Starting group, we also included first occurrence of co-medication. The
14 modeling strategy was to build, first, a fully saturated model (including all variables), in order
15 to avoid missing relevant information by leaving out non-significant variables. Second,
16 backward elimination was carried out to find the best model fit.

17
18
19
20
21
22
23
24
25
26
27
28 Models for Starter and Continuation groups were run separately, given different sample
29 selection criteria. The ordered logistic multivariable regression model was chosen above the
30 multinomial model, as the latter does not consider the natural order in our data regarding
31 development of chronic pain treatment, ranging from de-escalation to neutral to escalation.

32
33
34
35
36 Proportional odds were assumed in the models of escalation and de-escalation of analgesic
37 treatment, and analyses inspected for violation of this assumption. Test on the proportional
38 odds assumption showed significance, which gave us the confidence to use the ordered
39 logistic model. If a determinant was positively associated with escalation of analgesics,
40 absence of this variable was associated negatively with escalation or positively with de-
41 escalation in analgesic treatment (and vice versa). This offered advantage compared to
42 separate models for escalation and de-escalation (such as consistency of model estimates)
43 and avoided double use of patients with a neutral development of analgesic treatment.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Overall, 449,410 patients were included, of which 166,374 were in the Starter group and 283,036 in the Continuation group. The baseline characteristics of both groups are shown in table 2.

Table 2: Baseline characteristics of the patient population with chronic analgesic treatment

		Starter group			Continuation Group		
		Deprived	Urbanicity ¹	Urbanicity	Deprived	Urbanicity	Urbanicity
		nb.hoods	1	2-5	nb. hoods	1	2-5
Patients	(Absolute)	12,485	45,458	120,916	21,799	78,358	204,678
Change in	Analgesics ²						
	De-escalation	13.3%	12.1%	10.4%	13.2%	12.5%	11.2%
	Neutral	70.1%	71.6%	74.5%	70.0%	71.4%	73.7%
	Escalation	16.5%	16.3%	15.1%	16.8%	16.1%	15.1%
Gender	Male	39.8%	39.3%	40.3%	36.7%	35.2%	34.6%
	Female	60.2%	60.7%	59.7%	63.3%	64.8%	65.4%
Age (years)	15-25	6.3%	6.1%	6.5%	1.8%	1.6%	1.8%
	26-40	23.8%	19.2%	16.3%	14.0%	10.8%	9.7%
	41-65	50.0%	49.6%	50.9%	56.9%	53.4%	51.8%
	65-85	19.8%	25.2%	26.2%	27.3%	34.2%	36.7%
First	Analgesics						
	Level 1	3.2%	3.9%	4.0%	3.0%	3.8%	4.1%
	Level 2	64.8%	66.6%	72.6%	47.8%	47.1%	53.6%
	Level 3	2.2%	2.5%	2.6%	6.4%	8.1%	8.9%
	Level 4	27.4%	24.2%	18.3%	36.1%	33.9%	27.6%
	Level 5	2.4%	2.9%	2.6%	6.8%	7.2%	5.9%
	level 4/5	29.8%	27.0%	20.8%	42.8%	41.1%	33.5%
Last	Analgesics						
	Level 1	3.4%	3.9%	4.0%	3.4%	4.1%	4.3%
	Level 2	61.9%	63.0%	68.4%	44.5%	44.1%	50.1%
	Level 3	3.0%	3.3%	3.4%	7.0%	8.4%	9.2%
	Level 4	27.6%	24.6%	18.9%	36.8%	34.5%	28.4%
	Level 5	4.1%	5.2%	5.3%	8.3%	9.0%	7.9%
	Level 4/5	31.7%	29.8%	24.2%	45.1%	43.4%	36.3%
Concomitant	Medication ³						
	Any concomitant drug	78.8%	79.0%	77.3%	89.3%	89.6%	88.0%
	Migraine medication	3.9%	3.6%	3.8%	5.9%	5.2%	5.1%
	Any psychotropic medication	35.1%	36.6%	34.8%	51.6%	53.2%	50.2%
	TCA	5.2%	5.0%	5.0%	9.5%	9.4%	9.6%
	Other AD	2.4%	2.0%	1.6%	4.0%	3.3%	2.7%
	Antipsychotics total	4.1%	3.9%	3.1%	6.7%	6.1%	4.9%
	Antipsychotics atypical	2.4%	2.2%	1.5%	4.1%	3.5%	2.5%
	Antipsychotics classic	2.0%	2.1%	1.8%	3.2%	3.2%	2.7%
	Burpropion	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%
	MAO inhibitors	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%
	Mood stabilizers	0.2%	0.3%	0.2%	0.3%	0.4%	0.4%
	Sedatives	27.0%	29.0%	27.4%	41.5%	43.4%	40.6%
	SNRI	2.6%	2.4%	2.2%	4.5%	4.0%	3.5%
	SSRI	7.5%	7.0%	6.4%	10.3%	10.0%	9.0%
	Psycho-stimulants	0.4%	0.5%	0.5%	0.3%	0.5%	0.4%
	Any somatic medication	72.3%	72.6%	71.0%	83.0%	82.9%	81.7%
	Cardiovascular medication ⁴	30.9%	31.4%	30.8%	35.2%	34.9%	34.9%
	Other Somatic medication ⁵	65.2%	65.5%	64.0%	76.9%	76.7%	75.4%

Legend: Patient characteristics are presented as percentages (e.g. age, gender, level of analgesic treatment, change in analgesic treatment (e.g. escalation, de-escalation, and neutral development of prescriptions), and concomitant medication). Absolute patient numbers are presented for the Starter and the Continuation group of chronic analgesic treatment concerning level of urbanicity and for neighbourhood deprivation.

- (1) Urbanicity = Urbanisation (level 1 = highest level of urbanisation; level 5 = rural environment)
- (2) Change in pain medication from first to last prescription (neutral = no change in level of potency, escalation = change to a higher level of analgesic potency, de-escalation = change to lower analgesic potency)
- (3) Concomitant drug use, observed during a period of 12 month
- (4) Cardiovascular medication: beta-blocker, calcium antagonist, ACE inhibitor, angiotensine II inhibitor
- (5) Gastro-intestinal medication: anti-diabetics, steroid-antiphogistics, respiratory medication

About 7.6% of all escalating patients were residing in a deprived neighbourhood, and approximately 27.6% were living in [an area of the highest level of urbanisation \(level 1\)](#) (Table 2). The majority [were](#) female, and there were more patients showing escalation (15.4%) than de-escalation (11.3%) of analgesic treatment. The majority of patients continued a neutral analgesic treatment regime (73.3%) (Table 2). Most of the patients were treated at level 2 or level 4 of analgesic potency. Almost all patients were using other medications, regardless of the different categories in table 1 (84.5%). Around half were using psychotropic medication (45.2%), most were using somatic co-medication (78.1%), and more than a third were using both (38.8%) (Table 2).

The Starter group mainly initiated an analgesic at level 2 (70.9%) and level 4 (19.9), whereas only 2.6% directly initiated at level 5. However, analgesic potency level 4 and 5 increased up to 20.5% respectively 5.2% by the time of the last prescription in the Starter group (Table 2).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In the Continuation group, patients already received analgesics at a higher level of potency at inclusion compared to the last observed level of medication potency in the Starter group. Level 4 and 5 was observed in 35.6% at the start of the observation period, increasing to 38.3% at the end of observation period (Table 2).

Escalation of analgesic treatment was observed more often in deprived neighbourhoods and in areas of the highest levels of urbanisation (16.8% and 16.1% in the Continuation group, respectively 16.5% and 16.3% in the Starting group) compared to rural areas (15.1%) and non-deprived neighbourhoods (15.3%) (Table 2). The proportion of patients with neutral development of analgesic treatment was lower in deprived neighbourhoods and areas with the highest degree of urbanisation compared to less densely populated areas (Table 2).

In the Starter group, escalation was positively associated with lower level of first observed pain medication (highest adjusted Odds Ratio (OR) 58.23 at analgesic level 1; 95% Confidence Interval (CI) 53.60 to 63.27; lowest OR 1.36 at analgesic level 4; 95% CI 1.27 to 1.45; compared to reference level 5) (Table 3). Escalation was furthermore associated, in a dose-response fashion, with level of urbanisation (highest adjusted OR 1.24 at urbanisation level 1; 95% CI 1.18 to 1.30; compared to reference level 5) (Table 3). Furthermore, a weak but independent association existed between escalation and neighbourhood deprivation (OR 1.06; 95% CI 1.02 to 1.11) (Table 3). Use of tricyclic antidepressants (TCA), mood stabilizers (OR 1.36; 95% CI 1.07 to 1.42), sedatives, cardiovascular medication (OR 1.16; 95% CI 1.13 to 1.19) and medications for other somatic conditions was associated with analgesics escalation, when prescribed *before* start of analgesics (Table 3). Similarly, in the Starter group, escalation of analgesic treatment was also associated with the use of selective

1
2
3
4
5
6
7 noradrenalin serotonin reuptake inhibitors (SNRI), sedatives (OR 1.82; 95% CI 1.74 to 1.89),
8
9 TCA (OR 2.19; 95% CI 2.03 to 2.36), and antipsychotics (OR 2.43; 95% CI 2.19 to 2.68) when
10
11 prescribed *after* start of analgesics (Table 3). Negative associations with escalation (i.e.
12
13 positive association with de-escalation) were apparent for younger age, female sex, and
14
15 pharmacological migraine treatment. Furthermore, use of antipsychotics was negatively
16
17 associated with escalation if started *simultaneously* with analgesic treatment (OR 0.70; 95%
18
19 CI 0.58 to 0.84) (Table 3).

20
21
22 The use of selective serotonin reuptake inhibitors (SSRI), before, at or after start of
23
24 analgesic treatment was not associated with escalation of analgesics in the Starter group
25
26 (Table 3).

27
28 In the Starter group, the original fully saturated model and the model after backward
29
30 elimination revealed the same variables associated significantly with escalation in chronic
31
32 pharmacological pain treatment (Table 3).

33
34
35 **Table 3: Associations with escalation in pharmacological pain treatment for the Starter**
36
37 **Group of chronic analgesic treatment**

Exposure		Adj. Odds Ratio	95% CI ¹	
			Lower	Upper
Analgesics ²	Level 1	58.23	53.60	63.27
	Level 2	17.92	16.75	19.16
	Level 3	4.66	4.23	5.14
	Level 4	1.36	1.27	1.45
	Level 5	Reference	-	-
Gender	Female	0.97	0.95	0.99
	Male	Reference	0.00	0.00
Age (years)	15-25	0.73	0.69	0.77
	26-40	0.81	0.78	0.84
	41-65	0.87	0.85	0.90
	66-85	Reference	-	-
Urbanization ³	1	1.24	1.18	1.30
	2	1.16	1.11	1.22
	3	1.11	1.06	1.17
	4	1.07	1.02	1.13
	5	Reference	-	-
Deprived	Yes	1.07	1.02	1.11
Neighbourhood	No	Reference	-	-
SNRI	⁴ Before start of analgesics	1.05	0.96	1.14
	Same start date	1.28	0.97	1.69
	After analgesics started	1.26	1.09	1.45
	None	Reference	-	-
SSRI	Before start of analgesics	0.97	0.92	1.02
	Same start date	0.97	0.83	1.15
	After analgesics started	1.07	0.97	1.18
	None	Reference	-	-
TCA	Before start of analgesics	1.23	1.15	1.32
	Same start date	1.32	1.12	1.54
	After analgesics started	2.19	2.03	2.36
	None	Reference	-	-
Other AD	Before start of analgesics	1.03	0.93	1.15
	Same start date	0.93	0.71	1.21
	After analgesics started	1.22	1.06	1.42
	None	Reference	-	-
Antipsychotics	Before start of analgesics	0.92	0.85	1.01
	Same start date	0.69	0.58	0.83
	After analgesics started	2.42	2.18	2.67
	None	Reference	-	-
Mood stabilizers	Before start of analgesics	1.40	1.10	1.79
	Same start date	0.91	0.43	1.89
	After analgesics started	0.71	0.39	1.31
	None	Reference	-	-
Sedatives	Before start of analgesics	1.24	1.20	1.28
	Same start date	1.25	1.18	1.33
	After analgesics started	1.82	1.74	1.89
	None	Reference	-	-
Cardio-Vascular drugs	Before start of analgesics	1.16	1.13	1.19
	Same start date	0.86	0.79	0.95
	After analgesics started	1.35	1.26	1.45
	None	Reference	-	-
Other Somatic drugs	Before start of analgesics	1.25	1.22	1.29
	Same start date	1.11	1.07	1.15
	After analgesics started	1.19	1.15	1.23
	None	Reference	-	-
Migraine medication	Before start of analgesics	0.83	0.77	0.89
	Same start date	0.95	0.78	1.17
	After analgesics started	0.91	0.81	1.02
	None	Reference	-	-

Legend:

- (1) 95% CI: confidence interval
- (2) Escalation = change to a higher level of analgesic potency, level 5 = highest level
- (3) 1 = highest level of urbanisation, 5 = rural environment
- (4) Starting date of medication (before, at the same day or after start of analgesics)

In the Continuation group, escalation of analgesics was positively associated with

lowest levels of first observed analgesics (highest adjusted OR 16.00 at analgesic level 1; 95% CI 15.20 to 16.85; lowest OR 1.55 at analgesic level 4; 95% CI 1.50 to 1.61; compared to reference level 5) (Table 4). Furthermore, escalation was associated with level of urbanisation in a dose response fashion (highest adjusted OR 1.19 at level 1; 95% CI 1.14 to 1.23; compared to reference level 5) (Table 4). There was also an association between escalation and deprived neighbourhoods, use of SSRI, SNRI, TCA, all antipsychotics, and sedatives (OR 1.31; 95% CI 1.29 to 1.33) as well as use of somatic co-medication (OR 1.12; 95% CI 1.10 to 1.14) (Table 4). De-escalation was associated with female sex, younger age, treatment of migraine, and use of second-generation antipsychotics (OR 0.80; 95% CI 0.70 to 0.91) (Table 4).

The saturated model showed that 22 out of 29 variables had significant associations. All these variables remained significant in the backward elimination approach. One additional variable displayed a significant association after backward elimination: 'TCA high dosage'. The OR's did not (16 variables), or only minimally (6 variables) differ between the fully saturated model and the backward elimination model. The only variable showing a degree of difference was 'TCA total' (fully saturated model: OR = 1.19 (CI: 1.06 – 1.32); backward elimination model: OR = 1.33 (CI: 1.29 – 1.36)) (Table 4).

Table 4: Associations with escalation in pharmacological pain treatment for the Continuation Group of chronic analgesic treatment

Exposure		Adjusted Odds Ratio	95% CI ¹	
			Lower	Upper
Analgesics ²	Level 1	16.00	15.20	16.85
	Level 2	7.87	7.59	8.16
	Level 3	3.14	3.00	3.28
	Level 4	1.55	1.50	1.61
	Level 5	Reference	-	-
Gender	Female	0.96	0.94	0.98
	Male	Reference	-	-
Age (years)	15-25	0.91	0.85	0.97
	26-40	0.98	0.95	1.01
	41-65	0.99	0.97	1.01
	66-85	Reference	-	-
Urbanization ³	1	1.18	1.14	1.23
	2	1.14	1.10	1.17
	3	1.08	1.04	1.12
	4	1.05	1.01	1.09
	5	Reference	-	-
Deprived Neighbourhood	Yes	1.04	1.01	1.08
	No	Reference	-	-
SNRI		1.19	1.02	1.40
SSRI		1.03	1.004	1.07
TCA ⁴		1.19	1.06	1.32
Other AD		1.08	1.03	1.14
Antipsychotics	Total	1.24	1.08	1.43
	1 st generation	1.01	0.88	1.15
	2 nd generation	0.80	0.70	0.91
Mood stabilizers		0.97	0.85	1.10
Sedatives		1.31	1.29	1.34
Migraine		0.95	0.91	0.99
Cardio Vascular Drugs		1.12	1.10	1.14
Other Somatic Drug classes		1.12	1.10	1.14

Legend:

(1) 95% CI: confidence interval

(2) Escalation = change to a higher level of analgesic potency, level 5 = highest level

(3) 1 = highest level of urbanisation, 5 = rural environment

(4) TCA total (fully saturated model: OR = 1.19 (CI: 1.06 – 1.32); BWE model: OR = 1.33 (CI: 1.29 – 1.36))

Over time, the escalation process continues even after the first 6 months of chronic analgesic treatment. In the Starter group, opioid-analgesics (level 4/5) were dispensed in 29.8% of patients living in a deprived neighbourhood. In contrast, 42.8% of patients in deprived neighbourhoods used opioids in the Continuation group, after one year of prescription. A similar, but attenuated development was seen at urbanisation level 1 and level 2 to 5 (Table 2).

Discussion

Escalation of chronic analgesic treatment was observed more often in urban areas and deprived neighbourhoods within urban areas, suggesting pain outcomes either are associated with individual characteristics that are more prevalent in urban and deprived areas, or subject to contextual influences, like area-level stress or social fragmentation, regardless of individual level characteristics. One individual level variable that may explain part of the association with urbanicity and deprivation is socio-economic status^{27 28}, which was not available for inclusion in the model. Nevertheless, the fact that the association with urbanicity remained with deprivation adjusted for in the same model, suggests that urban effects may not be reducible entirely to individual-level socio-economic status. However, the findings could also be attributed to reverse causation, i.e. patients with worsening pain may move into more urban and deprived neighbourhoods as a consequence of being disabled due to ill health. Although unlikely to entirely explain the current findings, it cannot be excluded.

Regardless of the underlying mechanism, results clearly echo findings of unconfounded higher rates of poor mental health in areas of higher levels of urbanisation and greater neighbourhood deprivation^{11 29}, and suggest that the outcome of mental disorder comorbidity associated with somatic disorders shows similar predictable variation. Functional pain syndromes and psychiatric disorders show high levels of interdependency³⁰⁻³⁵, and psychiatric conditions enhance severity of somatic symptoms³⁶. Thus, part of the mechanism underlying the association between pharmacological pain escalation and urban environment may be explained by urbanisation increasing the risk for mental ill health. This hypothesis is supported by the findings, as in both the Starter and the Continuation groups, escalation of chronic analgesic treatment was associated not only with urban environment

1
2
3
4
5
6
7 and neighbourhood deprivation, but also with prescription of various psychotropic
8
9 medications prescribed in association. In general, the positive association of escalating
10
11 analgesic treatment with psychotropic medication was as strong or even stronger than the
12
13 association with prescribed somatic co-medication, with the exception of the observed de-
14
15 escalating effect, in the Continuation group, of second-generation antipsychotics, which
16
17 possess powerful analgesic properties^{37,38}. This is accordance with the literature, given the
18
19 fact that psychiatric conditions can enhance symptom severity in somatic patients³⁶, which
20
21 sometimes may impact even more that the somatic condition itself³⁹.

22
23
24 Although the absolute difference between analgesic escalation in the urban vs. less
25
26 urban environment was small, this difference may be relevant from a public health
27
28 perspective, given the high rate of painful conditions in the general population.

29
30 Furthermore, prevention of persistent pain states is relevant with regard to costs⁴⁰. A more
31
32 effective treatment of persistent pain, including treatment of psychiatric comorbidity, may
33
34 have a cost-saving effect. Targeting populations with painful conditions for early recognition
35
36 and treatment of mental health problems may not only be cost-effective from a public
37
38 health perspective, but also represent an area of considerable unmet clinical need, since
39
40 opioid escalation is a frequent inflationary development in the treatment of painful
41
42 conditions^{41,42}. Moreover, broadening the pain agenda to a better understanding of
43
44 associated mental health problems could minimize failed surgery outcomes, for example in
45
46 patients with undetected mental disorders. For instance, new surgical procedures were
47
48 found to be more common in chronic back pain (CBP) patients *with* Post-traumatic Stress
49
50 Disorder compared to CBP patients without⁴³. Similarly, depression was demonstrated in
51
52 47.4 % of patients with low back pain who had no surgery, in 50% of those with one surgical
53
54 procedure, and in 62.5 % of those who had undergone surgery more than once⁴⁴. Influencing

1
2
3
4
5
6
7 central pain sensitization by [providing](#) adequate antidepressant treatment in depressive
8 conditions may help [prevent](#) surgical [escalation](#).
9

10
11 [Odds ratios for escalation of analgesics in relation to original level of analgesics may](#)
12 [represent ceiling effects in both starter and continuation groups - patients already at level 5](#)
13 [have nowhere stronger to go; treatment of patients at level 1 at baseline can escalate to](#)
14 [stronger medication. Ceiling effects may reflect the pattern of prescribing analgesics in](#)
15 [general practice. Given these, it has been suggested that the WHO analgesic ladder is in](#)
16 [need of updating](#)⁴⁵. For example, Vargas-Schaffer is broadening the ladder with a 4th surgical
17 [step; in the current article, however, we guide attention to treatment aspects related to](#)
18 [underestimated mental disorder comorbidity in persistent pain states.](#)
19
20
21
22
23
24
25
26
27

28 The ~~speculative~~ question remains to what degree escalation of analgesic treatment
29 and its association with psychotropic medication reflects therapeutic [paradigms](#) to remedy
30 pain, treatment of psychiatric comorbidity, or a cause of psychopathology. In the Starter
31 and the Continuation group of chronic analgesic treatment, escalation of analgesics was
32 consistently and positively associated with the use of TCA. This prescription habit may reflect
33 routine [off-label](#) paradigms in the pharmacological treatment of pain syndromes^{10 46-48}.
34 However, given the evidence regarding TCA's efficacy in pain conditions, negative rather
35 than positive associations with escalation of analgesics should have been expected. More
36 likely, since the association with TCAs was as strong as the association of sedatives with
37 analgesic escalation, it may be a reflection of affective or addictive comorbidity in persistent
38 pain, for instance in vulnerable cases of opiate-induced sensitization, tolerance and
39 hyperalgesia⁴⁹⁻⁵⁵. [Our data indicate that escalation may represent an ongoing process after](#)
40 [even months of treatment, which occurs not exclusively in the context of environmental](#)
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1
2
3
4
5
6
7 deprivation. Escalation may also be driven to a degree by patient factors such as opioid
8 tolerance, opioid-induced hyperalgesia⁵², or disease progression.

9
10
11 Given the literature on this topic^{46-50 56}, negative associations of particularly
12 antidepressants with escalation of chronic analgesic treatment would have been expected.
13 Nevertheless, negative associations between escalation of chronic analgesic treatment were
14 also found, for example with migraine treatment (Tables 3 and 4). Moreover, the use of
15 antipsychotics was negatively associated with analgesic escalation in the Starter group - if
16 prescribed after start of analgesic treatment. In the Continuation group, de-escalation was
17 specifically associated with the use of second-generation antipsychotics. This outcome is
18 interesting and deserves further investigation, given that limited evidence for the efficacy of
19 antipsychotics in pain conditions already exists^{37 38}.

20
21
22
23
24
25
26
27
28
29
30
31 The results of the current study should be seen in the light of several limitations. The
32 use of routine data rather than a targeted data collection could have caused more random
33 error resulting in type II error. Unidentified confounding may have played a role, as
34 randomization was not possible and pre-post designs are sensitive to effects of unmeasured
35 changes affecting outcome measures over time. Another limitation is the lack of outcomes
36 other than urbanization, psychotropic medication or somatic co-medication. For instance,
37 there were no estimates regarding care consumption or illness-related sick leave. Changes in
38 patient-related outcomes like illness severity, global functioning, quality of life and
39 treatment satisfaction should also form part of prospective evaluations. The type of data
40 used is subject to the possibility of ecological fallacy: people whose pharmacy is in a
41 deprived or urban neighbourhood do not necessarily experience that level of deprivation or
42 urbanicity. Furthermore, this study only collected data over a twelve-month period. Affect

1
2
3
4
5
6
7 and pain monitoring deserves longer evaluation. Finally, due to the study design,
8
9 associations do not allow for causal inference.

10 11 WHAT IS ALREADY KNOWN ON THIS TOPIC

12
13
14 Numerous observational studies have observed higher rates of poor mental health in
15
16 urban and deprived neighbourhood environments.
17

18
19
20 Pain syndromes and [mental](#) disorders show high levels of interdependency, and
21
22 [mental disorders are known to](#) enhance severity of somatic symptoms.
23
24

25 26 WHAT THIS STUDY ADDS

27
28
29 Escalation of chronic analgesic treatment in persistent pain [states](#) is associated with
30
31 urban environments and deprived neighbourhoods, and occurs in a context of
32
33 increased levels of psychotropic medication [prescribing](#), suggesting persistent pain
34
35 outcomes are associated with area influences affecting mental health.
36
37

38
39 *Contributors:* CL, SB and JvO were principal investigators of the study. SB analysed the data
40
41 in collaboration with CL, JvO, and JS. CL and JvO drafted the paper. All authors contributed to
42
43 subsequent drafts of the paper, including the final version. JvO is guarantor.
44
45

46
47 *External funding:* Eli Lilly provided funding to IMS Health for data analysis. External funding
48
49 did not support any other aspect of the study. All authors contributed independently from
50
51 funders to this study; and all authors had full access to and can take responsibility for the
52
53 data and analyses.
54

1
2
3
4
5
6
7 *Competing interests:* All authors have completed the Unified Competing Interest form at
8 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
9 declare: no support from any organisation for the submitted work, with the exception of
10 above-mentioned funding to IMS Health for data analysis; no financial relationships with any
11 organisation that might have an interest in the submitted work; and no other relationships
12 or activities that could appear to have influenced the submitted work.
13
14
15
16
17

18
19 *License for publication:* All authors grant an exclusive license (or non exclusive for
20 government employees) on a worldwide basis to the BMJ Publishing Group LTD and its
21 licensees, to permit this article (if accepted) to be published in BMJ editions and any other
22 BMJPG products and to exploit all subsidiary rights, as set out on:
23
24
25
26 <http://resources.bmj.com/bmj/authors/checklists-forms/license-for-publication>.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Lofors J, Sundquist K. Low-linking social capital as a predictor of mental disorders: a cohort study of 4.5 million Swedes. *Social science & medicine* 2007;64(1):21-34.
2. Thomas H, Weaver N, Patterson J, et al. Mental health and quality of residential environment. *Br J Psychiatry* 2007;191:500-5.
3. Ivory VC CS, Blakely T, Dew K. When does neighbourhood matter? Multilevel relationships between neighbourhood social fragmentation and mental health. *Social science & medicine* 2011;72:1993-2002.
4. Lederbogen F, Kirsch P, Haddad L, et al. City living and urban upbringing affect neural stress processing in humans. *Nature* 2011;474(7352):498-501.
5. Hubbard CS Labus JS, Bueller J, et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. *J Neurosci* 2011;31(35):12491-500.
6. Murrough JW, Huang Y, Hu J, et al. Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. *Biol Psychiatry* 2011(Aug 17):[Epub ahead of print].
7. Smith HS HR, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. *Pain Physician* 2011;14(2):E217-45.
8. Price DD CJ, Zhou Q, Verne GN, et al. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models and neuroimaging. *Neuroimage* 2009;47(3):995-1001.
9. Wise TN, Fishbain DA, Holder-Perkins V. Painful physical symptoms in depression: a clinical challenge. *Pain medicine* 2007;8 Suppl 2:S75-82.
10. Goldenberg DL. Pain/Depression dyad: a key to a better understanding and treatment of functional somatic syndromes. *Am J Med* 2010;123(8):675-82.
11. [Peen J, Schoevers RA, Beekman AT, et al. The current status of urban-rural differences in psychiatric disorders. *Acta Psychiatr Scand* 2010;121\(2\):84-93.](#)
12. Crump C, Sundquist K, Sundquist J, et al. Neighborhood deprivation and psychiatric medication prescription: a Swedish national multilevel study. *Ann Epidemiol*;21(4):231-7.
13. Netelenbos JC, Geusens PP, Ypma G, et al. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands. *Osteoporos Int*;22(5):1537-46.
14. Buurma H, Bouvy ML, De Smet PA, et al. Prevalence and determinants of pharmacy shopping behaviour. *J Clin Pharm Ther* 2008;33(1):17-23.
15. <http://www.sfk.nl/nieuws-publicaties/PW/2003/2003-15.htm>.
16. [World Health Organization. *Traitement de la douleur cancéreuse*. Geneva, Switzerland: World Health Organization; 1987.](#)
17. [Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for acute and chronic pain in adults. *Cochrane Database Sys Rev* 2011;\(1\):CD005451.](#)
18. [Wiffen PJ, Derry S, Moore RA, et al. Lamotrigine for acute and chronic pain. *Cochrane Database Sys Rev* 2011;\(2\):CD006044.](#)
19. [Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. *Cochrane Database Sys Rev* 2011;\(3\):CD007938.](#)
20. [Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. *Cochrane Database Sys Rev* 2009;\(3\):CD007076.](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. *Lancet Neurol* 2011;10(5):446-56.
22. Van Os J, Hanssen M, Bijl RV, et al. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. *Arch Gen Psychiatry* Jul 2001;58:663-668.
23. Central Bureau of Statistics. Bevolking der gemeenten van Nederland. *The Hague, The Netherlands: CBS Publications* 1993.
24. Wieggers TA DW. Herijking stedelijke achterstandsgebieden. *Utrecht, The Netherlands: NIVEL publications* 2008.
25. Nza, tariefbeschikking 5000-1900-09-3, 30 juni 2009. <http://www.naz.nl/>.
26. <http://www.sas.com/>.
27. Drukker M, van Os J. Mediators of neighbourhood socioeconomic deprivation and quality of life. *Soc Psychiatry Psychiatric Epidemiol* 2003;38(12):698-706.
28. Skapinakis P, Weich S, Lewis G, et al. Socio-economic position and common mental disorders. Longitudinal study in the general population in the UK. *Br J Psychiatry* 2006;189:109-17.
29. March D, Hatch SL, Morgan C, et al. Psychosis and place. *Epidemiol Rev* 2008;30:84-100.
30. Hotopf M, Mayou R, Wadsworth M, et al. Temporal relationships between physical symptoms and psychiatric disorder. Results from a national birth cohort. *Br J Psychiatry* 1998;173:255-61.
31. Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. *Am J Med* 1997;103(5):339-47.
32. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. *Archives Gen Psychiatry* 2005;62(8):903-10.
33. Fink P, Hansen MS, Oxhøj ML. The prevalence of somatoform disorders among internal medical inpatients. *J Psychosom Res* 2004;56(4):413-8.
34. Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. *Gastroenterology* 2006;130(5):1447-58.
35. Leue C, Driessen G, Strik JJ, et al. Managing complex patients on a medical psychiatric unit: an observational study of university hospital costs associated with medical service use, length of stay, and psychiatric intervention. *J Psychosom Res* 2010;68(3):295-302.
36. Meyer T, Klemme H, Herrmann C. Depression but not anxiety is a significant predictor of physicians' assessments of medical status in physically ill patients. *Psychother Psychosom* 2000;69(3):147-54.
37. Freedendfeld RN, Murray M, Fuchs PN, et al. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. *Pain Pract* 2006;6(2):112-8.
38. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults. *Cochrane Database Sys Rev* 2008(4):CD004844.
39. Kim KW, Han JW, Cho HJ, et al. Association between comorbid depression and osteoarthritis symptom severity in patients with knee osteoarthritis. *J Bone Joint Surg Am* 2011;93(6):556-63.
40. Maniadakis N, Gray A. The economic burden of back pain in the UK. *Pain* 2000;84:95-103.

- 1
- 2
- 3
- 4
- 5
- 6
- 7 [41. Seal KH, Shi Y, Cohen BE, et al. Association of mental health disorders with prescription](#)
- 8 [opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. *JAMA*](#)
- 9 [2012;307\(9\):940-7.](#)
- 10 [42. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns](#)
- 11 [and opioid overdose-related deaths. *JAMA* 2011;305\(13\):1315-21.](#)
- 12 [43. Dersh J et al. Chronic pain and psychopathology: research findings and theoretical](#)
- 13 [considerations. *Psychosom Med* 2002;64:773-86.](#)
- 14 [44. Edit V, Eva S, Maria K, et al. Psychosocial, educational, and somatic factors in chronic](#)
- 15 [non-specific low back pain. *Rheumatol Int* 2012 Apr 3.\[Epub ahead of print\]](#)
- 16 [45. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? – Twenty-four years of](#)
- 17 [experience. *Can Fam Physician* 2010;56:514-7.](#)
- 18 46. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with
- 19 antidepressants: a meta-analysis. *JAMA* 2009;301(2):198-209.
- 20 47. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological
- 21 therapies in irritable bowel syndrome: systematic review and meta-analysis. *Gut*
- 22 2009;58(3):367-78.
- 23 48. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane Database Sys Rev*
- 24 2007(4):CD005454.
- 25 49. Krebs EE, Gaynes BN, Gartlehner G, et al. Treating the physical symptoms of depression
- 26 with second-generation antidepressants: a systematic review and metaanalysis.
- 27 *Psychosomatics* 2008;49(3):191-8.
- 28 50. Arnold LM, Hudson JI, Wang F, et al. Comparisons of the efficacy and safety of duloxetine
- 29 for the treatment of fibromyalgia in patients with versus without major depressive
- 30 disorder. *Clin J Pain* 2009;25(6):461-8.
- 31 51. Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric
- 32 disorders. *J Clin Psychiatry* 2006;67(8):1219-25.
- 33 52. Bekhit MH. Opioid-induced hyperalgesia and tolerance. *Am J Ther* 2010;17(5):498-510.
- 34 53. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic
- 35 dopamine pathway in social defeat stress. *Science* 2006;311(5762):864-8.
- 36 54. Upadhyay J, Maleki N, Potter J, et al. Alterations in brain structure and functional
- 37 connectivity in prescription opioid-dependent patients. *Brain* 2010;133(Pt 7):2098-
- 38 114.
- 39 55. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review.
- 40 *Anesthesiology* 2006;104(3):570-87.
- 41 56. Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people.
- 42 *Cochrane Database Sys Rev* 2010(3):CD007503.
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



Observational evidence that urbanisation and neighbourhood deprivation are associated with escalation in chronic pharmacological pain treatment - a longitudinal population-based study in the Netherlands

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2011-000731.R2
Article Type:	Research
Date Submitted by the Author:	22-Jun-2012
Complete List of Authors:	Leue, Carsten; Maastricht University Medical Centre, Department of Psychiatry and Medical Psychology Buijs, Servaas; IMS Helath, Strik, Jacqueline; Maastricht University Medical Centre, Psychiatry and Medical Psychology Lousberg, Richel; Maastricht University Medical Centre, Psychiatry and Medical Psychology Smit, Jasper; IMS Health, van Kleef, Maarten; Maastricht University Medical Centre, Anaesthesiology van Os, Jim; Maastricht University Medical Centre, Psychiatry and Medical Psychology
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Mental health, Health services research, Medical management, Anaesthesia, Pharmacology and therapeutics
Keywords:	Pain management < ANAESTHETICS, MENTAL HEALTH, PAIN MANAGEMENT, PRIMARY CARE, Substance misuse < PSYCHIATRY

SCHOLARONE™
Manuscripts

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting <http://www.adobe.com/products/acrobat/readstep2.html>.

For more assistance with Adobe Reader visit <http://www.adobe.com/support/products/acrreader.html>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract DONE
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found DONE
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported DONE
Objectives	3	State specific objectives, including any prespecified hypotheses DONE
Methods		
Study design	4	Present key elements of study design early in the paper DONE
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection DONE
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up DONE <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable DONE
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group DONE
Bias	9	Describe any efforts to address potential sources of bias DONE
Study size	10	Explain how the study size was arrived at DONE
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why DONE
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding DONE (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy
		(e) Describe any sensitivity analyses

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed DONE (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram DONE
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders DONE (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) DONE
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time DONE <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included DONE (b) Report category boundaries when continuous variables were categorized DONE (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives DONE
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias DONE
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence DONE
Generalisability	21	Discuss the generalisability (external validity) of the study results DONE

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based DONE
---------	----	--


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		Time (months)											
		period prior to observation						observation period					
		1	2	3	4	5	6	7	8	9	10	11	12
starting patients		no Rx for analgesics						first Rx	Rx - Rx ...				last Rx
continuing patients		first Rx						Rx - Rx - Rx ...				last Rx	

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



1
2
3
4
5
6
7 **Original article**

8
9 **Observational evidence that urbanisation and neighbourhood deprivation are**
10 **associated with escalation in chronic pharmacological pain treatment - a longitudinal**
11 **population-based study in the Netherlands**
12
13

14
15 Carsten Leue, consultant*¹, Servaas Buijs, statistician², Jacqueline Strik, consultant¹, Richel
16 Lousberg, lecturer¹, Jasper Smit, statistician², Maarten van Kleef, professor³, Jim van Os,
17 professor^{1,4}
18
19
20
21

22
23
24 ¹Department of Psychiatry and Psychology, South Limburg Mental Health Research and
25 Teaching Network, EURON, Maastricht University Medical Centre, Maastricht, The
26 Netherlands.
27
28

29
30
31 ²IMS Health BV, Capelle aan den IJssel, The Netherlands.
32
33

34 ³Department of Anaesthesiology, Maastricht University Medical Centre, Maastricht, The
35 Netherlands.
36
37

38
39 ⁴King's College London, King's Health Partners, Department of Psychosis Studies, Institute of
40 Psychiatry, London, United Kingdom.
41
42
43
44

45
46 *Correspondence:
47

48
49 C. Leue, Department of Psychiatry and Medical Psychology, Maastricht University Medical
50 Centre, PO BOX 616 (DRT 10), NL 6200 MD Maastricht, The Netherlands. Tel: ++31-43-
51 3877444. Fax: ++31-43-3875444. E-mail: c.leue@mumc.nl
52
53
54

Abstract:

Objective: To examine, [in the light of the association between urban environment and poor mental health](#), whether urbanisation and neighbourhood deprivation are associated with analgesic escalation in chronic pharmacological pain treatment, and whether escalation is associated with prescriptions of psychotropic medication.

Design: Longitudinal analysis of a population-based routine dispensing database in the Netherlands.

Setting: Representative sample of pharmacies, covering 73% of the Dutch nationwide medication consumption in the primary care and hospital outpatient settings.

Participants: 449,410 patients aged 15-85 years were included, of whom 166,374 were in the *Starter group* and 283,036 in the *Continuation group* of chronic analgesic treatment.

Main outcome measure: Escalation of analgesics (i.e. change to a higher level of analgesic potency, classified [across](#) five levels) in association with urbanisation (five levels) and dichotomous neighbourhood deprivation analysed over a six-month observation period.

Methods: Ordered logistic multivariate model evaluating analgesic treatment.

Results: In both *Starter* and *Continuation* groups, escalation was positively associated with urbanisation in a dose-response fashion (*Starter group*: OR (urbanisation level 1 compared to level 5): 1.24; 95% CI 1.18 to 1.30; *Continuation group*: OR 1.19; 95% CI 1.14 to 1.23). [An additional](#) association was apparent with neighbourhood deprivation (*Starter group*: OR 1.06; 95% CI 1.02 to 1.11; *Continuation group*: OR 1.04; 95% CI 1.01 to 1.08). Use of somatic and particularly psychotropic co-medication was associated with escalation in both groups.

1
2
3
4
5
6
7 *Conclusion:* Escalation of chronic analgesic treatment is associated with urban and deprived
8 environments, and occurs in a context of adding psychotropic medication prescriptions.
9
10 These findings suggest that pain outcomes and mental health outcomes share factors that
11 increase risk and remedy suffering.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The validity of the well-known epidemiological association between urban environment and mental health¹⁻³ is supported by work showing that urban living is associated with increased amygdala activity⁴, a key region in the regulation of stress, affective experience and pain^{5,6}. Pain is the natural comorbid mental experience of somatic conditions^{7,8}. In turn, pain is strongly influenced by comorbid common mental disorders particularly affective disorders^{9,10}. Given evidence of urban impact on risk for common mental disorders¹¹, including psychiatric medication prescriptions¹², we hypothesized that pain outcomes, indexed through prescriptions, would be poorer in urban environments and disadvantaged urban neighbourhoods. Pain outcomes were examined at the level of primary care and specialist outpatient care and defined in two ways: (i) escalation of analgesic treatment (i.e. prescription of more potent analgesics) and (ii) co-prescription of psychotropic medication in addition to analgesic treatment.

Objective

We examined the hypothesis that chronic pharmacological pain treatment of hospital outpatients and patients in primary care would show escalation of analgesics in association with the level of urbanisation and neighbourhood index of deprivation. It was predicted that the highest levels of urbanisation and neighbourhood deprivation would be associated with escalation of analgesic treatment to more potent pain medication (e.g. tramadol, morphine, methadone, etc.). Furthermore, we examined the hypothesis that prescriptions of psychotropic medication (e.g. antidepressants, antipsychotics, mood stabilizers, etc.) would

1
2
3
4
5
6
7 be associated with escalation or de-escalation of analgesics in patients prescribed chronic
8 analgesic treatment. Study hypotheses were specified before inspection of the data.
9

10 11 12 13 14 **Method**

15 16 *Data collection*

17
18
19 The investigation was carried out by analysing records pertaining to Dutch routine general
20 practice and hospital outpatient treatment settings. Data were obtained from the IMS
21 Health's longitudinal prescription database (Lifelink, affiliate Capelle ad IJssel, The
22 Netherlands)¹³. This data source consists of anonymous longitudinal prescription records
23 from a representative sample of pharmacies and dispensing GPs, covering 73% of the Dutch
24 nationwide medication consumption of outpatients and primary care patients. The
25 computerized *medication-dispensing histories* contain data regarding dispensed
26 medications, type of prescriber, dispensing date, dispensed amount of medication,
27 prescribed dosage, and length of prescription. Data for each patient were anonymously and
28 independently sampled without linkage of prescriptions to the same patient across
29 pharmacies, because patients in the Netherlands are usually loyal to a single pharmacy¹⁴.
30 Furthermore, research from the Dutch Foundation for Pharmaceutical Statistics (SFK)
31 revealed that in the Netherlands, almost all patients make use of a pharmacy located in their
32 area of living. Eighty-two percent of patients are living in a radius of 3 kilometres from their
33 pharmacy¹⁵. Potential bias caused by patients getting hospitalized, moving to another
34 address or dying was minimized by studying chronic pharmacological pain treatment,
35 because there were dispensing records for these patients during the whole study period.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 *Patient groups*

8
9 Patient selection started with the identification of chronic users of analgesic medication
10 during a six-month prescription period (hereafter: observation period). Chronic use was
11 defined as in receipt of analgesic pharmacotherapy during at least two distinct moments
12 covering an interval of at least two months. In order to track medication for other
13 therapeutic indications (i.e. psychotropic medication and pharmaco-treatment for somatic
14 disorders), patients were observed for a period of six months prior to initiation of analgesic
15 treatment. Next, the cohort with chronic use of analgesics was divided into two groups.
16
17 *Starters* were defined as patients who had not received any analgesics during the six-month
18 period prior to the observation period (hereafter: *Starter group*). Patients who *continued*
19 with pain medication that was already prescribed in the six month before the observation
20 period formed the second group (hereafter: *Continuation group*). The latter group consisted
21 of all patients who had already received analgesics in the first month of the six-month period
22 prior to the observation period, in order to define chronic analgesic treatment before
23 observation. All data captured a calendar period from May 2008 to September 2009 (Figure
24 1).

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 **Figure 1: Starter group and Continuation group of chronic analgesic treatment**

42
43
44
45 Insert Figure 1

46
47
48
49
50 Legend: Schedule of prescriptions (Rx) in Starter group (top) and Continuation group (bottom) of
51 chronic analgesic treatment covering a 12 month period. Months 7 to 12 are the observation period;
52 months 1 to 6 are the pre-observation period. Patients in the Continuation group received first
53 prescription of analgesics in month 1 of the pre-observation period; there was no follow-up whether
54 analgesics were continued over the entire six-month interval prior to the observation period. The
55

1
2
3
4
5
6
7 Starter group did not use any analgesics during the six month interval prior to the observation
8 period.
9

10
11 Data were obtained from the LRx database from month one to twelve as depicted in
12 Figure 1.. Use of other medications (e.g. psychotropic medication and medication for a broad
13 spectrum of somatic conditions) was collected for all patients as well, covering the period of
14 twelve months, consisting of (i) the pre-observation period (month one to six) and (ii) the
15 observation period (month seven to twelve).
16
17
18
19
20
21

22 23 24 25 *Escalation of pharmacological pain treatment* 26

27
28 All individual prescriptions of analgesics were observed for each patient in both the Starter
29 and Continuation groups during the observation period and during the six months prior to
30 the observation period. At each dispensing date, analgesics were classified *a priori* in five
31 levels, in order of analgesic potency (Figure 2). Five escalation levels were provided, based
32 on a minor adaptation of the 3-step WHO-analgesic ladder¹⁶. Level 5 and 4 are identical to
33 WHO steps 3 (strong opioids) and 2 (weak opioids), respectively. WHO step 1 (non-opioid
34 analgesics) was refined, in order to enable further and clinically relevant differentiation
35 between non-opioid analgesics (level 1: paracetamol, level 2: prostaglandin inhibitors, level
36 3: anticonvulsants)¹⁶⁻²⁰. Furthermore, anti-epileptics were divided in anticonvulsants
37 predominantly prescribed in pain conditions (level 3a: gabapentin and pregabalin) and
38 anticonvulsants with best evidence for epilepsy treatment (level 3b: carbamazepine, valproic
39 acid, lamotrigine)¹⁹⁻²¹. In order to avoid prescription for indications of mood stabilisation or
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 epilepsy, the latter group was classified at level 3b only if prescribed in combination with
8
9 analgesic medication at level 1 or 2 (i.e. pain indication) (Figure 2).

10
11 **Figure 2: 5 levels of analgesic potency, modified from the WHO-analgesic ladder¹⁶**
12
13

14
15
16 Insert Figure 2
17
18
19

20 Legend:

- 21 Level 1 (i.e. lowest potency) to level 5 (i.e. highest potency)
22 (a) Gabapentine, pregabalin in the absence of other anti-epileptic drugs
23 (b) Carbamazepine, valproic acid, lamotrigine in combination with medication at level 1 or 2
24 (c) Tramadol, codeine
25 (d) Methadone, oxycodone, hydromorphone, morphine, buprenorphine, fentanyl, sufentanil,
26 pethidine
27
28

29 Confirmation of escalation was based on the comparison of analgesic potency at the first
30 dispensing day and the last dispensing day within the observation period.
31
32

33
34 The comparison of first and last prescription of analgesics resulted in the following
35 categories of analgesic escalation: neutral (i.e. no change of analgesic potency), escalation in
36 analgesic treatment (i.e. change to a higher level of analgesic potency), or de-escalation in
37 pharmacological pain treatment (i.e. change to a lower analgesic potency) (Table 1).
38
39
40
41

42
43 If patients received several analgesics on the same day, both the highest and the
44 second highest level of analgesic potency were included in the analyses, in order to define
45 escalation categories (e.g. a change from level 5 plus level 2 to level 5 plus level 3 indicating
46 that escalation had occurred).
47
48
49
50
51
52
53
54
55

Determinants of escalation in analgesic treatment

Three groups of variables hypothesized to act as mediators or confounders were included in the analyses. The first group were patient characteristics such as sex (0=men, 1=women), age (in years) and the location of patient's pharmacy (defined by postal code). The latter variable defined the level of urbanisation following the definition of the Dutch Central Bureau of Statistics (CBS). [Conform previous work, and in line with the classification developed by CBS, level of urbanisation was defined by CBS as the number of addresses relative to area surface²²](#). Level 1 (i.e. highest level of urbanisation) consists of more than 2500 addresses per square-kilometre (km²); [level 2 = 1500 to 2500 addresses/km², level 3 = 1000 to 1500 addresses/km², level 4 = 500 to 1000 addresses/km²]. Level 5 (i.e. rural environment) consists of less than 500 addresses/km²; described in more detail elsewhere²³. More over, neighbourhood deprivation was defined dichotomously (0=no, 1=yes). The dichotomous measure of neighbourhood deprivation was developed by the Netherlands Institute of Research in Healthcare (NIVEL), using socio-economic indicators such as unemployment rate, average income, population density and ethnic variation. On the basis of empirical research in the Netherlands, NIVEL 's neighbourhood deprivation index (NDI) is calculated as follows: $NDI = ((\ln \text{percentage unemployed people} - 3.0236)/0.37706) - ((\ln \text{average income} - 2.8641)/0.14441) + ((\ln \text{population density} - 7.0132)/1.06699) + ((\ln \text{percentage people of "non-western" ethnicity})/1.11147)$. NDIs were expressed continuously by NIVEL from low to high. Furthermore, NIVEL defined a dichotomous measure of deprivation at a cut-off of 5.5% (i.e. 885,000 people), in order to assess trends in the proportion of the Dutch population inhabiting an area with the highest NDI and for use in epidemiological research²⁴. Healthcare professionals receive higher levels of funding for their services in these deprived areas²⁵. Neighbourhood deprivation was associated with

level of urbanisation: 86% of the sample living in deprived neighbourhoods lived in an area with the highest level of urbanisation. The other patients (14%) living in deprived neighbourhoods lived in an area with the second highest level of urbanisation. The majority (76%) of those living in an area of the highest level of urbanisation did not live in a deprived neighbourhood (Table 1).

Table 1: Sample, stratified by Urbanisation and Neighbourhood Deprivation

Type of patient	Urbanisation level	Deprived Neighbourhood				% within Deprived Neighbourh.
		No (patients)	No (%)	Yes (pat.)	Yes (%)	
Starter Group	1	34662	76.3%	10796	23.7%	86.5%
	2	48673	96.6%	1689	3.4%	13.5%
	3	31107	100.0%	0	0.0%	-
	4	28283	100.0%	0	0.0%	-
	5	11164	100.0%	0	0.0%	-
	total	153889	92.5%	12485	7.5%	100.0%
Continuation Group	1	59714	76.2%	18644	23.8%	85.5%
	2	81406	96.3%	3155	3.7%	14.5%
	3	50853	100.0%	0	0%	-
	4	48511	100.0%	0	0%	-
	5	20754	100.0%	0	0%	-
	total	261237	92.3%	21799	7.7%	100.0%
Total Patients		415126	92.4%	34284	7.6%	

Legend: The sample is described in absolute numbers for the Starter and the Continuation group, stratified by living in an urbanised area (level 1 to 5), and a dichotomous measure of neighbourhood deprivation. Furthermore, in the last column, tabulation is presented for living in a deprived neighbourhood as a function of level of urbanisation (e.g. in the Starter group, 86.5% of the sample living in deprived neighbourhoods lived in an area with urbanisation level 1).

Furthermore, psychotropic co-medication was classified into its different classes, and somatic co-medication was similarly grouped in 10 classes (ACE inhibitors, angiotensine II

1
2
3
4
5
6
7 inhibitors; antidiabetics; beta-blockers; calcium antagonists; functional bowel drugs;
8
9 laxatives; migraine medication; respiratory medication; steroid-antiphlogistics; stomach
10 protectors) (Table 1 to 3). In the Starting group, occurrence of co-medication was time-
11 coded at three levels according to the day of first occurrence (i.e. co-medication prescription
12 before start with analgesics, at the same day or after start of analgesic treatment) (Table 3).
13
14 In the Continuation group, occurrence of co-medication was recorded dichotomously
15 (presence/absence), since it was impossible to distinguish occurrence of co-medication as
16 before or at start of analgesic treatment (Table 4).
17
18
19
20
21
22
23
24
25

26 *Statistical analysis*

27
28
29 First, we analysed the pattern of (de-) escalation in analgesic treatment by means of an
30 ordered logistic multivariable regression model with adjusted odds ratios (and 95%
31 confidence interval) using SAS version 9²⁶. Statistical significance for the model was defined
32 at conventional alpha of 0.05. The dependent variable in this model was the development of
33 a patient's analgesic treatment (de-escalation, neutral, escalation). Independent variables,
34 entered simultaneously in the model, were demographic characteristics, neighbourhood
35 deprivation, and urbanisation, use of psychotropic medication and use of somatic
36 medication. In the Starter group, we also included first occurrence of co-medication. The
37 modeling strategy was to build, first, a fully saturated model (including all variables), in order
38 to avoid missing relevant information by leaving out non-significant variables. Second,
39 backward elimination was carried out to find the best model fit.
40
41
42
43
44
45
46
47
48
49
50

51
52 Models for Starter and Continuation groups were run separately, given different sample
53 selection criteria. The ordered logistic multivariable regression model was chosen above the
54
55

1
2
3
4
5
6
7 multinomial model, as the latter does not consider the natural order in our data regarding
8 development of chronic pain treatment, ranging from de-escalation to neutral to escalation.
9 Proportional odds were assumed in the models of escalation and de-escalation of analgesic
10 treatment, and analyses inspected for violation of this assumption. Test on the proportional
11 odds assumption showed significance, which gave us the confidence to use the ordered
12 logistic model. If a determinant was positively associated with escalation of analgesics,
13 absence of this variable was associated negatively with escalation or positively with de-
14 escalation in analgesic treatment (and vice versa). This offered advantage compared to
15 separate models for escalation and de-escalation (such as consistency of model estimates)
16 and avoided double use of patients with a neutral development of analgesic treatment.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Results**

31
32
33 Overall, 449,410 patients were included, of which 166,374 were in the Starter group and
34 283,036 in the Continuation group. The baseline characteristics of both groups are shown in
35 table 2.
36
37
38
39

40 **Table 2: Baseline characteristics of the patient population with chronic analgesic treatment**

		Starter group				Continuation group			
		Deprived Nb.hoods	Urbanicity ¹ 1	Urbanicity 2-5	Non Depr. Nb.hoods	Deprived Nb.hoods	Urbanicity 1	Urbanicity 2-5	Non Depr. Nb.hoods
Patients	(Absolute)	12485	45458	120916	153889	21799	78358	204678	261237
Change in	Analgesics ²								
	De-escalation	13.3%	12.1%	10.4%	10.7%	13.2%	12.5%	11.2%	11.4%
	Neutral	70.1%	71.6%	74.5%	74.0%	70.0%	71.4%	73.7%	73.3%
	Escalation	16.5%	16.3%	15.1%	15.3%	16.8%	16.1%	15.1%	15.3%
Gender	Male	39.8%	39.3%	40.3%	40.0%	36.7%	35.2%	34.6%	34.6%
	Female	60.2%	60.7%	59.7%	60.0%	63.3%	64.8%	65.4%	65.4%
Age (years)	15-25	6.3%	6.1%	6.5%	6.4%	1.8%	1.6%	1.8%	1.7%
	26-40	23.8%	19.2%	16.3%	16.6%	14.0%	10.8%	9.7%	9.7%
	41-65	50.0%	49.6%	50.9%	50.6%	56.9%	53.4%	51.8%	51.9%
	65-85	19.8%	25.2%	26.2%	26.4%	27.3%	34.2%	36.7%	36.7%
First	Analgesics								
	Level 1	3.2%	3.9%	4.0%	4.0%	3.0%	3.8%	4.1%	4.1%
	Level 2	64.8%	66.6%	72.6%	71.4%	47.8%	47.1%	53.6%	52.1%
	Level 3	2.2%	2.5%	2.6%	2.6%	6.4%	8.1%	8.9%	8.8%
	Level 4	27.4%	24.2%	18.3%	19.3%	36.1%	33.9%	27.6%	28.8%
	Level 5	2.4%	2.9%	2.6%	2.7%	6.8%	7.2%	5.9%	6.2%
	level 4/5	29.8%	27.0%	20.8%	21.9%	42.8%	41.1%	33.5%	35.0%
Last	Analgesics								
	Level 1	3.4%	3.9%	4.0%	4.0%	3.4%	4.1%	4.3%	4.3%
	Level 2	61.9%	63.0%	68.4%	67.4%	44.5%	44.1%	50.1%	48.8%
	Level 3	3.0%	3.3%	3.4%	3.4%	7.0%	8.4%	9.2%	9.1%
	Level 4	27.6%	24.6%	18.9%	19.9%	36.8%	34.5%	28.4%	29.6%
	Level 5	4.1%	5.2%	5.3%	5.3%	8.3%	9.0%	7.9%	8.2%
	Level 4/5	31.7%	29.8%	24.2%	25.2%	45.1%	43.4%	36.3%	37.7%
Concomitant	Medication ³								
	Any concomitant medication	78.8%	79.0%	77.3%	77.7%	89.3%	89.6%	88.0%	88.4%
	Migraine medication	3.9%	3.6%	3.8%	3.7%	5.9%	5.2%	5.1%	5.1%
	Any psychotropic medication	35.1%	36.6%	34.8%	35.3%	51.6%	53.2%	50.2%	51.0%
	Sedatives	27.0%	29.0%	27.4%	27.9%	41.5%	43.4%	40.6%	41.4%
	Mood stabilizers	0.2%	0.3%	0.2%	0.3%	0.3%	0.4%	0.4%	0.4%
	Antipsychotics total	4.1%	3.9%	3.1%	3.2%	6.7%	6.1%	4.9%	5.1%
	Antipsychotics 2 nd generation	2.4%	2.2%	1.5%	1.6%	4.1%	3.5%	2.5%	2.7%
	Antipsychotics classic	2.0%	2.1%	1.8%	1.8%	3.2%	3.2%	2.7%	2.8%
	Bupropion	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.1%
	MAO inhibitors	0.0%	0.0%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%
	TCA	5.2%	5.0%	5.0%	5.0%	9.5%	9.4%	9.6%	9.6%
	Other antidepressants ⁴	2.4%	2.0%	1.6%	1.7%	4.0%	3.3%	2.7%	2.8%
	SNRI	2.6%	2.4%	2.2%	2.2%	4.5%	4.0%	3.5%	3.6%
	SSRI	7.5%	7.0%	6.4%	6.5%	10.3%	10.0%	9.0%	9.2%
	Psycho-stimulants	0.4%	0.5%	0.5%	0.5%	0.3%	0.5%	0.4%	0.5%
	Any somatic medication	72.3%	72.6%	71.0%	71.4%	83.0%	82.9%	81.7%	81.9%
	Cardiovascular medication ⁵	30.9%	31.4%	30.8%	30.9%	35.2%	34.9%	34.9%	34.9%
	Other Somatic medication ⁶	65.2%	65.5%	64.0%	64.3%	76.9%	76.7%	75.4%	75.6%

1
2
3
4
5
6
7 Legend: Patient characteristics are presented as percentages (e.g. age, gender, level of analgesic
8 treatment, change in analgesic treatment (e.g. escalation, de-escalation, and neutral development of
9 prescriptions), and concomitant medication). Absolute patient numbers are presented for the Starter
10 and the Continuation group of chronic analgesic treatment concerning level of urbanicity and for
11 neighbourhood deprivation.

12 (1) Urbanicity = Urbanisation (level 1 = highest level of urbanisation; level 5 = rural environment)

13 ~~(1)~~(2) Change in pain medication from first to last prescription (neutral = no change in level of
14 potency, escalation = change to a higher level of analgesic potency, de-escalation = change to
15 lower analgesic potency)

16
17 ~~(1)~~(3) Concomitant drug use, observed during a period of 12 month

18 (4) Other than Bupropion, MAO inhibitors, SNRI, SSRI, and TCA

19
20 (5) Cardiovascular medication: beta-blocker, calcium antagonist, ACE inhibitor, angiotensine II
21 inhibitor

22
23 (6) Gastro-intestinal medication: anti-diabetics, steroid-antiphogistics, respiratory medication
24
25
26

27 About 7.6% of all escalating patients were residing in a deprived neighbourhood, and
28 approximately 27.6% were living in an area of the highest level of urbanisation (level 1)
29 (Table 2). The majority were female, and there were more patients showing escalation
30 (15.4%) than de-escalation (11.3%) of analgesic treatment. The majority of patients
31 continued a neutral analgesic treatment regime (73.3%) (Table 2). Most of the patients were
32 treated at level 2 or level 4 of analgesic potency. Almost all patients were using other
33 medications, regardless of the different categories in table 2 (84.5%). Around half were using
34 psychotropic medication (45.2%), most were using somatic co-medication (78.1%), and more
35 than a third were using both (38.8%) (Table 2).
36
37
38
39
40
41
42
43
44

45
46 The Starter group mainly initiated an analgesic at level 2 (70.9%) and level 4 (19.9%),
47 whereas only 2.6% directly initiated at level 5. However, analgesic potency level 4 and 5
48 increased up to 20.5% respectively 5.2% by the time of the last prescription in the Starter
49 group (Table 2).
50
51
52
53
54
55

1
2
3
4
5
6
7 In the Continuation group, patients already received analgesics at a higher level of
8
9 potency at inclusion compared to the last observed level of medication potency in the
10
11 Starter group. Level 4 and 5 was observed in 35.6% at the start of the observation period,
12
13 increasing to 38.3% at the end of observation period (Table 2).
14

15
16 Escalation of analgesic treatment was observed more often in deprived
17
18 neighbourhoods and in areas of the highest levels of urbanisation (16.8% and 16.1% in the
19
20 Continuation group, respectively 16.5% and 16.3% in the Starter group) compared to rural
21
22 areas (15.1%) and non-deprived neighbourhoods (15.3%) (Table 2). The proportion of
23
24 patients with neutral development of analgesic treatment was lower in deprived
25
26 neighbourhoods and areas with the highest degree of urbanisation compared to less densely
27
28 populated areas (Table 2).
29

30
31 In the Starter group, escalation was positively associated with lower level of first
32
33 observed pain medication (highest adjusted Odds Ratio (OR) 58.23 at analgesic level 1; 95%
34
35 Confidence Interval (CI) 53.60 to 63.27; lowest OR 1.36 at analgesic level 4; 95% CI 1.27 to
36
37 1.45; compared to reference level 5) (Table 3). Escalation was furthermore associated, in a
38
39 dose-response fashion, with level of urbanisation (highest adjusted OR 1.24 at urbanisation
40
41 level 1; 95% CI 1.18 to 1.30; compared to reference level 5) (Table 3). Furthermore, a weak
42
43 but additional association existed between escalation and neighbourhood deprivation (OR
44
45 1.06; 95% CI 1.02 to 1.11) (Table 3). Use of tricyclic antidepressants (TCA), mood stabilizers
46
47 (OR 1.36; 95% CI 1.07 to 1.42), sedatives, cardiovascular medication (OR 1.16; 95% CI 1.13 to
48
49 1.19) and medications for other somatic conditions was associated with analgesics
50
51 escalation, when prescribed *before* start of analgesics (Table 3). Similarly, in the Starter
52
53 group, escalation of analgesic treatment was also associated with the use of selective
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

noradrenalin serotonin reuptake inhibitors (SNRI), sedatives (OR 1.82; 95% CI 1.74 to 1.89), TCA (OR 2.19; 95% CI 2.03 to 2.36), and antipsychotics (OR 2.43; 95% CI 2.19 to 2.68) when prescribed *after* start of analgesics (Table 3). Negative associations with escalation (i.e. positive association with de-escalation) were apparent for younger age, female sex, and pharmacological migraine treatment. Furthermore, use of antipsychotics was negatively associated with escalation if started *simultaneously* with analgesic treatment (OR 0.70; 95% CI 0.58 to 0.84) (Table 3).

The use of selective serotonin reuptake inhibitors (SSRI), before, at or after start of analgesic treatment was not associated with escalation of analgesics in the Starter group (Table 3).

In the Starter group, the original fully saturated model and the model after backward elimination revealed the same variables associated significantly with escalation in chronic pharmacological pain treatment (Table 3).

Table 3: Associations with escalation in pharmacological pain treatment for the Starter group of chronic analgesic treatment

Exposure		Adj. Odds Ratio	95% CI ¹	
			Lower	Upper
Analgesics ²	Level 1	58.23	53.60	63.27
	Level 2	17.92	16.75	19.16
	Level 3	4.66	4.23	5.14
	Level 4	1.36	1.27	1.45
	Level 5	Reference	-	-
Gender	Female	0.97	0.95	0.99
	Male	Reference	0.00	0.00
Age (years)	15-25	0.73	0.69	0.77
	26-40	0.81	0.78	0.84
	41-65	0.87	0.85	0.90
	66-85	Reference	-	-
Urbanisation ³	1	1.24	1.18	1.30
	2	1.16	1.11	1.22
	3	1.11	1.06	1.17
	4	1.07	1.02	1.13
	5	Reference	-	-
Deprived	Yes	1.07	1.02	1.11
Neighbourhood	No	Reference	-	-
SNRI	Before start of analgesics ⁴	1.05	0.96	1.14
	Same start date	1.28	0.97	1.69
	After analgesics started	1.26	1.09	1.45
	None	Reference	-	-
SSRI	Before start of analgesics	0.97	0.92	1.02
	Same start date	0.97	0.83	1.15
	After analgesics started	1.07	0.97	1.18
	None	Reference	-	-
TCA	Before start of analgesics	1.23	1.15	1.32
	Same start date	1.32	1.12	1.54
	After analgesics started	2.19	2.03	2.36
	None	Reference	-	-
Other AD	Before start of analgesics	1.03	0.93	1.15
	Same start date	0.93	0.71	1.21
	After analgesics started	1.22	1.06	1.42
	None	Reference	-	-
Antipsychotics	Before start of analgesics	0.92	0.85	1.01
	Same start date	0.69	0.58	0.83
	After analgesics started	2.42	2.18	2.67
	None	Reference	-	-
Mood stabilizers	Before start of analgesics	1.40	1.10	1.79
	Same start date	0.91	0.43	1.89
	After analgesics started	0.71	0.39	1.31
	None	Reference	-	-
Sedatives	Before start of analgesics	1.24	1.20	1.28
	Same start date	1.25	1.18	1.33
	After analgesics started	1.82	1.74	1.89
	None	Reference	-	-
Cardio-Vascular drugs	Before start of analgesics	1.16	1.13	1.19
	Same start date	0.86	0.79	0.95
	After analgesics started	1.35	1.26	1.45
	None	Reference	-	-
Other Somatic drugs	Before start of analgesics	1.25	1.22	1.29
	Same start date	1.11	1.07	1.15
	After analgesics started	1.19	1.15	1.23
	None	Reference	-	-
Migraine medication	Before start of analgesics	0.83	0.77	0.89
	Same start date	0.95	0.78	1.17
	After analgesics started	0.91	0.81	1.02
	None	Reference	-	-

Legend:

- (1) 95% CI: confidence interval
 (2) Escalation = change to a higher level of analgesic potency, level 5 = highest level
 (3) 1 = highest level of urbanisation, 5 = rural environment
 (4) Starting date of medication (before, at the same day or after start of analgesics)

In the Continuation group, escalation of analgesics was positively associated with lowest levels of first observed analgesics (highest adjusted OR 16.00 at analgesic level 1; 95% CI 15.20 to 16.85; lowest OR 1.55 at analgesic level 4; 95% CI 1.50 to 1.61; compared to reference level 5) (Table 4). Furthermore, escalation was associated with level of urbanisation in a dose response fashion (highest adjusted OR 1.19 at level 1; 95% CI 1.14 to 1.23; compared to reference level 5) (Table 4). There was also an association between escalation and deprived neighbourhoods, use of SSRI, SNRI, TCA, all antipsychotics, and sedatives (OR 1.31; 95% CI 1.29 to 1.33) as well as use of somatic co-medication (OR 1.12; 95% CI 1.10 to 1.14) (Table 4). De-escalation was associated with female sex, younger age, treatment of migraine, and use of second-generation antipsychotics (OR 0.80; 95% CI 0.70 to 0.91) (Table 4).

The saturated model showed that 22 out of 29 variables had significant associations. All these variables remained significant in the backward elimination approach. One additional variable displayed a significant association after backward elimination: 'TCA high dosage'. The OR's did not (16 variables), or only minimally (6 variables) differ between the fully saturated model and the backward elimination model. The only variable showing a degree of difference was 'TCA total' (fully saturated model: OR = 1.19 (CI: 1.06 – 1.32); backward elimination model: OR = 1.33 (CI: 1.29 – 1.36)) (Table 4).

Table 4: Associations with escalation in pharmacological pain treatment for the Continuation group of chronic analgesic treatment

Exposure		Adjusted Odds Ratio	95% CI ¹	
			Lower	Upper
Analgesics ²	Level 1	16.00	15.20	16.85
	Level 2	7.87	7.59	8.16
	Level 3	3.14	3.00	3.28
	Level 4	1.55	1.50	1.61
	Level 5	Reference	-	-
Gender	Female	0.96	0.94	0.98
	Male	Reference	-	-
Age (years)	15-25	0.91	0.85	0.97
	26-40	0.98	0.95	1.01
	41-65	0.99	0.97	1.01
	66-85	Reference	-	-
Urbanisation ³	1	1.18	1.14	1.23
	2	1.14	1.10	1.17
	3	1.08	1.04	1.12
	4	1.05	1.01	1.09
	5	Reference	-	-
Deprived Neighbourhood	Yes	1.04	1.01	1.08
	No	Reference	-	-
SNRI		1.19	1.02	1.40
SSRI		1.03	1.004	1.07
TCA ⁴		1.19	1.06	1.32
Other AD		1.08	1.03	1.14
Antipsychotics	Total	1.24	1.08	1.43
	1 st generation	1.01	0.88	1.15
	2 nd generation	0.80	0.70	0.91
Mood stabilizers		0.97	0.85	1.10
Sedatives		1.31	1.29	1.34
Migraine		0.95	0.91	0.99
Cardio Vascular Drugs		1.12	1.10	1.14
Other Somatic Drug classes		1.12	1.10	1.14

Legend:

(1) 95% CI: confidence interval

(2) Escalation = change to a higher level of analgesic potency, level 5 = highest level

(3) 1 = highest level of urbanisation, 5 = rural environment

(4) TCA total (fully saturated model: OR = 1.19 (CI: 1.06 – 1.32); BWE model: OR = 1.33 (CI: 1.29 – 1.36))

Over time, the escalation process continues even after the first 6 months of chronic analgesic treatment. In the Starter group, opioid-analgesics (level 4/5) were dispensed in 29.8% of patients living in a deprived neighbourhood. In contrast, 42.8% of patients in deprived neighbourhoods used opioids in the Continuation group, after one year of prescription. A similar, but attenuated development was seen at urbanisation level 1 and level 2 to 5 (Table 2).

Discussion

Escalation of chronic analgesic treatment was observed more often in urban areas and deprived neighbourhoods within urban areas, suggesting pain outcomes either are associated with individual characteristics that are more prevalent in urban and deprived areas, or subject to contextual influences, like area-level stress or social fragmentation, regardless of individual level characteristics. One individual level variable that may explain part of the association with urbanicity and deprivation is socio-economic status^{27 28}, which was not available for inclusion in the model. Nevertheless, the fact that the association with urbanicity remained with deprivation adjusted for in the same model, suggests that urban effects may not be reducible entirely to individual-level socio-economic status. Furthermore, although neighbourhood deprivation and urbanicity are correlated, additional association of deprivation with escalation of analgesics exists over and above urbanisation, indicating that other parameters than population density are involved too. However, the findings could also be attributed to reverse causation, i.e. patients with worsening pain may move into more urban and deprived neighbourhoods as a consequence of being disabled due to ill health.

Although unlikely to entirely explain the current findings, it cannot be excluded.

Regardless of the underlying mechanism, results clearly echo findings of unconfounded higher rates of poor mental health in areas of higher levels of urbanisation and greater neighbourhood deprivation^{11 29}, and suggest that the outcome of mental disorder comorbidity associated with somatic disorders may show similar predictable variation. Functional pain syndromes and psychiatric disorders show high levels of interdependency³⁰⁻³⁵, and psychiatric conditions enhance severity of somatic symptoms³⁶. Thus, part of the mechanism underlying the association between pharmacological pain escalation and urban environment may be explained by urbanisation increasing the risk for mental ill health. This

1
2
3
4
5
6
7 hypothesis is supported by the findings, as in both the Starter and the Continuation groups,
8
9 escalation of chronic analgesic treatment was associated not only with urban environment
10
11 and neighbourhood deprivation, but also with prescription of various psychotropic
12
13 medications prescribed in association. In general, the positive association of escalating
14
15 analgesic treatment with psychotropic medication was as strong or even stronger than the
16
17 association with prescribed somatic co-medication, with the exception of the observed de-
18
19 escalating effect, in the Continuation group, of second-generation antipsychotics, which
20
21 possess powerful analgesic properties^{37 38}. This is accordance with the literature, given the
22
23 fact that psychiatric conditions can enhance symptom severity in somatic patients³⁶, which
24
25 sometimes may impact even more that the somatic condition itself³⁹.

26
27
28 Although the absolute difference between analgesic escalation in the urban vs. less
29
30 urban environment was small, this difference may be relevant from a public health
31
32 perspective, given the high rate of painful conditions in the general population.

33
34 Furthermore, prevention of persistent pain states is relevant with regard to costs⁴⁰. Given
35
36 the well known increase of health care costs in complex patients with frequent utilization of
37
38 health care, with or with out psychiatric comorbidity, only a small number of patients is
39
40 required to cause relevant clinical cost changes⁴¹. A more effective treatment of persistent
41
42 pain, including treatment of psychiatric comorbidity, may have a cost-saving effect.

43
44 Targeting populations with painful conditions for early recognition and treatment of mental
45
46 health problems may not only be cost-effective from a public health perspective, but also
47
48 represent an area of considerable unmet clinical need, since opioid escalation is an
49
50 inflationary development in the treatment of painful conditions^{42 43}. Moreover, broadening
51
52 the pain agenda to a better understanding of associated mental health problems could
53
54 minimize failed surgery outcomes, for example in patients with undetected mental
55

1
2
3
4
5
6
7 disorders. For instance, new surgical procedures were found to be more common in chronic
8
9 back pain (CBP) patients with Post-traumatic Stress Disorder compared to CBP patients
10
11 without⁴⁴. Similarly, depression was demonstrated in 47.4 % of patients with low back pain
12
13 who had no surgery, in 50% of those with one surgical procedure, and in 62.5 % of those
14
15 who had undergone surgery more than once⁴⁵. Influencing central pain sensitization by
16
17 providing adequate antidepressant treatment in depressive conditions may help prevent
18
19 surgical escalation.

20
21 Odds ratios for escalation of analgesics in relation to original level of analgesics may
22
23 represent ceiling effects in both starter and continuation groups - patients already at level 5
24
25 have nowhere stronger to go; treatment of patients at level 1 at baseline can escalate to
26
27 stronger medication. Ceiling effects may reflect the pattern of prescribing analgesics in
28
29 general practice. Given these, it has been suggested that the WHO analgesic ladder is in
30
31 need of updating⁴⁶. For example, Vargas-Schaffer is broadening the ladder with a 4th surgical
32
33 step; in the current article, however, we guide attention to treatment aspects related to
34
35 underestimated mental disorder comorbidity in persistent pain states.

36
37
38 The speculative question remains to what degree escalation of analgesic treatment
39
40 and its association with psychotropic medication reflects therapeutic paradigms to remedy
41
42 pain, treatment of psychiatric comorbidity, or a cause of psychopathology. For instance, in
43
44 the Starter and the Continuation group of chronic analgesic treatment, escalation of
45
46 analgesics was consistently and positively associated with the use of TCA. This prescription
47
48 habit may reflect routine off-label paradigms in the pharmacological treatment of pain
49
50 syndromes^{10 47-49}. However, given the evidence regarding TCA's efficacy in pain conditions,
51
52 negative rather than positive associations with escalation of analgesics should have been
53
54

1
2
3
4
5
6
7 expected. More likely, since the association with TCAs was as strong as the association of
8
9 sedatives with analgesic escalation, it may be a reflection of affective or addictive
10
11 comorbidity in persistent pain, for example in vulnerable cases of opiate-induced
12
13 sensitization, tolerance and hyperalgesia⁵⁰⁻⁵⁶. Our data indicate that escalation of analgesics
14
15 may represent an ongoing process after even months of treatment, which occurs not
16
17 exclusively in the context of environmental deprivation. Since prescriptions of psychotropic
18
19 and (attenuated) somatic medication show a similar pattern over time, escalation may also
20
21 be driven to a degree by patient factors such as opioid tolerance, opioid-induced
22
23 hyperalgesia⁵³, or disease progression.

24
25
26 Given the literature on this topic^{47-51 57}, negative associations of particularly
27
28 antidepressants with escalation of chronic analgesic treatment would have been expected.
29
30 Nevertheless, negative associations between escalation of chronic analgesic treatment were
31
32 also found, for example with migraine treatment (Tables 3 and 4). Moreover, the use of
33
34 antipsychotics was negatively associated with analgesic escalation in the Starter group - if
35
36 prescribed after start of analgesic treatment. In the Continuation group, de-escalation was
37
38 specifically associated with the use of second-generation antipsychotics. This outcome is
39
40 interesting and deserves further investigation, given that limited evidence for the efficacy of
41
42 antipsychotics in pain conditions already exists^{37 38}.

43
44
45 The results of the current study should be seen in the light of several limitations. The
46
47 use of routine data rather than a targeted data collection could have caused more random
48
49 error resulting in type II error. Unidentified confounding may have played a role, as
50
51 randomization was not possible and pre-post designs are sensitive to effects of unmeasured
52
53 changes affecting outcome measures over time. Another limitation is the lack of outcomes
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

other than urbanisation, psychotropic medication or somatic co-medication. For instance, there were no estimates regarding care consumption or illness-related sick leave. Changes in patient-related outcomes like illness severity, global functioning, quality of life and treatment satisfaction should also form part of prospective evaluations. The type of data used is subject to the possibility of ecological fallacy: people whose pharmacy is in a deprived or urban neighbourhood do not necessarily experience that level of deprivation or urbanicity. Furthermore, this study only collected data over a twelve-month period. Affect and pain monitoring deserves longer evaluation. Finally, due to the study design, associations do not allow for causal inference.

WHAT IS ALREADY KNOWN ON THIS TOPIC

Numerous observational studies have observed higher rates of poor mental health in urban and deprived neighbourhood environments.

Pain syndromes and mental disorders show high levels of interdependency, and mental disorders are known to enhance severity of somatic symptoms.

WHAT THIS STUDY ADDS

Escalation of chronic analgesic treatment in persistent pain is associated with urban environments and deprived neighbourhoods, and occurs in a context of increased levels of psychotropic medication prescribing, suggesting persistent pain outcomes are associated with area influences affecting mental health.

Contributors: CL, SB and JvO were principal investigators of the study. SB analysed the data

1
2
3
4
5
6
7 in collaboration with CL, JvO, and JS. CL and JvO drafted the paper. All authors contributed to
8
9 subsequent drafts of the paper, including the final version. JvO is guarantor.

10
11
12 *External funding:* Eli Lilly provided funding to IMS Health for data analysis. External funding
13
14 did not support any other aspect of the study. All authors contributed independently from
15
16 funders to this study; and all authors had full access to and can take responsibility for the
17
18 data and analyses.

19
20
21 *Competing interests:* All authors have completed the Unified Competing Interest form at
22
23 www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and
24
25 declare: no support from any organisation for the submitted work, with the exception of
26
27 above-mentioned funding to IMS Health for data analysis; no financial relationships with any
28
29 organisation that might have an interest in the submitted work; and no other relationships
30
31 or activities that could appear to have influenced the submitted work.

32
33
34 *License for publication:* All authors grant an exclusive license (or non exclusive for
35
36 government employees) on a worldwide basis to the BMJ Publishing Group LTD and its
37
38 licensees, to permit this article (if accepted) to be published in BMJ editions and any other
39
40 BMJPG products and to exploit all subsidiary rights, as set out on:
41
42 <http://resources.bmj.com/bmj/authors/checklists-forms/license-for-publication>.

43
44
45 [Statement on ethical approval: Data were anonymous, reflecting routine general practice. In](#)
46
47 [the Netherlands, no ethical commission approval is required for analyses using anonymous](#)
48
49 [data acquired in routine practice.](#)
50

References

1. Lofors J, Sundquist K. Low-linking social capital as a predictor of mental disorders: a cohort study of 4.5 million Swedes. *Social science & medicine* 2007;64(1):21-34.
2. Thomas H, Weaver N, Patterson J, et al. Mental health and quality of residential environment. *Br J Psychiatry* 2007;191:500-5.
3. Ivory VC CS, Blakely T, Dew K. When does neighbourhood matter? Multilevel relationships between neighbourhood social fragmentation and mental health. *Social science & medicine* 2011;72:1993-2002.
4. Lederbogen F KP, Haddad L, Streit F, et al. City living and urban upbringing affect neural stress processing in humans. *Nature* 2011;474(7352):498-501.
5. Hubbard Cs LJ, Bueller J, Stains J, et al. Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain. *J Neurosci* 2011;31(35):12491-500.
6. Murrough JW, Huang Y, Hu J, et al. Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. *Biol Psychiatry* 2011(Aug 17):[Epub ahead of print].
7. Smith HS HR, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. *Pain Physician* 2011;14(2):E217-45.
8. Price DD CJ, Zhou Q, Verne GN, et al. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models and neuroimaging. *Neuroimage* 2009;47(3):995-1001.
9. Wise TN, Fishbain DA, Holder-Perkins V. Painful physical symptoms in depression: a clinical challenge. *Pain medicine* 2007;8 Suppl 2:S75-82.
10. Goldenberg DL. Pain/Depression dyad: a key to a better understanding and treatment of functional somatic syndromes. *The American journal of medicine* 2010;123(8):675-82.
11. Peen J, Schoevers RA, Beekman AT, et al. The current status of urban-rural differences in psychiatric disorders. *Acta Psychiatr Scand* 2010;121(2):84-93.
12. Crump C, Sundquist K, Sundquist J, et al. Neighborhood deprivation and psychiatric medication prescription: a Swedish national multilevel study. *Ann Epidemiol*;21(4):231-7.
13. Netelenbos JC, Geusens PP, Ypma G, et al. Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands. *Osteoporos Int*;22(5):1537-46.
14. Buurma H, Bouvy ML, De Smet PA, et al. Prevalence and determinants of pharmacy shopping behaviour. *Journal of clinical pharmacy and therapeutics* 2008;33(1):17-23.
15. <http://www.sfk.nl/nieuws-publicaties/PW/2003/2003-15.htm>.
16. World Health Organization. Traitement de la douleur cancéreuse. Geneva, Switzerland: *World Health Organization*; 1987.
17. Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for acute and chronic pain in adults. *Cochrane Database Sys Rev* 2011;(1):CD005451.
18. Wiffen PJ, Derry S, Moore RA, et al. Lamotrigine for acute and chronic pain. *Cochrane Database Sys Rev* 2011;(2):CD006044.
19. Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. *Cochrane Database Sys Rev* 2011;(3):CD007938.

20. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. *Cochrane Database Sys Rev* 2009;(3):CD007076.
21. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. *Lancet Neurol* 2011;10(5):446-56.
22. Van Os J, Hanssen M, Bijl RV, et al. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. *Arch Gen Psychiatry* 2001;58:663-668.
23. Central Bureau of Statistics. Bevolking der gemeenten van Nederland. *The Hague, The Netherlands: CBS Publications* 1993.
24. Wiegers TA DW. Herijking stedelijke achterstandsgebieden. *Utrecht, The Netherlands: NIVEL publications* 2008.
25. Nza, tariefbeschikking 5000-1900-09-3, 30 juni 2009. <http://www.naz.nl/>.
26. <http://www.sas.com/>.
27. Drukker M, van Os J. Mediators of neighbourhood socioeconomic deprivation and quality of life. *Social psychiatry and psychiatric epidemiology* 2003;38(12):698-706.
28. Skapinakis P, Weich S, Lewis G, et al. Socio-economic position and common mental disorders. Longitudinal study in the general population in the UK. *Br J Psychiatry* 2006;189:109-17.
29. March D, Hatch SL, Morgan C, et al. Psychosis and place. *Epidemiol Rev* 2008;30:84-100.
30. Hotopf M, Mayou R, Wadsworth M, et al. Temporal relationships between physical symptoms and psychiatric disorder. Results from a national birth cohort. *Br J Psychiatry* 1998;173:255-61.
31. Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. *The American journal of medicine* 1997;103(5):339-47.
32. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. *Archives of general psychiatry* 2005;62(8):903-10.
33. Fink P, Hansen MS, Oxhøj ML. The prevalence of somatoform disorders among internal medical inpatients. *Journal of psychosomatic research* 2004;56(4):413-8.
34. Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. *Gastroenterology* 2006;130(5):1447-58.
35. Leue C, Driessen G, Strik JJ, et al. Managing complex patients on a medical psychiatric unit: an observational study of university hospital costs associated with medical service use, length of stay, and psychiatric intervention. *Journal of psychosomatic research* 2010;68(3):295-302.
36. Meyer T, Klemme H, Herrmann C. Depression but not anxiety is a significant predictor of physicians' assessments of medical status in physically ill patients. *Psychotherapy and psychosomatics* 2000;69(3):147-54.
37. Freeddenfeld RN, Murray M, Fuchs PN, et al. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. *Pain Pract* 2006;6(2):112-8.
38. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults. *Cochrane database of systematic reviews* 2008(4):CD004844.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

39. Kim KW, Han JW, Cho HJ, et al. Association between comorbid depression and osteoarthritis symptom severity in patients with knee osteoarthritis. *J Bone Joint Surg Am* 2011;93(6):556-63.
40. Maniadakis N, Gray A. The economic burden of back pain in the UK. *Pain* 2000;84:95-103.
41. [de Jonge P, Huysse FJ, Stiefel FC. Case and Care Complexity in the Medically Ill. *Med Clin N Am* 2006;90:679-92.](#)
42. Seal KH, Shi Y, Cohen BE, et al. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan. *JAMA* 2012;307(9):940-7.
43. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA* 2011;305(13):1315-21.
44. Dersh J et al. Chronic pain and psychopathology: research findings and theoretical considerations. *Psychosom Med* 2002;64:773-86.
45. Edit V, Eva S, Maria K, et al. Psychosocial, educational, and somatic factors in chronic non-specific low back pain. *Rheumatol Int* 2012 Apr 3. [Epub ahead of print]
46. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? – Twenty-four years of experience. *Can Fam Physician* 2010;56:514-7.
47. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. *JAMA* 2009;301(2):198-209.
48. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. *Gut* 2009;58(3):367-78.
49. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane database of systematic reviews* 2007(4):CD005454.
50. Krebs EE, Gaynes BN, Gartlehner G, et al. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. *Psychosomatics* 2008;49(3):191-8.
51. Arnold LM, Hudson JI, Wang F, et al. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. *Clin J Pain* 2009;25(6):461-8.
52. Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. *J Clin Psychiatry* 2006;67(8):1219-25.
53. Bekhit MH. Opioid-induced hyperalgesia and tolerance. *Am J Ther* 2010;17(5):498-510.
54. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science* 2006;311(5762):864-8.
55. Upadhyay J, Maleki N, Potter J, et al. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. *Brain* 2010;133(Pt 7):2098-114.
56. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. *Anesthesiology* 2006;104(3):570-87.
57. Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. *Cochrane database of systematic reviews* 2010(3):CD007503.

1
2
3 *Reply to reviewer's comments regarding Manuscript ID BMJopen-2011-*
4 *000731.R1 entitled "Observational evidence that urbanisation and*
5 *neighbourhood deprivation are associated with escalation in chronic*
6 *pharmacological pain treatment - a longitudinal population-based study in the*
7 *Netherlands" (after reviewer's recommendation for publication).*
8
9

10 Changes in the original manuscript are marked with "track changes".
11

12
13
14 **Reviewer Udo Reulbach**

15
16 The authors have responded sufficiently to all my queries. I have no further comments. From
17 my point of view, the quality of the article has greatly improved.
18

19
20
21 **Reviewer A.K. Mantel-Teeuwisse**

22 -The manuscript has been improved by the clarifications given and changes made by the
23 authors. In my view, the paper still lacks sufficient focus, especially in the discussion section.
24 It is clear that the authors advocate to "broaden the pain agenda to an understanding that
25 includes mental health perspectives". However, at least I missed a clear and concise link
26 with the aim of this study – to assess whether the level of urbanization and neighbourhood
27 deprivation are associated with analgesic escalation.
28

29
30 One may hypothesise that mental illness comes into play, but this has not been studied as
31 such in detail. For example, the authors conclude "Escalation of chronic analgesic treatment
32 is associated with urban and deprived environments, and occurs in a context of adding
33 psychotropic medications, suggesting pain outcomes in part reflect area influences affecting
34 mental health." I am not sure the last part of this sentence can be concluded from the
35 presented data. The increased risk of escalation when using psychotropic medication is an
36 independent risk, adjusted for many factors including level of urbanization and
37 neighbourhood deprivation. Similarly, both urbanization and neighbourhood deprivation are
38 independently associated with escalation as well (although I am not sure the remark by Dr
39 Kirkbride about the high correlation between these two has been sufficiently addressed).
40 But this does not necessarily mean that low level of urbanization and neighbourhood
41 deprivation lead to use of psychotropic medication (as a proxy for mental illness) which then
42 leads to dose escalation. Maybe I am missing the point here; I would be happy if the authors
43 could further share their thoughts on this.
44

45
46 **Reply:** We agree this needs further clarification. Our argument was based not only on the
47 independent risks linking urban environment and escalation on the one hand and
48 psychotropic medication and escalation on the other, but also on published findings on links
49 between urban environment and mental health on the one hand and urban environment
50 and use of psychotropic medication on the other (Peen J, Schoevers RA, Beekman AT, et al.
51 The current status of urban-rural differences in psychiatric disorders. *Acta Psychiatr Scand*
52 2010;121(2):84-93. Crump C, Sundquist K, Sundquist J, et al. Neighborhood deprivation and
53 psychiatric medication prescription: a Swedish national multilevel study. *Ann*
54 *Epidemiol*;21(4):231-7.). Given these findings, the abstract conclusion now reads as follows:
55 "Escalation of chronic analgesic treatment is associated with urban and deprived
56 environments, and occurs in a context of adding psychotropic medication prescriptions."
57
58
59
60

1
2
3 **These findings suggest that pain outcomes and mental health outcomes share factors that**
4 **increase risk and remedy suffering”.**
5
6
7

8 -I am also still a bit puzzled by the definition of “continuous use”. I now understand that the
9 authors wish to compare starters with those who have started 6 months earlier. Did all of
10 the continuous users use analgesics during the whole period of six months prior to the
11 observation period? If that was a requirement (I suppose so), it may be helpful to amend
12 Figure 1 to reflect this use during all of these months.
13

14 **Reply:** In order to ensure comparability, we measured analgesics’ escalation during an
15 interval of the same length for the Starter and the Continuation group. Regarding
16 “continuous use”, yes, we wished to compare starters with those who had started analgesic
17 treatment six months earlier. No, we did not follow up whether the Continuation group used
18 analgesics over the entire six month interval prior to the observation period. The Starter
19 group, however, did not use any analgesics during the six month interval prior to the
20 observation period. Technically, we could have measured escalation of continuing patients
21 over a longer time interval, but then the definition of escalation between both groups would
22 be different and a direct comparison of starters and continuing patients would have become
23 difficult.
24

25 We added the following text to the legend of Figure 1: **“Patients in the Continuation group**
26 **received first prescription of analgesics in month 1 of the pre-observation period; there**
27 **was no follow-up whether analgesics were continued over the entire six-month interval**
28 **prior to the observation period. The Starter group did not use any analgesics during the six**
29 **month interval prior to the observation period”.**
30
31

32
33 -Table 2: I do understand that the authors need to make some choices in which data to
34 present. However, I feel that the main study outcome, % of escalation, neutral or de-
35 escalation is now a bit “hidden” in table 2. The justification for comparing level 1 with levels
36 2-5 is still lacking (why not another combination?). Ideally, these % would therefore be
37 presented for each level and for neighbourhood deprivation yes/no. In the current table, %
38 is not displayed for those not living in a deprived neighbourhood, which hampers proper
39 interpretation of the % escalation in deprived neighbourhoods.
40

41 **Reply:** We added a column % of escalation in “non deprived neighbourhoods” to Table 2.
42 Given the small difference with column “urbanicity level 2-5” our choice to summarize levels
43 of urbanisation is justifiable. Please note that we had to make choices regarding data
44 presentation in order to guarantee overview and to avoid diluted results. In our opinion, this
45 table now makes for comfortable reading, without withholding any relevant information.
46 Thus, table 2 now reads:
47 (On the following page)
48
49
50
51
52
53
54
55
56
57
58
59
60

		Starter group				Continuation group			
		Deprived Nb.hoods	Urbanicity ¹ 1	Urbanicity 2-5	Non Depr. Nb.hoods	Deprived Nb. hoods	Urbanicity 1	Urbanicity 2-5	Non Depr. Nb.hoods
Patients	(Absolute)	12485	45458	120916	153889	21799	78358	204678	261237
Change in	Analgesics ²								
	De-escalation	13.3%	12.1%	10.4%	10.7%	13.2%	12.5%	11.2%	11.4%
	Neutral	70.1%	71.6%	74.5%	74.0%	70.0%	71.4%	73.7%	73.3%
	Escalation	16.5%	16.3%	15.1%	15.3%	16.8%	16.1%	15.1%	15.3%
Gender	Male	39.8%	39.3%	40.3%	40.0%	36.7%	35.2%	34.6%	34.6%
	Female	60.2%	60.7%	59.7%	60.0%	63.3%	64.8%	65.4%	65.4%
Age (years)	15-25	6.3%	6.1%	6.5%	6.4%	1.8%	1.6%	1.8%	1.7%
	26-40	23.8%	19.2%	16.3%	16.6%	14.0%	10.8%	9.7%	9.7%
	41-65	50.0%	49.6%	50.9%	50.6%	56.9%	53.4%	51.8%	51.9%
	65-85	19.8%	25.2%	26.2%	26.4%	27.3%	34.2%	36.7%	36.7%
First	Analgesics								
	Level 1	3.2%	3.9%	4.0%	4.0%	3.0%	3.8%	4.1%	4.1%
	Level 2	64.8%	66.6%	72.6%	71.4%	47.8%	47.1%	53.6%	52.1%
	Level 3	2.2%	2.5%	2.6%	2.6%	6.4%	8.1%	8.9%	8.8%
	Level 4	27.4%	24.2%	18.3%	19.3%	36.1%	33.9%	27.6%	28.8%
	Level 5	2.4%	2.9%	2.6%	2.7%	6.8%	7.2%	5.9%	6.2%
	level 4/5	29.8%	27.0%	20.8%	21.9%	42.8%	41.1%	33.5%	35.0%
Last	Analgesics								
	Level 1	3.4%	3.9%	4.0%	4.0%	3.4%	4.1%	4.3%	4.3%
	Level 2	61.9%	63.0%	68.4%	67.4%	44.5%	44.1%	50.1%	48.8%
	Level 3	3.0%	3.3%	3.4%	3.4%	7.0%	8.4%	9.2%	9.1%
	Level 4	27.6%	24.6%	18.9%	19.9%	36.8%	34.5%	28.4%	29.6%
	Level 5	4.1%	5.2%	5.3%	5.3%	8.3%	9.0%	7.9%	8.2%
	Level 4/5	31.7%	29.8%	24.2%	25.2%	45.1%	43.4%	36.3%	37.7%
Concomitant	Medication ³								
	Any concomitant medication	78.8%	79.0%	77.3%	77.7%	89.3%	89.6%	88.0%	88.4%
	Migraine medication	3.9%	3.6%	3.8%	3.7%	5.9%	5.2%	5.1%	5.1%
	Any psychotropic medication	35.1%	36.6%	34.8%	35.3%	51.6%	53.2%	50.2%	51.0%
	Sedatives	27.0%	29.0%	27.4%	27.9%	41.5%	43.4%	40.6%	41.4%
	Mood stabilizers	0.2%	0.3%	0.2%	0.3%	0.3%	0.4%	0.4%	0.4%
	Antipsychotics total	4.1%	3.9%	3.1%	3.2%	6.7%	6.1%	4.9%	5.1%
	Antipsychotics 2 nd generation	2.4%	2.2%	1.5%	1.6%	4.1%	3.5%	2.5%	2.7%
	Antipsychotics classic	2.0%	2.1%	1.8%	1.8%	3.2%	3.2%	2.7%	2.8%
	Bupropion	0.1%	0.1%	0.1%	0.1%	0.2%	0.2%	0.1%	0.1%
	MAO inhibitors	0.0%	0.0%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%
	TCA	5.2%	5.0%	5.0%	5.0%	9.5%	9.4%	9.6%	9.6%
	Other antidepressants ⁴	2.4%	2.0%	1.6%	1.7%	4.0%	3.3%	2.7%	2.8%
	SNRI	2.6%	2.4%	2.2%	2.2%	4.5%	4.0%	3.5%	3.6%
	SSRI	7.5%	7.0%	6.4%	6.5%	10.3%	10.0%	9.0%	9.2%
	Psycho-stimulants	0.4%	0.5%	0.5%	0.5%	0.3%	0.5%	0.4%	0.5%
	Any somatic medication	72.3%	72.6%	71.0%	71.4%	83.0%	82.9%	81.7%	81.9%
	Cardiovascular medication ⁵	30.9%	31.4%	30.8%	30.9%	35.2%	34.9%	34.9%	34.9%
	Other Somatic medication ⁶	65.2%	65.5%	64.0%	64.3%	76.9%	76.7%	75.4%	75.6%

-Tables 3-4: If the editor agrees I would prefer to present unadjusted ORs as well.

Reply: Of course we remain open to editorial advice in this issue. As we stated earlier, we decided to leave out crude ORs, as in our view they do not add information since they're not corrected for coincidental variation in the other variables. Given the already large amount of figures/tables, and the amount of information that would need to be added, we refrained from adding non-vital information. With regard to the complexity of the tables, as mentioned earlier by reviewer Mantel-Teeuwisse and Reulbach, our aim is to guarantee overview and readability.

-The absolute risk difference of (approximately) 1.5% in escalation between different levels of urbanicity would mean that for every 67 patients treated with analgesics, 1 additional escalation would be expected in the lowest level of urbanicity as compared to levels 2-5. One may indeed argue that this is important from a public health perspective. The discussion of the clinical implications of this finding could be a bit more focused in my opinion. The authors now directly assume that this is due to mental illness and elaborate on that (e.g. page 21, lines 46 and further). But I am not completely convinced this can be concluded – see comment above – and would therefore refrain from too much elaboration in that direction.

Reply: Given the well-known increase of health care costs in complex patients with frequent utilization of health care, with or with out psychiatric comorbidity, only a small number of patients is required to cause relevant clinical cost changes (de Jonge P, Huyse FJ, Stiefel FC. Case and Care Complexity in the Medically Ill. *Med Clin N Am* 2006;90:679-92.). Thus, even without psychiatric comorbidity, escalation of analgesics in chronic pain states is of clinical relevance.




Fig. 1. Matching levels of case complexity to complexity of care in the management of the medically ill.

Adapted from de Jonge et al. *Med Clin N Am* 2006.

Regarding somatic and psychiatric multi-morbidity, please see our reply above on first comment of reviewer Mantel-Teeuwisse.

1
2
3 We added a sentence to the discussion (page 21, lines 13 to 16 of the original manuscript):
4 **“Given the well known increase of health care costs in complex patients with frequent**
5 **utilization of health care, with or without psychiatric comorbidity, only a small number of**
6 **patients is required to cause relevant clinical cost changes⁴¹”.**
7
8

9
10 **Reviewer James B Kirkbride**

11
12 1. P9, line 7-9: the new sentence beginning “Urbanisation is defined by CBS...” does not read
13 correctly in English after the comma, and should be corrected.

14
15 **Reply:** P9, original manuscript line 6-8 reads correctly in English now: **“Conform previous**
16 **work, and in line with the classification developed by CBS, level of urbanisation was**
17 **defined as the number of addresses relative to area surface²²”.**
18

19
20 2. Neighbourhood Deprivation Index – thank you for providing the additional information
21 about this variable. However, I am unsure of the utility of using this variable in your analysis.
22 This dichotomized variable only distinguishes between the upper most deprived
23 neighbourhoods (5.5%) and the remainder. It would be preferable to use the raw scores
24 from NIVEL, rather than this dichotomous variable. Furthermore, the NDI includes
25 population density in it as a measure, which means your urbanicity and deprivation variables
26 are likely to be highly correlated.
27

28
29 **Reply:** Unfortunately, as we stated in the reply to reviewers’ comments regarding
30 Manuscript ID BMJopen-2011-000731 (03-May-2012), we do not have raw NDI scores from
31 NIVEL. Although neighbourhood deprivation and urbanicity are correlated, additional
32 association of deprivation with escalation of analgesics exists over and above urbanisation,
33 indicating that other parameters than population density are involved too.
34 We added a sentence to the discussion (page 20, lines 10 to 13 of the original manuscript):
35 **“Furthermore, although neighbourhood deprivation and urbanicity are correlated,**
36 **additional association of deprivation with escalation of analgesics exists over and above**
37 **urbanisation, indicating that other parameters than population density are involved too”.**
38

39
40 3. Table 1 – the presentation of the data in this table is very unclear. I cannot see easily how
41 the %s add up or why the NDI only appears on the first two rows of the urbanicity variable.
42 This needs greater clarification
43

44
45 **Reply:**

46
47 **Table 1** now reads: (on following page)
48
49
50
51
52
53
54
55
56
57
58
59
60

Type of patient	Urbanisation level	Deprived Neighbourhood				% within Deprived Neighbourh.
		No (patients)	No (%)	Yes (pat.)	Yes (%)	
Starter Group	1	34662	76.3%	10796	23.7%	86.5%
	2	48673	96.6%	1689	3.4%	13.5%
	3	31107	100.0%	0	0.0%	-
	4	28283	100.0%	0	0.0%	-
	5	11164	100.0%	0	0.0%	-
	total	153889	92.5%	12485	7.5%	100.0%
Continuation Group	1	59714	76.2%	18644	23.8%	85.5%
	2	81406	96.3%	3155	3.7%	14.5%
	3	50853	100.0%	0	0%	-
	4	48511	100.0%	0	0%	-
	5	20754	100.0%	0	0%	-
	total	261237	92.3%	21799	7.7%	100.0%
Total Patients		415126	92.4%	34284	7.6%	

We hope the presentation of the data is clear now. The NDI itself is not available in our data but the dichotomous variable Neighbourhood Deprivation (yes/no) is. All percentages are added up to clarify their calculation. Adapted Table 1 and the legend are added to the original manuscript (original manuscript page 10, line 7 to 27).

The legend now reads: **“The sample is described in absolute numbers for the Starter and the Continuation group, stratified by living in an urbanised area (level 1 to 5), and a dichotomous measure of neighbourhood deprivation. Furthermore, in the last column, tabulation is presented for living in a deprived neighbourhood as a function of level of urbanisation (e.g. in the Starter group, 86.5% of the sample living in deprived neighbourhoods lived in an area with urbanisation level 1)”**.

4. P20, line 32-33. Line beginning “Although unlikely to entirely explain the current findings...”. Why would this be unlikely? It could be entirely possible. You have no way of deducing the strength of this possibility in the data you have presented. It is important to have acknowledged the possibility of reverse causation, thank you for doing so, but I would drop this line.

Reply: P20, line 13-15 of the original manuscript now reads: **“However, the findings could also be attributed to reverse causation, i.e. patients with worsening pain may move into more urban and deprived neighbourhoods as a consequence of being disabled due to ill health”**.

Thus, we dropped the line suggested by reviewer Kirkbride.

1
2
3
4 5. A statement on ethical approval for this study is required according to the BMJ Open reviewer
5 criteria, but I couldn't see one. This could be easily addressed, I'm sure.
6

7 **Reply:** A statement on ethical approval is added at the end of the article now: "**Data were**
8 **anonymous, reflecting routine general practice. In the Netherlands, no ethical commission**
9 **approval is required for analyses using anonymous data acquired in routine practice"**
10 (page 25, line 17 to 19 of the original manuscript). This statement is identical to what has
11 been stated earlier (reply to reviewers' requests concerning manuscript ID BMJopen-2011-
12 000731, and the submission format, which has already been noticed by the editor).
13

14
15
16 -Well done again on all the changes, the paper reads extremely well now, and will be further
17 improved after consideration of the above points.
18

19 **Reply:** Thank you for the compliment!
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60